Pathology In Depth

Library › Clinical immunology: autoantibody testing, complement, immunodeficiency, allergy and histocompatibility

Clinical immunology: autoantibody testing, complement, immunodeficiency, allergy and histocompatibility

Last reviewed 2026-11-17 by a board-certified pathologist. 307 references.

Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP

Definition. Antinuclear antibodies (ANA) are detected by indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA), which reports a titer and a staining pattern (Damoiseaux 2019). The International Consensus on ANA Patterns (ICAP) codes each pattern as an anti-cell (AC) pattern, AC-0 to AC-31 (ICAP AC-0 page). Antigen-specific immunoassays then identify antibodies to extractable nuclear antigens (ENA), double-stranded DNA (dsDNA), myositis antigens, IgG Fc (rheumatoid factor, RF) and citrullinated peptides (anti-CCP) (Bossuyt 2020). Classification criteria for systemic lupus erythematosus (SLE), Sjögren disease, systemic sclerosis (SSc), rheumatoid arthritis (RA) and idiopathic inflammatory myopathies (IIM) give these antibodies weighted points (Aringer 2019a; Shiboski 2017; van den Hoogen 2013; Aletaha 2010; Lundberg 2017). Classification criteria are written for research cohorts and are not intended for diagnosis (Van Hoovels 2026).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (immunoassay formats, rheumatoid factor and heterophile interference, hook effect) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (anticardiolipin, anti-β2-glycoprotein I, lupus anticoagulant and the 2023 APS criteria) Related page: Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor (interpretation of low C3 and C4, cryoglobulins with RF activity) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (ANCA, autoimmune liver patterns AC-6, AC-12, AC-15 and AC-21) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (cryoglobulin collection and typing)

HEp-2 indirect immunofluorescence: method, cutoff and reporting

  • Sources of variation. HEp-2 IFA results vary with subjective visual reading, serum screening dilution, substrate manufacture, microscope components and the fluorescent conjugate. The EFLM, EASI and ICAP recommendations (2023) contain 35 statements on testing and reporting, substrate and conjugate selection, computer-aided diagnosis (CAD), quality assurance, verification and solid-phase assays (Bonroy 2023).
  • Cutoff. ICAP states that the positive-negative cutoff is set locally with apparently healthy, age-relevant controls. The cutoff depends on slide manufacturer, lot, conjugate, optics, light power, camera, monitor settings and screening dilution (ICAP AC-0 page).
  • Screening dilution. ICAP recommends 1:160 for samples with low pretest probability, such as general population screening, and 1:80 for samples with high pretest probability. The report states the screening dilution used (ICAP AC-0 page).
  • Report content. The ICAP pro forma report contains the endpoint titer, the pattern with its AC code, remarks on follow-up or reflex testing and possible antibody associations. It covers mixed and compound patterns and separate titers for several patterns in one sample (von Mühlen 2021).
  • Cytoplasmic and mitotic staining. ICAP reports clear cytoplasmic or mitotic staining as a positive HEp-2 IFA result (Chan 2015). Previous convention: before ICAP there was no consensus on whether non-nuclear staining was reported as a positive or a negative ANA test (Damoiseaux 2019).
  • Terminology. ICAP uses the term HEp-2 IFA and codes patterns as anti-cell (AC) patterns. The term ANA is kept for historical reasons and for laboratory coding and invoicing (Chan 2015). The EASI/IUIS recommendations suggested the term anticellular antibodies (Damoiseaux 2019; Agmon-Levin 2014).
  • Competent and expert levels. ICAP competent-level patterns are 6 nuclear (homogeneous, speckled, dense fine speckled, centromere, discrete nuclear dots, nucleolar) and 5 cytoplasmic (fibrillar, speckled, reticular/AMA, polar/Golgi-like, rods and rings). All other patterns are expert level (Chan 2015). Laboratories may restrict reports to competent-level patterns (Damoiseaux 2019).
  • Negative result (AC-0). A negative HEp-2 IFA gives a very low probability of a systemic autoimmune rheumatic disease (SARD) and does not exclude other autoimmune diseases. HEp-2 IFA is less sensitive for antibodies to TRIM21/Ro52, TROVE2/Ro60, tRNA synthetases and ribosomal P (ICAP AC-0 page).

ANA in apparently healthy people.

Population Finding Source
Healthy adults aged 20–60 years, 15 laboratories, HEp-2 Positive in 31.7% at 1:40, 13.3% at 1:80, 5.0% at 1:160 and 3.3% at 1:320; frequency did not differ across age groups Tan 1997
US population aged ≥12 years (NHANES 1999–2004, n = 4,754) Prevalence 13.8%; 17.8% in females and 9.6% in males; prevalence increased with age Satoh 2012
  • Titer and probability. Higher antibody levels associate more strongly with SARD and more often identify the antigen on follow-up testing (Damoiseaux 2019). Likelihood ratios for SARD increase with antibody level for both IFA and solid-phase assays (Claessens 2018).

Computer-aided readers and solid-phase screening assays

  • Computer-aided diagnosis. In 1,222 sera an automated HEp-2 reader agreed with visual reading with κ = 0.828, and 8.0% of sera were discrepant for positive versus negative (Egerer 2010). Another system agreed with experts in 98.9% of ANA samples (Melegari 2012). ICAP notes that AC-0 on CAD systems does not always correspond to the traditional microscope (ICAP AC-0 page).
  • Solid-phase ANA screens. A screen with 17 antigens had sensitivities of 74% for SLE, 72% for SSc, 89% for Sjögren disease, 100% for mixed connective tissue disease (MCTD) and 39% for IIM. A negative IFA had a lower likelihood ratio than a negative solid-phase screen, so IFA had the higher negative predictive value (Op De Beeck 2011).
  • Automated IFA compared with solid-phase assays. At manufacturer cutoffs, sensitivity and specificity for ANA-associated rheumatic disease were 95% and 61% for automated IFA, 80.5% and 97.5% for a fluorescence enzyme immunoassay and 86% and 88% for a chemiluminescence assay. Double positivity of IFA and a solid-phase assay increased the likelihood ratio (Claessens 2018).
  • SLE entry criterion. The 2019 SLE criteria accept a solid-phase ANA screening immunoassay with at least equivalent performance to HEp-2 IFA at 1:80 (Aringer 2019b).

ICAP pattern codes, antigens and follow-up tests

The 2019 ICAP consensus described the clinical relevance of 29 patterns: 15 nuclear (AC-1 to AC-14 and AC-29), 9 cytoplasmic (AC-15 to AC-23) and 5 mitotic (AC-24 to AC-28) (Damoiseaux 2019). The ICAP names keep the descriptive terms used before the codes. Older synonyms include diffuse for homogeneous, granular for speckled and kinetochore for centromere. In pre-ICAP naming, the nuclear rim, nuclear membrane or membranous pattern corresponds to AC-11 (smooth nuclear envelope; lamins), and the nuclear membrane pores pattern to AC-12. The dsDNA-associated pattern is reported as AC-1 homogeneous (Chan 2015).

ICAP HEp-2 IFA patterns with antigen associations and recommended follow-up tests.

Code Pattern Main antigens Follow-up test in the clinical setting Source
AC-0 Negative None Antigen-specific test when Ro52, Ro60, synthetase or ribosomal P antibodies are suspected ICAP AC-0 page
AC-1 Homogeneous dsDNA, nucleosomes, histones Anti-dsDNA with or without nucleosome antibodies when SLE is suspected Damoiseaux 2019; Chan 2015
AC-2 Dense fine speckled DFS70 (LEDGF/p75) Anti-DFS70 confirmation Damoiseaux 2019
AC-3 Centromere CENP-B, CENP-A CENP-B immunoassay, especially at low titer Damoiseaux 2019
AC-4 Fine speckled TROVE2/Ro60, SSB/La, Mi-2, TIF1-γ, Ku Ro60 and La; myositis profile when IIM is suspected Damoiseaux 2019
AC-5 Large/coarse speckled Sm, U1-RNP, RNA polymerase III Sm and U1-RNP; RNA polymerase III when SSc is suspected Damoiseaux 2019
AC-6 Multiple nuclear dots Sp100, PML, MJ/NXP2 Sp100 when primary biliary cholangitis (PBC) is suspected; NXP2 when dermatomyositis is suspected Damoiseaux 2019
AC-7 Few nuclear dots p80-coilin, SMN No commercial assay Damoiseaux 2019
AC-8 Homogeneous nucleolar Th/To, PM/Scl Th/To in limited SSc; PM/Scl in SSc-myositis overlap Damoiseaux 2019
AC-9 Clumpy nucleolar U3-RNP/fibrillarin Fibrillarin immunoassay Damoiseaux 2019
AC-10 Punctate nucleolar RNA polymerase I, NOR-90/hUBF NOR-90; RNA polymerase III because RNA polymerase I antibodies coexist with it Damoiseaux 2019
AC-11 Smooth nuclear envelope Lamins, LAP-2 No commercial assay Damoiseaux 2019
AC-12 Punctate nuclear envelope gp210, nucleoporin p62 gp210 when PBC is suspected Damoiseaux 2019
AC-13 PCNA-like PCNA PCNA immunoassay; SLE specificity is debated Damoiseaux 2019
AC-14 CENP-F-like CENP-F No commercial assay; mostly neoplastic conditions Damoiseaux 2019
AC-29 Topo I-like Topoisomerase I (Scl-70) Topoisomerase I immunoassay Damoiseaux 2019
AC-15 Fibrillar linear F-actin Smooth muscle antibody on rodent tissue in autoimmune hepatitis Damoiseaux 2019
AC-16 to AC-18 Fibrillar filamentous, fibrillar segmental, discrete dots Cytokeratins, vimentin, α-actinin, GW and endosome antigens No commercial assays Damoiseaux 2019
AC-19 Cytoplasmic dense fine speckled Ribosomal P, tRNA synthetases, SRP Ribosomal P in SLE; synthetases or SRP in myositis Damoiseaux 2019
AC-20 Cytoplasmic fine speckled Jo-1 (histidyl-tRNA synthetase) Jo-1 immunoassay Damoiseaux 2019
AC-21 Reticular/AMA PDC-E2 Antimitochondrial antibody immunoassay Damoiseaux 2019
AC-22 Polar/Golgi-like Giantin, golgins No commercial assay Damoiseaux 2019
AC-23 Rods and rings IMPDH2 No commercial assay; mainly HCV treated with interferon-α and ribavirin Damoiseaux 2019
AC-24 to AC-28 Centrosome, spindle fibers, NuMA-like, intercellular bridge, mitotic chromosomal Enolases, HsEg5, NuMA, CENP-E, MCA antigens No commercial assays; low positive predictive value for any disease, except NuMA-like with SARD features in about half Damoiseaux 2019
  • AC-2 and SARD. AC-2 is common at high titer in apparently healthy people. Its negative association with SARD holds only when reactivity is confirmed against DFS70 and no other ENA antibody is present (Damoiseaux 2019). Antibodies that produce a DFS-like pattern without DFS70 reactivity have been characterized, so confirmatory testing is recommended for a putative DFS pattern (Sanchez-Hernandez 2023).
  • AC-3. With Raynaud phenomenon, the centromere pattern predicts limited cutaneous SSc. It also occurs in a subset of patients with PBC (Damoiseaux 2019).
  • AC-19 and AC-20. The distinction depends on substrate and antibody concentration. Ribosomal P, synthetase and Jo-1 antibodies can be missed by HEp-2 IFA screening (Damoiseaux 2019).

Patterns added after the 2019 consensus: AC-30 and AC-31

The ICAP website lists AC-30 and AC-31, last updated July 2025 (ICAP AC-30 page; ICAP AC-31 page).

Code Current name Previous name Antigen association Source
AC-30 Fine speckled with mitotic plate Pseudo-DFS; nuclear speckled with positive metaphases; nuclear homogeneous speckled; nuclear homo/speckled Often no known antibody; can arise from coexisting dsDNA, nucleosome, Sm, U1-RNP, topoisomerase I, Ro60 or La antibodies; common in people without autoimmune disease ICAP AC-30 page
AC-31 Myriad discrete speckled AC-4a, nuclear fine speckled Strongly associated with anti-TROVE2/Ro60; frequent in SLE and Sjögren disease; uncommon in healthy people ICAP AC-31 page

Extractable nuclear antigen antibodies and their disease associations

ENA antibodies are measured by ELISA, line or dot immunoassay, multiplex bead (Luminex) assays, fluorescence enzyme immunoassay and chemiluminescence immunoassay (Ghillani 2011; Claessens 2018).

Antigen Usual HEp-2 pattern Disease association and clinical meaning Source
Sm AC-5 SLE-specific antibody; 6 points in the 2019 SLE criteria Aringer 2019b
U1-RNP AC-5 MCTD (high titer, diagnostic criteria for MCTD); also SLE and SSc Damoiseaux 2019; Tanaka 2025
TROVE2/Ro60 AC-4 or AC-31 Sjögren disease (the 2016 criteria score anti-SSA/Ro without distinguishing Ro60 from Ro52/TRIM21), SLE, subacute cutaneous lupus, neonatal lupus and congenital heart block Damoiseaux 2019; Shiboski 2017
TRIM21/Ro52 Often AC-0 Isolated in 57% of Ro52-positive, Ro60-negative sera; myositis, SLE, Sjögren disease, SSc, autoimmune hepatitis; pulmonary disease Ghillani 2011
SSB/La AC-4 Sjögren disease and SLE; no longer counts alone in Sjögren criteria Damoiseaux 2019; Shiboski 2017
Ribosomal P AC-19 SLE; reported frequency 10%–47% depending on assay; sensitivity 26% and specificity 80% for neuropsychiatric SLE Choi 2020; Karassa 2006
PCNA AC-13 SLE specificity debated; also SSc, myositis, RA and HCV Damoiseaux 2019
  • Anti-Ro and pregnancy. In a prospective study of 100 anti-Ro-positive women with 122 pregnancies, 2 infants had congenital heart block. Pregnancy loss, preterm birth, preeclampsia and growth restriction did not differ from anti-Ro-negative women (Brucato 2002). After one child with cardiac neonatal lupus, cardiac disease recurred in 17.4% of 161 subsequent pregnancies of 129 anti-Ro-positive mothers. Recurrence was unaffected by maternal diagnosis, steroid use, antibody status or the sex of the child (Llanos 2009).
  • Isolated anti-Ro52. Among 155 Ro52-positive, Ro60-negative sera, 22% of patients had pulmonary manifestations, half of them with synthetase, SRP or Ku antibodies and half with isolated Ro52. Separate detection of Ro52 supports the diagnosis of antisynthetase syndrome (Ghillani 2011).

Anti-double-stranded DNA assays

Comparison of anti-dsDNA methods in one cohort (52 SLE, 28 other connective tissue disease, 36 HCV, 24 acute viral infection).

Method Sensitivity for SLE Specificity Source
Farr radioimmunoassay 78.8% 90.9% Antico 2010
Crithidia luciliae IFA (CLIFT) 55.8% 96.5% Antico 2010
EIA, synthetic oligonucleotide 84.6% 82.9% Antico 2010
EIA, circular plasmid 73% 97.7% Antico 2010
EIA, recombinant DNA 82.7% 96.5% Antico 2010
EIA, purified extracted DNA 84.6% 94.3% Antico 2010
  • CLIFT. Crithidia luciliae contains a kinetoplast of compacted native dsDNA. CLIFT is semiquantitative by serial dilution, detects higher-avidity antibodies and is used as a confirmatory second-line test after a positive quantitative immunoassay (González Rodríguez 2021).
  • Farr assay. The Farr radioimmunoassay requires radioactive material and is labor intensive. In 99 SLE patients and 154 controls, Farr performed best for diagnosis and for separating quiescent from active disease at 93 IU/mL. Some EIAs lost sensitivity when set to 95% specificity, and manufacturer cutoffs did not separate quiescent from active SLE (Launay 2010).
  • Criteria thresholds. The 2019 SLE criteria require an anti-dsDNA immunoassay with demonstrated ≥90% specificity for SLE against relevant disease controls (Aringer 2019b). Previous rule (SLICC 2012): anti-dsDNA above the laboratory reference range, or twice the reference range for ELISA (Petri 2012).

SLE classification criteria and their immunologic items

2019 EULAR/ACR SLE classification criteria (Aringer 2019b). Entry criterion: ANA ≥1:80 on HEp-2 cells or an equivalent positive test at least once. Classification also requires at least 1 clinical criterion and a total of ≥10 points (Petri 2021). A criterion counts only when no more likely explanation exists, and only the highest-weighted criterion in each domain is counted (Aringer 2019b).

Domain Criterion Points Source
Constitutional Fever >38.3 °C 2 Aringer 2019b
Hematologic Leukopenia <4,000/mm³ 3 Aringer 2019b
Hematologic Thrombocytopenia <100,000/mm³ 4 Aringer 2019b
Hematologic Autoimmune hemolysis with positive direct antiglobulin test 4 Aringer 2019b
Neuropsychiatric Delirium; psychosis; seizure 2; 3; 5 Aringer 2019b
Mucocutaneous Nonscarring alopecia; oral ulcers; subacute cutaneous or discoid lupus; acute cutaneous lupus 2; 2; 4; 6 Aringer 2019b
Serosal Pleural or pericardial effusion; acute pericarditis 5; 6 Aringer 2019b
Musculoskeletal Joint involvement 6 Aringer 2019b
Renal Proteinuria >0.5 g/24 h; class II or V lupus nephritis; class III or IV lupus nephritis 4; 8; 10 Aringer 2019b
Antiphospholipid antibodies Anticardiolipin >40 units or >99th percentile, anti-β2-glycoprotein I, or lupus anticoagulant 2 Aringer 2019b
Complement proteins Low C3 or low C4; low C3 and low C4 3; 4 Aringer 2019b
SLE-specific antibodies Anti-dsDNA in an assay with ≥90% specificity, or anti-Sm 6 Aringer 2019b
  • Domains. The criteria have 7 clinical and 3 immunologic domains, a theoretical maximum of 51 points and a threshold of ≥10 (Aringer 2019b).
  • Antiphospholipid domain. The antibody definitions are taught in Thrombophilia Testing and Antiphospholipid Antibody Testing.
  • Previous rule, SLICC 2012: at least 4 of 17 criteria, including at least 1 clinical and 1 immunologic criterion, or biopsy-proven lupus nephritis with ANA or anti-dsDNA. Criteria are cumulative and need not be present at the same time. The 6 immunologic criteria are ANA, anti-dsDNA, anti-Sm, antiphospholipid antibody, low complement (C3, C4 or CH50) and a positive direct antiglobulin test without hemolytic anemia (Petri 2012).
  • Previous rule, ACR 1997 update of the 1982 revised criteria: SLE is classified when 4 or more of the 11 criteria are met (Petri 2012), and each manifestation counts equally (Petri 2021). The 1982 criteria added fluorescent ANA and antibodies to native DNA and Sm (Tan 1982). In the old immunologic criterion, anti-dsDNA, anti-Sm, lupus anticoagulant, a false-positive syphilis test and anticardiolipin were combined into one item (Petri 2012).

Performance of the three SLE criteria sets in the EULAR/ACR validation cohort (696 SLE, 574 controls).

Criteria set Sensitivity Specificity Source
ACR 1997 83% 93% Aringer 2019b
SLICC 2012 97% 84% Aringer 2019b
EULAR/ACR 2019 96% 93% Aringer 2019b

In the SLICC scenario data set, the 2019 criteria had lower sensitivity and higher specificity than SLICC 2012, with no significant difference in overall agreement with physician diagnosis (Petri 2021).

Drug-induced lupus and antihistone antibodies

Antihistone antibodies were present in 82% of patients with symptomatic drug-induced lupus and in 32% of patients with drug-induced ANA without symptoms. Among patients taking procainamide, the proportions were 92% and 33% (Epstein 1985). Procainamide and hydralazine are strongly associated with drug-induced lupus. Lupus induced by tumor necrosis factor inhibitors more often shows hypocomplementemia and significant anti-dsDNA titers and less often antihistone antibodies (Katz 2010).

Sjögren disease classification and its serology

2016 ACR/EULAR classification criteria for primary Sjögren disease (Shiboski 2017). The criteria apply to patients with ocular or oral dryness or suspected systemic disease. A total score of ≥4 classifies the patient.

Item Points Source
Focal lymphocytic sialadenitis with focus score ≥1 focus/4 mm² 3 Shiboski 2017
Anti-SSA/Ro positivity 3 Shiboski 2017
Ocular staining score ≥5 (or van Bijsterveld score ≥4) in at least one eye 1 Shiboski 2017
Schirmer test ≤5 mm/5 min in at least one eye 1 Shiboski 2017
Unstimulated whole saliva flow ≤0.1 mL/min 1 Shiboski 2017
  • Performance. Sensitivity was 96% and specificity 95% in the validation cohort (Shiboski 2017).
  • Previous rule, ACR 2012 (SICCA): at least 2 of 3 items, namely anti-SSA and/or anti-SSB, or positive RF with ANA titer ≥1:320; ocular staining score ≥3; and focus score ≥1 focus/4 mm² (Shiboski 2012).
  • Previous rule, AECG 2002: a revision of the European criteria that defined rules for primary and secondary Sjögren syndrome and exclusion criteria (Vitali 2002).
  • Changes from the 2002 and 2012 Sjögren criteria. Anti-SSB/La without anti-SSA/Ro no longer counts, and high-titer ANA and RF were removed as items. In the validation cohort, 12 of 15 patients with isolated anti-SSB would have met both earlier criteria sets (Shiboski 2017).

Systemic sclerosis, MCTD and their antibodies

2013 ACR/EULAR SSc classification criteria (van den Hoogen 2013). Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints is sufficient. Otherwise the highest item in each category is added, and ≥9 points classifies SSc.

Item Sub-item Points Source
Skin thickening of the fingers proximal to the MCP joints Sufficient criterion 9 van den Hoogen 2013
Skin thickening of the fingers Puffy fingers; sclerodactyly distal to MCP 2; 4 van den Hoogen 2013
Fingertip lesions Digital tip ulcers; pitting scars 2; 3 van den Hoogen 2013
Telangiectasia Present 2 van den Hoogen 2013
Abnormal nailfold capillaries Present 2 van den Hoogen 2013
Pulmonary arterial hypertension and/or interstitial lung disease Maximum 2 2 van den Hoogen 2013
Raynaud phenomenon Present 3 van den Hoogen 2013
SSc-related antibodies Anticentromere (or centromere pattern), anti-topoisomerase I, anti-RNA polymerase III; maximum 3 3 van den Hoogen 2013
  • Performance and previous rule. In the validation sample, sensitivity and specificity were 0.91 and 0.92 for the 2013 criteria and 0.75 and 0.72 for the 1980 ARA criteria (van den Hoogen 2013). The 1980 criteria required proximal scleroderma, or at least 2 of sclerodactyly, digital pitting scars and bibasilar pulmonary fibrosis, and contained no antibody item (Masi 1980).

SSc-associated antibodies.

Antibody Pattern Clinical association Source
Anticentromere (CENP-B) AC-3 Limited cutaneous SSc; 26% of a 2,177-patient cohort Damoiseaux 2019; Moinzadeh 2014
Topoisomerase I AC-29 Diffuse cutaneous and more aggressive SSc; 18.2% of the cohort Damoiseaux 2019; Moinzadeh 2014
RNA polymerase III AC-5 Cancer in 14.2% compared with 6.3% (topoisomerase I) and 6.8% (centromere), close in time to SSc onset; 26.6% of the cohort; diffuse cutaneous SSc with higher risk of scleroderma renal crisis and gastric antral vascular ectasia Moinzadeh 2014; Didier 2018
Th/To AC-8 Limited cutaneous SSc Damoiseaux 2019
U3-RNP/fibrillarin AC-9 Diffuse SSc, pulmonary arterial hypertension, skeletal muscle, cardiac and gastrointestinal involvement; more common in African American and Latin American patients Damoiseaux 2019
PM/Scl AC-8 with nuclear fine speckles SSc-myositis overlap; isolated PM/Scl in SSc with muscle involvement, ILD with good functional outcome, calcinosis and cutaneous dermatomyositis signs Damoiseaux 2019; Lazzaroni 2021
Ku AC-4 or AC-5 SSc-myositis and SLE-SSc-myositis overlap Damoiseaux 2019
  • Anti-PM/Scl myopathy. Muscle weakness was a presenting feature in 37% of anti-PM/Scl-positive patients and developed in 93%. ILD was present at onset in 10% and occurred in 61% during follow-up (De Lorenzo 2018).
  • MCTD. MCTD was described in 1972 as overlapping SLE, SSc and polymyositis features with high-titer anti-U1-RNP. Revised Japanese diagnostic criteria were published in 2019 (Tanaka 2025).
  • Interstitial pneumonia with autoimmune features (IPAF). The ERS/ATS research statement classifies IPAF by combining a clinical domain, a serologic domain of specific autoantibodies and a morphologic domain, in patients who do not meet criteria for a defined connective tissue disease (Fischer 2015).

Myositis-specific and myositis-associated antibodies

Antibody Phenotype Source
Jo-1 and other tRNA synthetases Antisynthetase syndrome: ILD, polyarthritis, Raynaud phenomenon, mechanic's hands Damoiseaux 2019
MDA5 Dermatomyositis with rapidly progressive ILD; positive Ro52 and high anti-MDA5 titer predict rapidly progressive ILD Liu 2026
TIF1-γ Cancer-associated dermatomyositis in adults; pooled cancer prevalence 0.41 and diagnostic odds ratio 9.37 Best 2019
NXP2 (MJ) Up to one third of juvenile dermatomyositis; malignancy in adults Damoiseaux 2019
Mi-2 Dermatomyositis Damoiseaux 2019
SAE Dermatomyositis-specific antibody Tanboon 2022
SRP Immune-mediated necrotizing myopathy (IMNM) Allenbach 2020
HMGCR IMNM; statin exposure in 92.3% of patients aged ≥50 years Mammen 2011
PM/Scl, Ku, Ro52 Myositis-associated overlap antibodies Damoiseaux 2019; Ghillani 2011
  • IMNM subclasses. Most IMNM is associated with anti-SRP or anti-HMGCR antibodies. About 20% of patients are seronegative, and seronegative IMNM can accompany cancer. IMNM shows high creatine kinase and is often rapidly progressive (Allenbach 2020).
  • HMGCR specificity. Anti-HMGCR antibodies were found in 6% of 750 patients at a myositis center. Statins upregulate HMGCR, and regenerating muscle fibers express it (Mammen 2011). No participant among 1,966 community subjects, including 763 statin users, and none of 51 patients with self-limited statin intolerance had anti-HMGCR antibodies (Mammen 2012).
  • Line immunoassay false positives. Myositis line blots had a positive predictive value of 63% in suspected IIM: 47% for weak-positive and 75% for moderate or strong results (Chang 2024).
  • 2017 EULAR/ACR IIM criteria. Anti-Jo-1 is the only antibody item, with a weight of 3.9 without and 3.8 with muscle biopsy data. Other myositis-specific antibodies lacked enough observations for inclusion. A probability ≥55% (score ≥5.5 without biopsy, ≥6.7 with biopsy) classifies IIM, and 50% to <55% is possible IIM. A probability ≥55% to <90% is probable IIM, and ≥90% (score ≥7.5 without and ≥8.7 with biopsy) is definite IIM (Lundberg 2017).

Rheumatoid factor and anticitrullinated protein antibodies

  • RF methods and isotypes. RF is an antibody to the Fc region of IgG. Nephelometry and ELISA replaced semiquantitative agglutination methods. IgM, IgA and IgG RF together occur in up to 52% of RA patients and in fewer than 5% of patients with other connective tissue diseases (Ingegnoli 2013).
  • Interference. RF binds the Fc portion of assay antibodies and can interfere with immunoassays, as taught in Analytical Methods and Immunoassays in Clinical Chemistry.

RF frequency outside RA.

Condition RF-positive Source
Chronic hepatitis C 40%–50%, up to 76%; the leading cause of raised RF Ingegnoli 2013
Subacute bacterial endocarditis 40% Ingegnoli 2013
Primary Sjögren disease About 60% Ingegnoli 2013
Healthy 50-year-olds 5% Ingegnoli 2013
Healthy 70-year-olds 10%–25% Ingegnoli 2013

Accuracy of RF and anti-CCP for RA (meta-analysis).

Test Sensitivity Specificity LR+ LR− Source
Anti-CCP 67% 95% 12.46 0.36 Nishimura 2007
IgM RF 69% 85% 4.86 0.38 Nishimura 2007
  • Anti-CCP assay generations. At a fixed specificity of 92%, an anti-CCP3 assay had 75% sensitivity and three anti-CCP2 assays had 63%–72%. One automated CCP2 assay gave the most false positives, especially with viral infections and connective tissue diseases (Debaugnies 2013).
  • Antibody level. Likelihood ratios for RA were 2.4–8.7 for low-positive RF and 9.8–17.8 for high-positive RF. For ACPA they were 1.1–16.3 (low positive) and 24.9–37.1 (high positive) (Van Hoovels 2026).

2010 ACR/EULAR RA classification criteria. Patients need synovitis in at least 1 joint without a better explanation. A total of ≥6 of 10 points classifies definite RA (Aletaha 2010).

Domain Category Points Source
Joint involvement Number and site of joints 0–5 Aletaha 2010
Serology Negative RF and negative ACPA 0 Van Hoovels 2026
Serology Low-positive RF or ACPA (>ULN and ≤3 × ULN) 2 Van Hoovels 2026; Neogi 2010
Serology High-positive RF or ACPA (>3 × ULN) 3 Van Hoovels 2026; Neogi 2010
Acute-phase reactants Abnormal CRP or ESR 1 Van Hoovels 2026
Symptom duration ≥6 weeks 1 Van Hoovels 2026; Neogi 2010
  • Serology rules. Categories use the local laboratory upper limit of normal. A missing result counts as negative, and a patient is scored only when at least 1 serologic test is available (Neogi 2010).
  • Previous rule, ACR 1987: at least 4 of 7 criteria, with RF as the only serologic item and radiographic erosions as another item (Arnett 1988).
  • Performance change. In an international very early arthritis cohort (Biliavska et al., cited in Van Hoovels 2026), sensitivity was 85% for the 2010 criteria and 65% for the 1987 criteria, and specificity was 64% and 80%. Among non-RA patients scoring ≥6, 20.5% were autoantibody positive (Van Hoovels 2026). A low-positive RF without ACPA is not specific for RA, and RF with ACPA together is highly specific (Steiner 2024).

2019 EULAR/ACR classification score for systemic lupus erythematosus

ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System

Definition. Antineutrophil cytoplasmic antibodies (ANCA) to proteinase 3 (PR3) and myeloperoxidase (MPO) are markers of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (Bossuyt 2017). Anti-glomerular basement membrane (GBM) antibodies target the α3 chain of type IV collagen (McAdoo 2025). Organ-specific autoantibody interpretation depends on assay format: cell-based and tissue-based assays for neural surface antigens, immunoassays for most intracellular antigens, and method-specific interference for thyroglobulin (Graus 2021; Spencer 1998).

Related page: Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP (HEp-2 IFA, ICAP patterns AC-6, AC-12, AC-15 and AC-21) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (immunoassay formats and interference) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (IgG4 measurement and prozone, CSF oligoclonal bands and kappa FLC index) Related page: Liver, Kidney and Gastrointestinal Function Tests (celiac serology) Related page: Small Intestinal Mucosal Disease: Celiac Disease and Its Mimics, Infections, Drug Injury and Immune Enteropathies (celiac disease histology) Related page: Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome (ANCA, anti-GBM and lupus nephritis pathology) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (membranous nephropathy antigen staining) Related page: Macrocytic Anemias and Vitamin B12 and Folate Testing (parietal cell and intrinsic factor antibodies in autoimmune gastritis) Related page: Diagnostic Enzymes and Serum Tumor Markers (thyroglobulin as a tumor marker)

ANCA indirect immunofluorescence on ethanol- and formalin-fixed neutrophils

  • Patterns. IIF on ethanol-fixed neutrophils gives a cytoplasmic (cANCA) or a perinuclear (pANCA) pattern (Can 2026). Most ANCA-positive EGPA sera show pANCA with MPO specificity, and 20% of anti-MPO sera in one EGPA cohort had atypical patterns (Sinico 2005).
  • Fixation artifact. Ethanol fixation can redistribute cytoplasmic antigens toward the nucleus and produce artifactual perinuclear staining. Formalin fixation separates MPO-associated pANCA from this redistribution (Can 2026).
  • Formalin resistance. In 7,276 patients tested on ethanol- and formalin-fixed neutrophils, MPO antibodies were present in 75.7% of formalin-resistant pANCA and in 4.4% of formalin-sensitive pANCA (odds ratio 67.3) (Can 2026).
  • ANA interference. An ANA with homogeneous or peripheral nuclear fluorescence can mimic pANCA, and such samples are tested for PR3- and MPO-ANCA (Savige 1999).
  • IIF sensitivity for PR3. In the same cohort, 59% of PR3-positive samples were IIF negative, and 77% of MPO-positive samples were IIF positive. Simultaneous PR3 and MPO positivity occurred in 0.16% of patients (Can 2026).
  • Titer and MPO. MPO positivity rose from 0.4% in IIF-negative samples to 33.3% in the highest IIF titer category, and PR3 positivity showed a weaker relation to titer (Can 2026).
  • Interlaboratory variation. Two IIF methods tested on the same 1,175 sera had areas under the ROC curve of 0.923 and 0.843 for ANCA-associated vasculitis (Damoiseaux 2017).
  • Atypical pANCA. Atypical pANCA in ulcerative colitis, primary sclerosing cholangitis (PSC) and autoimmune hepatitis recognize a 50-kD myeloid-specific nuclear envelope protein and give a nuclear rim-like fluorescence (Terjung 2000).

ANCA testing algorithm: 2017 consensus and the 1999 consensus

Item 2017 revised international consensus (current) 1999 international consensus (previous) Source
Screening method for GPA and MPA High-quality PR3- and MPO-ANCA immunoassays, without the categorical need for IIF IIF on all new samples Bossuyt 2017; Savige 1999
Follow-up and reporting of a positive IIF screen IIF is optional Samples with ANCA, other cytoplasmic fluorescence or a homogeneous or peripheral ANA are tested by PR3 and MPO ELISA; an IIF report issued before ELISA results states that positive fluorescence alone is not specific for GPA or MPA Bossuyt 2017; Savige 1999
Evidence base EUVAS multicenter study: 251 patients with ANCA-associated vasculitis and 924 controls Expert consensus Damoiseaux 2017; Savige 1999
  • Immunoassay performance. The areas under the ROC curve of 8 PR3- and MPO-ANCA immunoassays ranged from 0.919 to 0.959, and dual IIF and immunoassay testing of each sample was not necessary for maximal diagnostic accuracy (Damoiseaux 2017).
  • Immunoassay generations. First-generation ELISAs coat antigen directly on the plate, which masks and deforms epitopes. Second-generation (capture) ELISAs bind the antigen with capture antibodies, and third-generation (anchor) ELISAs immobilize it with anchor molecules. In one comparison, PR3-ANCA sensitivity was 96.0% for anchor ELISA, 92.0% for IIF, 72.0% for capture ELISA and 60.0% for direct ELISA (Silva de Souza 2015).
  • ANCA frequency by disease. ANCA occur in 75%–95% of patients with GPA or MPA (Sinico 2005). In eosinophilic granulomatosis with polyangiitis (EGPA), ANCA were present in 37.6% of 93 patients by IIF (Sinico 2005) and in 31.0% of 348 patients in the French cohort (Comarmond 2013).
  • ANCA status and EGPA phenotype. ANCA-positive EGPA had more ear, nose and throat disease, peripheral neuropathy and renal involvement and fewer cardiac manifestations (Comarmond 2013). ANCA positivity was mainly associated with glomerular and alveolar capillaritis (Sinico 2005).
  • Serial ANCA in remission. A rise in ANCA during remission had a positive likelihood ratio of 2.84 for relapse, and persistent ANCA had 1.97. Serial ANCA measurement has limited use for treatment decisions in individual patients (Tomasson 2012).
  • Drug-induced ANCA vasculitis. Hydralazine, propylthiouracil, levamisole and immune checkpoint inhibitors have mechanisms supporting causality, including increased neutrophil extracellular trap formation. Long-term prognosis is more favorable than in idiopathic ANCA-associated vasculitis (Cohen Tervaert 2026). Levamisole contaminates an estimated 71% of US cocaine samples and causes ANCA vasculitis with cutaneous, renal and pulmonary disease (Jin 2018).

Chapel Hill 2012 definitions of ANCA-associated vasculitis

Entity CHCC 2012 definition Source
GPA Necrotizing granulomatous inflammation usually of the upper and lower respiratory tract, and necrotizing vasculitis of predominantly small to medium vessels; necrotizing glomerulonephritis is common Ross 2022; Okazaki 2017
MPA Necrotizing vasculitis with few or no immune deposits, predominantly of small vessels; necrotizing glomerulonephritis is very common, pulmonary capillaritis often occurs and granulomatous inflammation is absent Ross 2022; Okazaki 2017
EGPA Eosinophil-rich and necrotizing granulomatous inflammation often of the respiratory tract, and necrotizing vasculitis of predominantly small to medium vessels, with asthma and eosinophilia; ANCA is more frequent with glomerulonephritis Ross 2022; Okazaki 2017
ANCA-associated vasculitis Few or no immune deposits; a prefix states ANCA reactivity (MPO-ANCA, PR3-ANCA or ANCA-negative) Ross 2022
Anti-GBM disease Immune complex small-vessel vasculitis; formerly Goodpasture syndrome Okazaki 2017

ACR/EULAR 2022 classification criteria serology items

The 2022 criteria apply after a diagnosis of small- or medium-vessel vasculitis has been made and mimics of vasculitis are excluded (Robson 2022; Suppiah 2022; Grayson 2022).

Item GPA weight MPA weight EGPA weight Source
cANCA or PR3-ANCA positive +5 −1 −3 Robson 2022; Suppiah 2022; Grayson 2022
pANCA or MPO-ANCA positive −1 +6 Not an item Robson 2022; Suppiah 2022
Eosinophil count ≥1 × 10⁹/L −4 −4 +5 Robson 2022; Suppiah 2022; Grayson 2022
Pauci-immune glomerulonephritis +1 +3 Not an item Robson 2022; Suppiah 2022
Granuloma or giant cells on biopsy +2 Not an item Not an item Robson 2022
Extravascular eosinophil-predominant inflammation Not an item Not an item +2 Grayson 2022
Hematuria Not an item Not an item −1 Grayson 2022
Nasal, sinus or airway items Bloody discharge, crusting or congestion +3; cartilage +2; sinus imaging +1 Sino-nasal symptoms −3 Obstructive airway disease +3; nasal polyps +3 Robson 2022; Suppiah 2022; Grayson 2022
Other items Hearing loss +1; lung nodules, mass or cavitation +2 Lung fibrosis or interstitial lung disease +3 Mononeuritis multiplex or motor neuropathy +1 Robson 2022; Suppiah 2022; Grayson 2022
Classification threshold ≥5 ≥5 ≥6 Robson 2022; Suppiah 2022; Grayson 2022
Validation sensitivity and specificity 93% and 94% 91% and 94% 85% and 99% Robson 2022; Suppiah 2022; Grayson 2022
  • Previous rule, ACR 1990 criteria for Wegener granulomatosis: at least 2 of 4 criteria, namely abnormal urinary sediment (red cell casts or >5 red cells per high-power field), nodules, cavities or fixed infiltrates on chest radiograph, oral ulcers or nasal discharge, and granulomatous inflammation on biopsy. ANCA was not an item. Sensitivity was 88.2% and specificity 92.0% (Leavitt 1990).

Anti-glomerular basement membrane antibodies

Autoimmune liver disease autoantibodies

Autoimmune hepatitis serologic types (Zachou 2004).

Type Antibodies Target antigens and notes Source
AIH type 1 ANA, smooth muscle antibody (SMA), atypical pANCA, anti-SLA/LP SMA targets F-actin (AC-15); anti-SLA/LP is not detected by IIF on common substrates and is measured by ELISA Zachou 2004; Damoiseaux 2019
AIH type 2 Anti-LKM-1, anti-LKM-3, anti-LC1 LKM-1 targets cytochrome P450 2D6 Zachou 2004
  • Seronegative acute AIH. In 86 Japanese patients with acute-onset AIH, 27% were ANA negative (<1:40), and more than 50% had normal serum IgG (Tanaka 2020).
  • Specificity limits. Anti-LKM-1 occurs in 0%–7% of patients with chronic hepatitis C (Zachou 2004). Anti-SLA/LP is not found in AIH type 2, PBC, PSC, viral hepatitis or nonhepatic autoimmune disease by standardized ELISA (Zachou 2004).
  • Guidelines. Current European guideline: EASL 2025 (EASL 2025). US guidance: AASLD 2019 practice guidance (Mack 2020).

IAIHG simplified diagnostic criteria for autoimmune hepatitis (Hennes 2008).

Variable Cutoff Points Source
ANA or SMA 1:40 1 Tanaka 2020
ANA or SMA ≥1:80 2 Tanaka 2020
LKM ≥1:40 2 Tanaka 2020
SLA Positive 2 Tanaka 2020
IgG >ULN; >1.1 × ULN 1; 2 Tanaka 2020
Liver histology Compatible; typical 1; 2 Tanaka 2020
Absence of viral hepatitis Yes 2 Tanaka 2020

Points for all autoantibodies are summed to a maximum of 2 (Wang 2021; KASL 2023). A score ≥6 indicates probable AIH and ≥7 definite AIH (Hennes 2008). In the validation set, a score ≥6 had 88% sensitivity and 97% specificity, and ≥7 had 81% sensitivity and 99% specificity (Hennes 2008).

Thyroid autoantibodies

Antibody Key data Source
Thyroid peroxidase antibody (TPOAb) Positive in 11.3% of the US population; more frequent in women and with age; less frequent in Black (4.5%) than White (12.3%) individuals; associated with hypothyroidism and hyperthyroidism Hollowell 2002
Thyroglobulin antibody (TgAb) Positive in 10.4% of the US population; not associated with thyroid dysfunction Hollowell 2002
TSH receptor antibody (TRAb) Pooled sensitivity and specificity of 97.1% and 97.4% (2nd generation) and 98.3% and 99.2% (3rd generation) for Graves disease; a positive result made Graves disease 1,367- to 3,420-fold more likely depending on assay Tozzoli 2012
  • TgAb interference with thyroglobulin. TgAb interference, defined as discordance between radioimmunoassay (RIA) and immunometric assay (IMA), was found in 69% of TgAb-positive sera. IMA underestimated thyroglobulin, and exogenous recovery tests did not detect the interference reliably (Spencer 1998). TgAb prevalence and the mechanism of falsely low sandwich-assay thyroglobulin are taught in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Method comparison. In TgAb-positive patients with distant metastatic differentiated thyroid cancer (DTC), IMA and liquid chromatography–tandem mass spectrometry detected no thyroglobulin in about 50%, and RIA failed in 6%. The TgAb trend measured by the same method serves as a surrogate tumor marker (Petrovic 2024).
  • TRAb in pregnancy. Transplacental TRAb can cause fetal or neonatal thyroid dysfunction. In a Dutch cohort, trimester-specific thresholds of 25-, 19- and 6-fold the upper limit of normal had a negative predictive value of 100% in women with previous Graves disease. Neonatal hyperthyroidism occurred despite low maternal TRAb in mothers treated with antithyroid drugs (Saleh 2026).
  • Guidelines. ATA 2016 for hyperthyroidism (Ross 2016); ATA 2026 for pregnancy, which replaced the 2017 pregnancy guideline (Korevaar 2026; Alexander 2017).

Type 1 diabetes, adrenal, membranous nephropathy and bullous disease autoantibodies

Stages of type 1 diabetes defined by islet autoantibodies (Insel 2015).

Stage Definition Risk Source
Stage 1 ≥2 islet autoantibodies (insulin, GAD65, IA-2, ZnT8) with normoglycemia 5-year risk about 44% and 10-year risk about 70% Insel 2015
Stage 2 Islet autoimmunity with dysglycemia 5-year risk about 75% Insel 2015
Stage 3 Symptomatic disease Disease present Insel 2015
  • Number of antibodies. In TEDDY, the 5-year risk of symptomatic diabetes was 11%, 36% and 47% with 1, 2 and 3 autoantibodies. About 85% of people with a single autoantibody do not progress within 10 years (Insel 2015).
  • Order, titer and timing of islet autoantibodies. Children with HLA-DQ8 genotypes developed insulin autoantibodies first, and DQ2/2 children developed GAD65 autoantibodies first. Higher titers of insulin and IA-2 autoantibodies associate with earlier onset. In at-risk children followed from birth, islet autoantibodies rarely appeared before 6 months and peaked between 9 and 24 months of age (Insel 2015).
  • Guideline. The ADA Standards of Care are updated annually, and section 2 of the 2026 Standards covers diagnosis and classification (ADA 2026).
  • Autoimmune adrenal insufficiency. Autoimmune primary adrenal insufficiency is characterized by 21-hydroxylase autoantibodies. Other causes are sought when they are absent (Husebye 2014).
  • Anti-PLA2R. Serum from 70% of patients with idiopathic membranous nephropathy identified the M-type phospholipase A2 receptor, and sera from secondary membranous nephropathy did not. The antibodies were mainly IgG4 (Beck 2009).
  • Bullous pemphigoid. BP180 ELISA had a pooled sensitivity of 82.0% and specificity of 94.1%, and BP230 ELISA had 58.6% and 94.8% (Grochowska-Rak 2026).
  • Pemphigus. Mucosal-dominant pemphigus vulgaris is anti-desmoglein 3 positive and anti-desmoglein 1 negative. Mucocutaneous pemphigus vulgaris is positive for both, and pemphigus foliaceus is positive for desmoglein 1 only (Amagai 1999).
  • Guidelines. EADV S2K guidelines for bullous pemphigoid (Borradori 2022) and pemphigus (Joly 2020).

Neural autoantibodies in paraneoplastic and autoimmune neurologic disease

PNS-Care 2021 antibody groups by frequency of cancer association (Graus 2021; Li 2023).

Group Antibodies Source
High risk (>70% associated with cancer) Hu (ANNA-1), CV2/CRMP5, SOX1, PCA2 (MAP1B), amphiphysin, Ri (ANNA-2), Yo (PCA-1), Ma2 and/or Ma, Tr (DNER), KLHL11 Li 2023
Intermediate risk (30%–70%) AMPAR, GABA-B receptor, mGluR5, P/Q-type VGCC, NMDAR Li 2023
Lower risk (<30%) mGluR1, GABA-A receptor, CASPR2, GFAP, GAD65, LGI1, DPPX, glycine receptor, AQP4, MOG Li 2023
  • Changes from the 2004 PNS criteria. The 2004 criteria used "classical syndromes" and "well-characterised onconeural antibodies" with two levels of evidence, definite and possible (Graus 2004). The 2021 criteria replaced these with high-risk and intermediate-risk phenotypes and antibodies, three levels (definite, probable, possible) and the PNS-Care Score. Definite PNS requires a score ≥8 and the presence of cancer (Graus 2021).
  • Antigen location. Most high-risk antibodies target intracellular antigens and are biomarkers of PNS without a direct pathogenic effect (Graus 2021).
  • Repeat tumor screening. When the initial screen is negative in a high-risk phenotype with a high-risk antibody, tumor screening is repeated every 4–6 months for 2 years (Graus 2021).
  • Tumor association by antibody. In limbic encephalitis, LGI1 antibodies rarely accompany a tumor. At least 50% of patients with GABA-B receptor antibodies have small cell lung cancer (SCLC); more than 50% with AMPAR antibodies have thymoma, lung or breast cancer; and more than 85% with Hu antibodies have SCLC (Graus 2021).
  • Anti-NMDAR encephalitis. The antibodies are CSF IgG to the GluN1 subunit. In 577 patients, 95% were younger than 45 years, 37% were younger than 18 years and the female-to-male ratio was 4:1 (Graus 2016). Women aged 18–35 years have an ovarian teratoma in 35%–50% of cases, and children and young men rarely have tumors (Graus 2021).
  • Post-herpes simplex encephalitis. A relapsing autoimmune encephalitis with NMDAR antibodies follows herpes simplex encephalitis in 20% of patients, and CSF NMDAR antibody testing is mandatory in this setting (Graus 2016).

Methods for neural autoantibodies.

Antigen class Screening and confirmation Limitation Source
Intracellular (Hu, Yo, CV2, Ma2, SOX1) Rodent brain immunohistochemistry or immunofluorescence, confirmed by immunoblot with recombinant protein Line blots give many false-positive and false-negative results for Yo, Ma2, CV2/CRMP5 and SOX1 Graus 2021
Cell surface or synaptic (NMDAR, LGI1, CASPR2, GABA-B, AMPA) Rodent brain tissue assay plus cell-based assay (CBA) Serum-only CBA gives false positives and negatives; CSF screening is obligatory in suspected encephalitis Graus 2021
P/Q-type VGCC, glycine receptor Assays other than brain immunohistochemistry Brain immunohistochemistry is not useful Graus 2021
  • Sample type. Testing of both serum and CSF is recommended. LGI1 antibodies are detected better in serum, and CSF shows lower sensitivity (Graus 2021). All 250 patients with anti-NMDAR encephalitis had CSF antibodies, and 85.6% had serum antibodies. CSF titer change related more closely to relapse than serum titer (Gresa-Arribas 2014). Analysis of CSF avoids false-negative or false-positive diagnoses from serum-only testing (Graus 2016).
  • Method sensitivity. For paraneoplastic antibodies, sensitivity was 28.9% for IIF on primate cerebellum, 26.3% for Western blot and 36.8% for line blot, with specificities of 95.2%, 97.1% and 98.1% (Tampoia et al., cited in Li 2023).

AQP4-IgG, MOG-IgG and neuromuscular junction antibodies.

Antibody Assay and performance Source
AQP4-IgG (NMOSD) CBA recommended; mean sensitivity 76.7% and 0.1% false positives; IIF and ELISA 63%–64% sensitivity with occasional low-titer ELISA false positives (0.5%–1.3%) Wingerchuk 2015
AQP4-IgG Sensitivity 60%–94% across 5 assays, highest for CBAs; fixed and live CBA nearly identical; MOG antibodies in 10% of residual AQP4-negative suspected NMOSD Prain 2019
MOG-IgG Positive predictive value 82.1% for a fixed CBA and 95.5%–100% for two live CBAs Waters 2019
AChR, MuSK MuSK antibodies are predominantly IgG4 (Zisimopoulou 2014); 10%–20% of myasthenia gravis is double seronegative (Gligora 2026); antibodies to AChR, MuSK or other postsynaptic proteins cause the disease (Gilhus 2019) Gilhus 2019; Zisimopoulou 2014; Gligora 2026
LRP4 18.7% of 635 double-seronegative patients by CBA (range 7%–32.7%), mainly IgG1 and IgG2; 27% of ocular double-seronegative patients Zisimopoulou 2014
LRP4 2% of 302 MG patients by methanol-fixed CBA, none by live CBA; detection rare and inconsistent Gligora 2026
P/Q-type VGCC Lambert-Eaton myasthenic syndrome; present in nearly 90%, in paraneoplastic and nonparaneoplastic forms alike; half of patients have SCLC Graus 2021; Titulaer 2011
GQ1b IgG Present in all 6 typical Miller Fisher syndrome patients and absent in controls including Guillain-Barré syndrome Chiba 1992
  • NMOSD criteria (2015). The criteria define NMOSD with AQP4-IgG, NMOSD without AQP4-IgG and NMOSD with unknown AQP4-IgG status (Wingerchuk 2015).
  • MOGAD criteria (2023). The International MOGAD Panel criteria make MOG-IgG a core criterion, state that CBAs are important for diagnostic accuracy and require exclusion of diagnoses such as multiple sclerosis (Banwell 2023). They combine a core demyelinating event, the MOG-IgG titer and supporting clinical or MRI features. A serum titer ≥1:100 is a clear positive result. Low-titer serum MOG-IgG counts only with supporting clinical or MRI features, and the 2023 criteria classify short-segment or MRI-negative myelitis with low-titer MOG-IgG as non-MOGAD (Cai 2025). Previous rules: two 2018 sets of MOG-IgG-associated disease criteria. In a Chinese cohort, the 2023 criteria had 91% sensitivity and 56% specificity against clinical diagnosis (Cai 2025).
  • Ganglioside antibodies. GQ1b IgG was detected in 17.65% of 51 tested Miller Fisher patients in one center, lower after the COVID-19 pandemic (Shao 2025). Anti-GM1 and anti-GQ1b antibodies, especially to glycolipid complexes, best separated motor Guillain-Barré syndrome and Miller Fisher syndrome from controls. Of 1,413 patients with Guillain-Barré syndrome, 92.6% had at least one anti-glycolipid antibody (Thomma 2025).
  • CSF oligoclonal bands and the kappa free light chain index are taught in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.

Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor

Definition. The complement system is a cascade of soluble and cell-bound proteins activated through the classical, lectin and alternative pathways. All three converge at C3 and share the terminal pathway, whose outputs are lytic killing, release of anaphylatoxins and opsonization (Willrich 2021). Complement testing detects inherited deficiencies, consumption in immune complex disease and dysregulation in kidney disease, and it monitors complement-targeted therapy (Prohászka 2016). Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency is diagnosed by C1-INH function, C1-INH protein and C4 (Maurer 2022a).

Related page: Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP (complement items in the SLE criteria) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (cryoglobulin collection, typing and CRP) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (complement inhibitors and PNH flow cytometry) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (complement on red cells and cold agglutinins) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (atypical hemolytic uremic syndrome) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (HLH-2004 criteria) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (IUIS classification of inborn errors of immunity) Related page: Nephritic and Hematuric Glomerular Diseases: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Infection-Related, Cryoglobulinemic, ANCA and Anti-GBM Glomerulonephritis, Alport Syndrome (C3 glomerulopathy and cryoglobulinemic glomerulonephritis pathology) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (nephelometry and immunoassay principles)

Complement pathways, regulators and the membrane attack complex

  • Alternative pathway. The alternative pathway turns over continuously because of a labile thioester bond in C3 and needs no antibody or lectin to start. Properdin stabilizes the alternative pathway convertases (Brodszki 2020).
  • Membrane attack complex. Terminal pathway activation forms C5b-9. Bound to vitronectin (S-protein), it circulates as soluble C5b-9 (sC5b-9), a measure of terminal pathway activation and of therapeutic inhibition whose predictive use is not yet established (Frazer-Abel 2021).
  • Share of inborn errors. Complement deficiencies make up 1%–10% of reported primary immunodeficiencies in international registries (Brodszki 2020).

Complement regulator and receptor defects (ESID/ERN RITA 2020).

Protein Inheritance Associated disorder Source
C3 gain of function Autosomal dominant; 2%–8% of atypical HUS Atypical HUS Brodszki 2020
CFHR1–CFHR3 deletion Complex; 3.4% in the UK Atypical HUS, often with anti-factor H antibodies; SLE Brodszki 2020
CD46 (membrane cofactor protein), thrombomodulin Mostly heterozygous; autosomal dominant Atypical HUS Brodszki 2020
CD55 (DAF) Autosomal recessive; rare Protein-losing enteropathy (CHAPLE) Brodszki 2020
CD59 Autosomal recessive; <20 patients Chronic hemolysis with relapsing peripheral demyelinating disease and cerebral infarction Brodszki 2020
C4A or C4B partial deficiency Complex; 1:250 Susceptibility to SLE, lymphoma, sarcoidosis and celiac disease Brodszki 2020
MASP2 0.03% Respiratory infections, mostly asymptomatic Brodszki 2020
CR3 and CR4 (CD18) Autosomal recessive; 1:1 million Leukocyte adhesion deficiency Brodszki 2020
  • PNH. Acquired loss of CD55 and CD59 on GPI-deficient clones causes PNH (somatic PIGA; 1–2 per million) (Brodszki 2020).
  • Genetic testing. Genetic testing confirms a single component deficiency found by quantitative and functional tests. Copy number variation, point variants and pseudogenes complicate the analysis, and next-generation sequencing panels allow parallel testing (Brodszki 2020).

Complement tests and what each measures

Test Principle What a low or positive result indicates Source
CH50 Serum dilution lysing 50% of sensitized erythrocytes; liposome version with an enzyme readout on chemistry analyzers Classical and terminal pathway function Brodszki 2020; Frazer-Abel 2021
AH50 Hemolysis through the alternative pathway Alternative and terminal pathway function Brodszki 2020
Lectin pathway function Hemolytic or ELISA-based assay Lectin pathway function Brodszki 2020
ELISA-based pathway assays Pathway-specific activators with detection of the C9 neoepitope of the membrane attack complex Function of each pathway in one platform Frazer-Abel 2021; Brodszki 2020
C3, C4 and other components Nephelometry or immunoprecipitation Concentration of single components Brodszki 2020
Activation products (C3a, C4d, C5a, Bb, sC5b-9) Immunoassay for cleavage fragments and complexes In vivo activation; separates consumption from deficiency Brodszki 2020; Frazer-Abel 2021
Complement autoantibodies Anti-C1q, C3, C4 and C5 nephritic factors, anti-factor H, anti-C1-INH Autoimmune consumption or dysregulation Frazer-Abel 2021; Prohászka 2016
  • Liposome CH50. A homogeneous assay of complement-mediated lysis of dinitrophenyl-labeled liposomes reads released glucose-6-phosphate dehydrogenase on automated analyzers. Its results correlated with a hemolytic assay (r = 0.92), and RF, M-protein, bilirubin and hemoglobin did not interfere (Yamamoto 1995). Enzyme and liposome immunoassays compared well with a hemolytic CH50 assay in routine sera (Jaskowski 1999).
  • Two tiers. Functional assays of each pathway are performed first, followed by concentration or function of individual components (Brodszki 2020).
  • Deficiency compared with consumption. In a true deficiency, the component is low or absent and its activation marker is normal. The ratio of a native component to its cleavage product, such as C3a/C3, is recommended because consumption lowers the amount available for cleavage (Brodszki 2020; Frazer-Abel 2021).
  • Acute-phase effect. Complement levels reflect a balance of consumption and production, and many components are acute-phase reactants (Brodszki 2020).
  • Standardization. C3 and C4 are the only well-standardized complement tests (Brodszki 2020). In the international external quality assessment, average success rates for C1q, factor H and factor I never reached 80% in any year from 2016 to 2020 (Frazer-Abel 2021).

Specimen handling for complement analysis

  • Tube type. Serum is used for pathway function, component concentrations and autoantibodies. Activation products are measured in EDTA plasma, because EDTA at ≥10 mM chelates calcium and magnesium and blocks ex vivo activation (Frazer-Abel 2021). EDTA samples are not usually compatible with functional testing (Brodszki 2020).
  • Processing. Serum and EDTA plasma are separated from cells as soon as possible, then analyzed at once or frozen at −80 °C and shipped on dry ice (Frazer-Abel 2021). Samples are frozen within 2 hours of collection (Brodszki 2020).
  • Effect of poor handling. Functional results decrease and activation markers increase with poor post-draw handling. C3 and C4 assays are designed for stability (Frazer-Abel 2021).
  • Several low components. More than one deficient component in one person is very rare, except in the lectin pathway. Several low components suggest improper handling, a regulator deficiency or autoantibodies (Brodszki 2020).

Interpretation of complement result patterns

CH50 AH50 C3 C4 Interpretation Source
Absent or markedly low Normal Normal Normal Early classical pathway deficiency (C1q, C1r, C1s or C2); homozygous C2 deficiency gives CH50 below the reference range Poli 2025; Brodszki 2020
Low Normal Normal Low or absent Total C4 deficiency Brodszki 2020
Normal Low Normal Normal Alternative pathway component deficiency (factor B, factor D or properdin) Brodszki 2020
Low or absent Low or absent Normal Normal Terminal pathway deficiency: C5–C8 deficiency gives absent CH50 and AH50, and C9 deficiency gives reduced but detectable activity; or ex vivo loss of function from handling Poli 2025; Brodszki 2020; Frazer-Abel 2021
Low Low Low Normal C3 deficiency, factor H or factor I deficiency, or C3 nephritic factor Brodszki 2020; Servais 2012
Low Low or normal Low Low Classical pathway consumption by immune complexes, as in SLE or cryoglobulinemic vasculitis Aringer 2019; Petri 2012; De Vita 2011
Not required Not required Normal Low C1-INH deficiency (HAE-1, HAE-2 or acquired); C1q low in acquired deficiency Maurer 2022a
  • Infants. C4 is frequently low in healthy infants and is not useful for diagnosing HAE below 12 months of age (Maurer 2022a).

Inherited complement deficiencies

Deficiency Inheritance and frequency Clinical association Source
C1q, C1r/C1s, C2, C4 Autosomal recessive; C2 about 1:20,000 SLE and infections with encapsulated bacteria Brodszki 2020
C3 Autosomal recessive; about 40 patients Severe early pyogenic and neisserial infections; glomerulonephritis Brodszki 2020
Factor H, factor I Autosomal recessive; rare Recurrent bacterial infection and autoimmunity; haploinsufficiency with age-related macular degeneration Brodszki 2020
C5, C6, C7, C8 Autosomal recessive; C6 about 1:2,000 in African Americans Neisserial infections; absent CH50 and AH50 Brodszki 2020; Poli 2025
C9 Autosomal recessive; 1:1,000 in Japan Neisserial infections, mostly asymptomatic; reduced CH50 and AP50 Brodszki 2020; Poli 2025
Properdin X-linked recessive Neisserial meningitis Brodszki 2020
Mannose-binding lectin (MBL) Polymorphism; about 5% Contradictory clinical data Brodszki 2020
C1-INH Autosomal dominant; 1:50,000 HAE with C1-INH deficiency Brodszki 2020
  • Frequency in disease. Inherited complement deficiency was found in 5.9% of patients with SLE and in 10%–25% of adults with sporadic meningococcal disease. Over 40% of late-component-deficient homozygotes had neisserial infection, with a median age of 17 years at first infection, recurrence in 45% and a predilection for serogroup Y. Mortality from meningococcal disease was lower in late-component-deficient patients than in normal hosts, whereas properdin-deficient patients had fulminant infections with high mortality (Ross 1984).
  • Meningococcal risk. Compared with the general population, the risk of meningococcal meningitis is 1,400 times higher with C9 deficiency and 7,000 to 10,000 times higher with other terminal component deficiencies (Brodszki 2020).
  • MBL deficiency. In 9,245 Danish adults, MBL-deficient homozygotes had no excess hospitalization or death from infection (Dahl 2004).
  • Clinical pattern. Recurrent pneumococcal infection suggests early component deficiency, neisserial infection to late component deficiency, atypical HUS and membranoproliferative glomerulonephritis to alternative pathway dysregulation, and angioedema without urticaria to C1-INH deficiency (Brodszki 2020).
  • Vaccination and prophylaxis. Patients with complement deficiency receive the same vaccines as healthy people, with emphasis on conjugated vaccines against pneumococcus, Haemophilus influenzae and Neisseria meningitidis. Unconjugated polysaccharide vaccines are not immunogenic before age 2 years. Antibiotic prophylaxis is reserved for recurrent infection despite vaccination (Brodszki 2020).
  • Complement inhibitors. Eculizumab increases the incidence of meningococcal disease 1,000- to 2,000-fold. Of 16 US cases in eculizumab recipients from 2008 to 2016, 14 patients had received at least 1 dose of meningococcal vaccine and 11 cases were caused by nongroupable Neisseria meningitidis (McNamara 2017). Laboratory effects of complement inhibitors are taught in Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria.

Complement in SLE and immune complex disease

  • SLE criteria. The complement items of the 2019 EULAR/ACR and SLICC 2012 criteria are taught in Autoantibody Testing in Systemic Autoimmune Rheumatic Diseases: ANA, ENA, Anti-dsDNA, Myositis Antibodies, Rheumatoid Factor and Anti-CCP.
  • Complement levels as activity markers. Classical pathway proteins, especially C1, C4 and C2, fall with active SLE, and C3 is usually at the low end of the normal range. Complement levels are a poor surrogate of disease activity because of wide interindividual and genetic variation and the balance of synthesis and catabolism (Walport 2002).
  • Anti-C1q. For lupus nephritis, anti-C1q had a pooled sensitivity of 0.58 and specificity of 0.75. For active compared with inactive nephritis, sensitivity was 0.74 and specificity 0.77 (Yin 2012). A second meta-analysis estimated 70.4% sensitivity and 73.5% specificity for a history of nephritis, and a negative result left a 33.0% post-test probability at a 55% pretest probability (Eggleton 2014). Anti-C1q is associated with hypocomplementemic urticarial vasculitis and proliferative lupus nephritis (Brodszki 2020).
  • Hypocomplementemic urticarial vasculitis. In 12 patients with biopsy-proven kidney involvement, 8 had anti-C1q antibodies. Biopsies showed membranoproliferative glomerulonephritis in 8 patients and frequent C1q deposits (Corthier 2022).

C3 glomerulopathy, nephritic factors and factor H autoantibodies

  • Nephritic factors. Nephritic factors are autoantibodies to the C3, C4 and C5 convertases (Frazer-Abel 2021).
  • C3 glomerulopathy series. In 134 patients with dense deposit disease, glomerulonephritis with isolated C3 deposits or primary membranoproliferative glomerulonephritis type I, 53 had low C3 and 65 had C3 nephritic factor, more often in dense deposit disease. CFH or CFI variants were found in 24 patients, half with C3 nephritic factor (Servais 2012).
  • Mayo Clinic series. Among 114 patients with C3 glomerulopathy, C3 was low in 44.6% and C4 in 11.8%. C3 nephritic factor was present in 43.5%, a complement gene variant in 37.1% and other autoantibodies in 13.4%. A monoclonal immunoglobulin was found in 37.9% overall and in 65.1% of patients aged ≥50 years (Ravindran 2018).
  • Anti-factor H antibodies. In 48 children with atypical HUS, 3 with recurrent disease had IgG anti-factor H antibodies. Factor H function was decreased with normal antigen and a normal gene, an acquired functional deficiency (Dragon-Durey 2005).
  • Anti-factor H antibodies in glomerulopathy. In 17 patients with alternative pathway glomerulopathy, anti-factor H IgG had lower affinity than in atypical HUS, bound mainly the N-terminal domain and occurred without homozygous CFHR1/CFHR3 deletion. They accompanied C3 nephritic factor in children and monoclonal gammopathy in adults (Blanc 2015).

Hereditary angioedema and acquired C1 inhibitor deficiency

Angioedema types and laboratory profiles (WAO/EAACI 2021; Maurer 2022a; open text Maurer 2022b).

Type C1-INH function C1-INH protein C4 Other features Source
HAE-1 Low (<50%) Low (<50%) Low About 85% of HAE-1/2 Maurer 2022a
HAE-2 Low (<50%) Normal or high Low Dysfunctional protein Maurer 2022a
Acquired C1-INH deficiency (AAE-C1-INH) Low Low Low Later onset; lymphoma or MGUS; C1q often low; autoantibodies to C1-INH Maurer 2022a
HAE with normal C1-INH (HAE-nC1-INH) Normal Normal Normal Variants in F12, ANGPT1, PLG, KNG1, MYOF or HS3ST6, or unknown Maurer 2022a
  • Onset. Half of female patients have a first attack before age 12 and 90% by age 23. In male patients the ages are 13 and 25 years. Family history is absent in up to 25% (Maurer 2022a).
  • Combined testing. C1-INH function, C1-INH protein and C4 together have higher diagnostic accuracy than any one alone, and all three are measured in suspected HAE. C3 is normal in HAE, and its measurement does not help (Maurer 2022a).
  • C4 as a screen. The sensitivity of low C4 for HAE in untreated patients was 81%, and C4 was normal on 9 occasions in 5 untreated patients (Tarzi 2007). C4 is not recommended as a screen or as the only diagnostic test (Maurer 2022a).
  • C1-INH function assays. Commercial kits use a chromogenic substrate or measure C1-INH–C1s complex formation, and the readout affects the apparent function (Maurer 2022a). An interlaboratory study recommended the chromogenic assay, and the complex ELISA needed further investigation (Wagenaar-Bos 2008). With supplied reference ranges, one functional ELISA had 57% sensitivity, and after optimization it had 78% sensitivity and 100% specificity (Tarzi 2007). C1-INH function is a specialized test performed in a reference laboratory with careful sample drawing, handling and shipping. Mishandling is common, so a low result is confirmed on a repeat sample (Bowen 2010). Serum is separated promptly and frozen at −80 °C within 2 hours (Brodszki 2020).
  • Confirmation. Results pointing to HAE-1/2 are confirmed by repeat testing, ideally in a certified laboratory. Repeat testing applies only to the initial diagnosis and does not delay treatment (Maurer 2022a).
  • Genetic testing. SERPING1 sequencing supports some diagnoses, including prenatal diagnosis and mosaicism, and can miss variants such as cryptic splice sites. Biochemical testing is effective and less expensive (Maurer 2022a). The SERPING1 update documented 748 variants, mostly heterozygous, with 72 de novo probands (Ponard 2020).
  • Children. Cord blood C1-INH antigen and function are about 70% and 62% of adult values. C1-INH antigen or function is low in most affected children younger than 1 year, and early tests in offspring of HAE patients are repeated after age 1 year (Maurer 2022a).
  • Pregnancy. C1-INH levels decrease during normal pregnancy, and diagnostic measurements are repeated after delivery (Maurer 2022a).
  • Acquired C1-INH deficiency. C1q is measured in new angioedema after age 30 years without family history. C1q is nearly always normal in HAE and low in 75% of AAE-C1-INH, and it can be normal in patients taking androgens (Maurer 2022a). In 77 Milan patients, the median age at diagnosis was 64 years, 68% had C1-INH autoantibodies and AAE was diagnosed once for every 8.8 HAE diagnoses. The diagnostic criteria were C1-INH antigen and/or function and C4 below 50% of normal, onset after 40 years and no family history. Eight of 49 patients treated with plasma-derived C1-INH became nonresponsive, and all 8 had C1-INH autoantibodies (Zanichelli 2017).
  • ACE inhibitor angioedema (ACEI-AE). ACEI-AE is bradykinin mediated, because ACE normally degrades bradykinin. Patients with ACEI-AE are tested for HAE-1/2, because angioedema after starting an ACE inhibitor can unmask HAE (Maurer 2022a).
  • Epidemiology. HAE with C1-INH deficiency has a prevalence of 1.1–1.6 per 100,000. The first-year cumulative incidence of ACEI-AE is 0.12–0.30 per 100 patient-years, and AAE-C1-INH prevalence was 0.15 per 100,000 in Denmark. ACEI-AE is about 10 times more common than HAE, which is about 10 times more common than AAE (Aygören-Pürsün 2018).
  • Previous guideline (2017 revision). The 2017 WAO/EAACI revision covered HAE-1 and HAE-2 (Maurer 2018). The 2021 revision adds a recommendation for genetic testing in patients with normal C1-INH and suspected HAE (Maurer 2022a), and the US HAEA 2020 guideline also addresses HAE with normal C1-INH (Busse 2021).

Cryoglobulins and mixed cryoglobulinemic vasculitis

  • Types and collection. Cryoglobulin types, collection at 37 °C and typing are taught in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
  • Composition. Mixed cryoglobulins are immune complexes of monoclonal (type II) or polyclonal (type III) RF bound to polyclonal IgG (De Vita 2011).
  • Mechanisms. Cryoglobulins damage organs through vascular sludging with hyperviscosity, mainly in type I, and through immune-mediated vasculitis, mainly in mixed cryoglobulinemia (Ramos-Casals 2012).
  • Causes. Hepatitis C infection is the most common cause, and more than 90% of cases have a known underlying cause. Cutaneous purpura is the most common manifestation of cryoglobulinemic vasculitis (Ramos-Casals 2012).

Laboratory items of the preliminary classification criteria for cryoglobulinemic vasculitis (De Vita 2011). Serum cryoglobulin positivity is an essential condition.

Laboratory item Sensitivity Specificity Source
Low serum C4 69.6% 74.5% De Vita 2011
RF positivity 85.8% 53.7% De Vita 2011
Serum M component 83.1% 72.8% De Vita 2011
At least 2 of the 3 laboratory items 84.2% 79.6% De Vita 2011
  • Questionnaire items. The 3 questions ask about past small red spots on the skin, mainly of the lower limbs, red spots on the legs that leave a brownish color, and a past diagnosis of viral hepatitis (De Vita 2011).
  • Criteria rule. Classification requires positive cryoglobulins plus a positive result in 2 of the 3 item sets (questionnaire, clinical, laboratory). Sensitivity was 88.5% and specificity 93.6% against cryoglobulin-positive controls (De Vita 2011).
  • Cohort profile. Among 272 patients with cryoglobulinemic vasculitis, type II cryoglobulins were found in 71.3% and hepatitis C infection in 84.6% (De Vita 2011).

Serum sickness and circulating immune complex assays

  • Serum sickness. Of 12 patients given horse antithymocyte globulin, 11 developed serum sickness 8–13 days after starting therapy. Circulating immune complexes peaked at days 10–12, C3 and C4 fell precipitously with a nadir on day 10, C3a rose, and skin vessels showed IgM, IgE, IgA or C3 deposits (Lawley 1984).
  • Larger series. In 35 patients treated with equine antithymocyte globulin, serum sickness developed in 86%, beginning on day 7 ± 1 in the 10-day course with fever, malaise and rash. A serpiginous band of erythema and purpura along the sides of the fingers, toes, palms and soles preceded other symptoms in 75%. C3, C4 and CH50 fell by 50%–80% on day 10 ± 2, and ESR and CRP rose (Bielory 1988).
  • Immune complex assays. Circulating immune complexes measured by the C1q-binding assay rose from 12% to 45% in serum sickness (Bielory 1988). The fluid-phase and solid-phase C1q-binding assays correlated poorly in SLE, and the solid-phase assay mainly measures autoantibodies to C1q. Adding 1 M sodium chloride converts it into a specific anti-C1q assay (Walport 2002).

Cytokines, soluble IL-2 receptor and cytokine release syndrome

  • CRS after CAR T-cell therapy. CRS developed in 70% of 133 adults given CD19 CAR T cells. Grades 1, 2 and 3 occurred in 26%, 32% and 4.5% of patients, and grades 4 and 5 each in 3.8%. High marrow tumor burden, cyclophosphamide and fludarabine lymphodepletion, a higher CAR T-cell dose and thrombocytopenia before lymphodepletion predicted CRS. Severe CRS showed hemodynamic instability, capillary leak and consumptive coagulopathy, and angiopoietin-2 and von Willebrand factor rose with severe disease (Hay 2017).
  • Cytokine profile. Peak levels of 24 cytokines, including interferon-γ, IL-6, soluble gp130 and soluble IL-6 receptor, were associated with severe CRS, and a three-cytokine signature predicted it. CRP and ferritin were associated with CRS and failed to predict severe CRS (Teachey 2016).
  • Grading without laboratory values. The ASTCT consensus does not include laboratory parameters in the definition or grading of CRS. Cytokine results are rarely available in time, and CRP is not specific for CRS. CRS overlaps with HLH and macrophage activation syndrome, shown by ferritin elevation in many patients (Lee 2019). The 2026 ASTCT update revisits CRS, neurotoxicity and IEC-associated HLH-like syndrome grading and adds other toxicities (Perales 2026).
  • Soluble IL-2 receptor in HLH. In the HLH-2004 pediatric data set, sIL-2R ≥2,400 U/mL had 93% sensitivity and 100% specificity (Lin 2017). In 78 adults, sIL-2R had an AUC of 0.90 for HLH compared with 0.78 for ferritin. Levels ≤2,400 U/mL ruled out HLH (100% sensitivity), and levels >10,000 U/mL had 93% specificity. Mean levels were 20,241 U/mL in malignancy-associated HLH, 9,720 U/mL in infection-associated HLH and 5,008 U/mL in macrophage activation syndrome (Hayden 2017). sIL-2R falls with response to treatment (Lin 2017). HLH-2004 criteria are taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.
  • Acute-phase reactants. CRP and procalcitonin are taught in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.

Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency

Definition. Inborn errors of immunity (IEIs) are caused by damaging germline variants in single genes and present as susceptibility to infection, autoimmunity, autoinflammation, allergy, bone marrow failure or malignancy (Poli 2025). The International Union of Immunological Societies (IUIS) uses the term "inborn errors of immunity". Earlier AAAAI documents use "primary immunodeficiency" for the same disorders (Bonilla 2015; Chinn 2020). Secondary hypogammaglobulinemia is a reduction of immunoglobulin from acquired causes of decreased production or increased loss (Otani 2022). The laboratory evaluation measures immunoglobulins and specific antibody responses, enumerates lymphocyte subsets, tests T-cell function and confirms the defect by protein expression or genetic testing (Kanegane 2018; Chinn 2020).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (nephelometry, turbidimetry and immunoassay interference) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (serum protein electrophoresis and the gamma fraction) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (dihydrorhodamine flow cytometry for chronic granulomatous disease, leukocyte adhesion deficiency, myeloperoxidase deficiency, neutropenia and HLH criteria) Related page: Transfusion Reactions (anaphylaxis from anti-IgA in IgA deficiency) Related page: Liver, Kidney and Gastrointestinal Function Tests (celiac serology and IgA deficiency) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (interferon-gamma release assays) Related page: Allergy and Hypersensitivity Testing: Total and Specific IgE, Component Diagnostics, Tryptase and Basophil Activation (total IgE) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (chimerism testing methods)

Immune cells and the markers measured in the immunodeficiency evaluation

Cell population Markers or assay Defect it detects Source
T cells: helper and cytotoxic CD3, CD4, CD8; absolute counts by age SCID, combined immunodeficiency, 22q11.2 deletion Shearer 2003; Dvorak 2023
Naive and memory CD4 T cells CD45RA (naive) and CD45RO (memory) Thymic output; leaky SCID; Omenn syndrome (>80% memory) Shearer 2003; Dvorak 2023
Regulatory T cells CD4+ CD25+ FOXP3+ IPEX Poli 2025
Double-negative T cells TCRαβ+ CD4− CD8− ALPS Poli 2025; Palmisani 2023
B cells CD19; switched memory and CD21-low subsets Agammaglobulinemia; CVID subgroups Shearer 2003; Wehr 2008
NK cells NK cell count in T, B and NK enumeration SCID phenotype (T−B−NK− and related patterns) Dvorak 2023
Monocytes Intracellular BTK protein X-linked agammaglobulinemia Igonina 2026
Lymphocytes, monocytes, neutrophils WAS protein Wiskott-Aldrich syndrome and carriers Basu 2024
Neutrophils CD18; oxidative burst LAD1; chronic granulomatous disease (taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders) Poli 2025

IUIS classification of inborn errors of immunity: 2024 update and the 2022 edition

  • Current edition (IUIS 2024). The 2024 update, published in 2025, classifies IEIs involving 508 genes and 17 phenocopies. It adds 67 monogenic defects and 2 phenocopies reported since the June 2022 update (Poli 2025). The accompanying phenotypic classification describes 559 IEIs and presents them as decision trees for bedside use (Bousfiha 2025).
  • Previous edition (IUIS 2022). The 2022 update listed 485 IEIs, including 55 novel monogenic defects and 1 autoantibody phenocopy (Tangye 2022).
  • Unchanged structure. Both editions sort IEIs into the same 10 tables (Tangye 2022; Poli 2025). Variants of one gene that cause distinct diseases by gain or loss of function are listed as separate entries according to the clinical phenotype (Poli 2025).
  • Changed placement. GATA2 deficiency moved from the nonlymphoid defect table to Table 6, subtable 9, in the 2024 update (Poli 2025).

IUIS 2024 tables with the first-line laboratory tests for each category.

IUIS table Category Representative entries (gene) First-line laboratory tests Source
1 Combined immunodeficiencies T−B+ and T−B− SCID; CD40 ligand deficiency (CD40LG); DOCK8 deficiency CBC with absolute lymphocyte count; T, B and NK cells; naive and memory CD4 T cells; TRECs; immunoglobulins Poli 2025; Dvorak 2023
2 Combined immunodeficiencies with syndromic features Wiskott-Aldrich syndrome (WAS); 22q11.2 deletion; STAT3 hyper-IgE syndrome Platelet count and size; T-cell count; IgE; genetic testing Poli 2025
3 Predominantly antibody deficiencies BTK deficiency; CVID; selective IgA deficiency; specific antibody deficiency IgG, IgA, IgM; B-cell count; vaccine responses; isohemagglutinins Poli 2025; Bonilla 2016
4 Diseases of immune dysregulation IPEX (FOXP3); ALPS-FAS Regulatory T cells; double-negative T cells; FAS ligand and vitamin B12 Poli 2025; Rensing-Ehl 2013
5 Congenital defects of phagocyte number or function ELANE neutropenia; LAD1–3; chronic granulomatous disease Neutrophil count; neutrophil function tests in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders Poli 2025
6 Defects in intrinsic and innate immunity Mendelian susceptibility to mycobacterial disease; GATA2 deficiency Genetic testing Poli 2025; Chinn 2020
7 Autoinflammatory diseases Type 1 interferonopathies; inflammasome defects Genetic testing Poli 2025; Chinn 2020
8 Complement deficiencies C1q, C2, C3, C5–C9, properdin, factor H and factor I deficiency; C1 inhibitor deficiency CH50 and AH50; taught in Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor Poli 2025
9 Bone marrow failure Inherited bone marrow failure syndromes CBC; genetic testing Poli 2025; Chinn 2020
10 Phenocopies of IEIs Somatic FAS variants; neutralizing anticytokine autoantibodies Anticytokine autoantibody assays; somatic variant testing Poli 2025

IUIS 2024 phagocyte entries outside the neutropenia workup

Neutrophil function tests, LAD1 and ELANE neutropenia are taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders. IUIS Table 5 adds the following entries.

  • LAD2 (SLC35C1). Autosomal recessive defect of rolling and chemotaxis with mild LAD1 features, the hh blood group, growth retardation and developmental delay (Poli 2025).
  • LAD3 (FERMT3). Autosomal recessive defect of adherence and chemotaxis with LAD1 features and a bleeding tendency (Poli 2025).
  • X-linked chronic granulomatous disease (CYBB). Deletions that extend into the contiguous Kell locus produce the McLeod phenotype (Poli 2025).

Phenocopies of inborn errors of immunity

Phenocopies reproduce an IEI phenotype through a somatic variant or a neutralizing autoantibody (Poli 2025).

Phenocopy Mechanism IEI it resembles Source
ALPS-SFAS Somatic TNFRSF6 (FAS) variant with increased double-negative T cells ALPS-FAS Poli 2025
Adult-onset susceptibility to environmental mycobacteria Autoantibody to interferon-γ Mendelian susceptibility to mycobacterial disease Poli 2025
Chronic mucocutaneous candidiasis with endocrinopathy Autoantibody to IL-17A and/or IL-17F Chronic mucocutaneous candidiasis Poli 2025
Pulmonary alveolar proteinosis Autoantibody to GM-CSF CSF2RA deficiency Poli 2025
Recurrent staphylococcal skin infection Autoantibody to IL-6 STAT3 deficiency Poli 2025
Acquired angioedema Autoantibody to C1 inhibitor C1 inhibitor deficiency Poli 2025
Thymoma with hypogammaglobulinemia (Good syndrome) Autoantibodies to cytokines including type I interferons; absent B cells, low CD4 T cells Not specified Poli 2025
VEXAS syndrome Somatic UBA1 variant; late-onset inflammatory syndrome Not specified Poli 2025
  • Isotypes measured. IgG, IgA, IgM and IgE are measured in the evaluation of antibody deficiency. Age-related local reference intervals are required, and 2.5%–5% of healthy people fall below the defined norms for each age group (Bonilla 2016). Rate nephelometry established reference intervals for IgG, IgA and IgM in 750 children and 120 adults, and earlier intervals were based on immunodiffusion (Jolliff 1982).
  • Postnatal course. IgG is high at birth from transplacental maternal transfer, reaches a nadir between 3 and 6 months and then rises (Bonilla 2016). IgA is very low in the newborn period and increases with age (Bayram 2019).
  • Repeat measurement. Intercurrent illness and fluid shifts alter immunoglobulin concentrations. A diagnosis requires persistently low levels before IgG therapy is started (Bonilla 2016).

Serum immunoglobulins in healthy children by nephelometry (mg/dL, mean ± SD; 30 children per group).

Age IgG IgA IgM Source
0–30 days 953 ± 262 6.8 ± 0.5 20 ± 9 Bayram 2019
4–6 months 482 ± 237 20 ± 10 75 ± 30 Bayram 2019
13–24 months 762 ± 239 38 ± 17 123 ± 42 Bayram 2019
6–8 years 1015 ± 256 107 ± 50 115 ± 41 Bayram 2019
16–18 years 1323 ± 362 202 ± 90 143 ± 64 Bayram 2019

Specific antibody responses to vaccines and isohemagglutinins

  • Protein antigens (T-dependent responses). Diphtheria and tetanus toxoids and Haemophilus influenzae type b conjugate vaccine test T-dependent responses. Protective levels are 0.15 IU/mL for diphtheria and tetanus toxoids and 1 µg/mL for H influenzae type b polysaccharide. When levels are low, the vaccine is given and specific IgG is measured again after 3–6 weeks (Bonilla 2016).
  • Polysaccharide antigens (T-independent responses). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) tests T-independent responses. A postimmunization sample is required because preimmunization sera contain cross-reactive antipolysaccharide antibodies (Bonilla 2016). A type-specific IgG of 1.3 µg/mL after a pure polysaccharide vaccine is considered protective for that serotype (Bonilla 2016).
  • Isohemagglutinins. Isohemagglutinins are naturally occurring IgM and IgG antibodies to ABO polysaccharide antigens. Their titers assess T-independent function in young children and in patients already receiving IgG therapy (Bonilla 2016).
  • Assay variability. Interpretation of pneumococcal responses is complicated by historical changes in assays and by varying cut points, particularly for serotype data from multiplex assays (Daly 2015).

Interpretation of the PPSV23 response (Orange 2012, as restated by Zuzolo 2025).

Item Rule Source
Protective response to one serotype ≥1.3 µg/mL with a 2- to 4-fold rise from baseline Zuzolo 2025
Normal response, age 2–5 years ≥50% of serotypes tested Zuzolo 2025
Normal response, age 6–65 years ≥70% of serotypes tested Zuzolo 2025
Severe phenotype, both age groups ≤2 protective titers after vaccination Zuzolo 2025
Interpretable serotypes after PCV13 11 serotypes in PPSV23 and absent from PCV13 Zuzolo 2025
Interpretable serotypes after PCV20 4 serotypes (2, 9N, 17F and 20) Zuzolo 2025
  • Conjugate vaccines and polysaccharide assessment. Conjugate pneumococcal vaccine responses are T-dependent. Widespread PCV13, PCV15 and PCV20 use leaves few unique PPSV23 serotypes for a T-independent assessment (Zuzolo 2025).
  • Performance of reduced serotype panels. In a retrospective series, analysis of the 11 serotypes absent from PCV13, or the 4 serotypes absent from PCV20, kept a diagnostic accuracy of 81%–84% (Zuzolo 2025). Serotype immunogenicity varied: 19F and 22F were protective in 97.4% of subjects, and 12F in 43.2% (Zuzolo 2025).

Lymphocyte subsets and T-cell function

  • Age dependence. In 807 healthy children from birth through 18 years, age was the most important variable for 24 lymphocyte subsets, including CD4 and CD8 T cells, CD19 B cells and naive (CD4 CD45RA CD62L) T cells. The testing laboratory was also an important variable (Shearer 2003).
  • Flow cytometry for IEI. Flow cytometry identifies SCID, X-linked agammaglobulinemia, hyper-IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome, familial HLH, ALPS, IPEX, CTLA4 and LRBA deficiency and chronic granulomatous disease by cell populations, intracellular proteins and functional readouts (Kanegane 2018). Methods for lymphocyte subset enumeration are taught in the hematopathology flow cytometry hub.
  • Proliferation to mitogens. In 307 PIDTC patients with SCID, flow cytometric PHA proliferation assays gave higher responses than tritiated thymidine assays when CD3 T cells were 51–300 cells/µL. Many SCID patients with profound T lymphopenia had normal flow-based proliferation, and the test is considered supportive only (Abraham 2024).
  • Interferon-gamma release assays. All indeterminate QuantiFERON-TB Gold In-Tube results in an inpatient series were due to a low mitogen response. Lymphopenia (adjusted odds ratio 2.21) and hypoalbuminemia (adjusted odds ratio 6.81) predicted indeterminate results (Fabre 2014). IGRA methods are taught in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.

Common variable immunodeficiency

ICON 2016 consensus definition. Hypogammaglobulinemia (IgG) defined by the age-adjusted reference range of the testing laboratory and low on at least 2 measurements more than 3 weeks apart; IgA or IgM also low; when IgG is >100 mg/dL, impaired response to at least 1 type of antigen (T-dependent or T-independent); and exclusion of other causes of hypogammaglobulinemia (Bonilla 2016). Repeat measurement may be omitted when IgG is very low (<100–300 mg/dL depending on age) (Bonilla 2016).

  • Previous definition (ESID/PAGID 1999, as quoted in ICON). IgG at least 2 SD below the mean for age with a marked decrease in IgM or IgA, onset after age 2 years, absent isohemagglutinins and/or a poor vaccine response, and exclusion of defined causes (Bonilla 2016).

  • Age at diagnosis. The diagnosis is best not conferred before 4 years of age (Bonilla 2016).

  • IgG level. An absolute adult lower limit of 4.5 g/L has been proposed, and some patients have IgG up to 6 g/L with impaired specific antibody formation (Bonilla 2016). Specific antibody testing may be omitted when IgG is <100 mg/dL (Bonilla 2016).

  • Normal or high IgM. Low IgG and IgA with normal or high IgM prompts evaluation for hyper-IgM syndromes and class-switch recombination defects before CVID is diagnosed (Bonilla 2016).

  • Monogenic causes. Apart from known monogenic forms, no cause is found in 98% of patients with CVID (Bonilla 2016). Application of the ESID registry criteria reclassified 8% of adults and 27% of children registered as CVID to 22 other immunodeficiencies (Seidel 2019).

  • EUROclass B-cell phenotyping. In 303 patients, EUROclass separated nearly absent B cells (<1%), severely reduced switched memory B cells (<2%), expanded transitional B cells (>9%) and expanded CD21-low B cells (>10%). Reduced switched memory B cells were associated with splenomegaly and granulomatous disease, and expanded CD21-low B cells marked splenomegaly (Wehr 2008).

  • IUIS placement. CVID with no gene defect specified is listed in the IUIS table of antibody deficiencies with low IgG and IgA and/or IgM (Poli 2025).

Selective IgA deficiency and specific antibody deficiency

  • Definition of IgA deficiency. Serum IgA <7 mg/dL (0.07 g/L) with normal IgG and IgM in a patient older than 4 years, after exclusion of other causes of hypogammaglobulinemia. The 4-year threshold avoids diagnosing transient IgA deficiency from delayed ontogeny. IgA above 7 mg/dL but more than 2 SD below the mean for age is called partial IgA deficiency (Yel 2010).
  • Associations. IgA deficiency is associated with giardiasis, celiac disease and autoimmune disease. IgE anti-IgA is the isotype capable of a type I reaction, but the test is not readily available, and IgG anti-IgA is measured as a screening tool (Yel 2010). Anaphylaxis to blood products from anti-IgA is taught in Transfusion Reactions, and celiac serology in IgA deficiency in Liver, Kidney and Gastrointestinal Function Tests.
  • Specific antibody deficiency. IUIS defines specific antibody deficiency as normal immunoglobulin levels and normal B cells with a reduced ability to produce antibodies to specific antigens (Poli 2025).
  • Transient hypogammaglobulinemia of infancy. IgG and IgA are decreased, vaccine responses are normal and significant infections are uncommon (Poli 2025).

Severe combined immunodeficiency: PIDTC 2022 definitions and the 2014 criteria

Typical SCID (PIDTC 2022). Autologous T cells <0.05 × 10⁹/L on repeated testing, plus a pathogenic variant in a SCID gene, very low or undetectable TRECs or <20% naive CD4 T cells, and/or transplacental maternal T-cell engraftment (Dvorak 2023).

  • Previous rule (PIDTC 2014). In the absence of maternal engraftment, the T-cell threshold for typical SCID was <0.3 × 10⁹/L (Dvorak 2023). The 2014 criteria were applied to 332 children treated at 27 North American centers from 2000 to 2009. Failure to show impaired lymphocyte proliferation or maternal engraftment was the main reason for ineligibility (Shearer 2014).
  • Repeat counts. T-cell enumeration is repeated before treatment. Without an identified variant, counts must stay <0.05 × 10⁹/L for at least 8 weeks, and the second value assigns the subtype (Dvorak 2023).
  • Genetics. Seven genes (IL2RG, RAG1, RAG2, ADA, DCLRE1C, IL7R and JAK3) account for at least 80% of SCID cases (Dvorak 2023). The ClinGen SCID variant curation expert panel modified 20 of the 28 ACMG/AMP criteria for these 7 genes (Jacovas 2026).

Lymphocyte phenotypes of SCID and related combined immunodeficiencies (IUIS 2024, Table 1).

Disease (gene, inheritance) T cells B cells NK cells and other features Source
γc deficiency (IL2RG, XL) Very low Normal to high Low NK Poli 2025
JAK3 deficiency (JAK3, AR) Very low Normal to high Low NK Poli 2025
IL-7Rα deficiency (IL7R, AR) Very low Normal to high Normal NK Poli 2025
RAG deficiency (RAG1, RAG2, AR) Very low Very low Normal NK Poli 2025
Artemis deficiency (DCLRE1C, AR) Very low Very low Normal NK; radiation sensitivity Poli 2025
ADA deficiency (ADA, AR) Very low Low, decreasing Low NK; bone defects; sensorineural deafness Poli 2025
Reticular dysgenesis (AK2, AR) Very low Very low Neutropenia; deafness Poli 2025
PNP deficiency (PNP, AR) Progressive decrease Normal Autoimmune hemolytic anemia; neurologic impairment Poli 2025
MHC class II deficiency (CIITA, RFXANK, RFX5, RFXAP, AR) Low CD4 T cells; reduced MHC class II expression on lymphocytes Normal Gastrointestinal and respiratory infections; liver and biliary disease Poli 2025
ZAP-70 deficiency (ZAP70, AR) Low CD8 T cells; normal CD4 number with poor function Normal Immune dysregulation and autoimmunity Poli 2025

Leaky/atypical SCID and Omenn syndrome (PIDTC 2022).

Category 2022 definition Source
Leaky/atypical SCID ≥2 of: T cells <0.6 × 10⁹/L at any age (<0.8 at 2–4 years, <1.0 under 2 years); oligoclonal T cells; low naive T cells and/or low or undetectable TRECs. A pathogenic SCID gene variant or PHA, anti-CD3 or anti-CD28 proliferation <50% of the lower reference limit is also required Dvorak 2023
Omenn syndrome Generalized erythematous rash; absent maternal engraftment; >80% of CD4 T cells CD45RO-positive; any T-cell number; confirmed genotype; ≥2 of abnormal TRECs, eosinophilia, elevated IgE, lymphadenopathy, organomegaly, oligoclonal T cells Dvorak 2023 (Table I)
Suspected SCID CD3 T cells <0.3 × 10⁹/L or <20% naive CD4 T cells with an abnormal TREC result, family history or recurrent or opportunistic infection; a temporary assignment pending a definitive diagnosis Dvorak 2023
  • Omenn syndrome, previous rule. The PIDTC 2014 criteria required more than 0.3 × 10⁹/L T cells for Omenn syndrome. The 2022 definitions accept any T-cell number (Dvorak 2023).
  • TRECs in Omenn syndrome. Normal TRECs exclude Omenn syndrome (Dvorak 2023).
  • Maternal T-cell engraftment. Maternal engraftment is found in about 50% of patients with typical SCID (Dvorak 2023). In 121 infants with SCID, maternal T cells were detected in 48 and ranged from fewer than 100/µL to more than 2000/µL. Prominent skin graft-versus-host disease was associated with CD4-predominant maternal T cells that responded to mitogens (Müller 2001). Engraftment is tested in whole blood or isolated CD3 T cells by short tandem repeat DNA typing. FISH for a second X chromosome in male infants was used historically (Dvorak 2023). Chimerism methods are covered in HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.
  • Non-SCID T lymphopenia. Thymic defects (22q11.2 deletion and FOXN1, TBX1 or CHD7 variants), vascular leakage, in utero immunosuppressive exposure, congenital HIV infection, folate transport defects and aneuploidy are excluded from the definition of SCID (Dvorak 2023).

TREC newborn screening for SCID

  • Method. TRECs are DNA episomes of newly formed T cells, quantified by real-time PCR on DNA from dried blood spots with a control gene such as β-actin (Chan 2005). In the original study, routine newborn spots had a mean of 1020 TRECs in two 3-mm punches, and 23 infants with SCID had <30 TRECs (Chan 2005).
  • KRECs. A triplex PCR of TRECs and κ-deleting recombination excision circles (KRECs) on one Guthrie card punch identified SCID, X-linked agammaglobulinemia, ataxia-telangiectasia and Nijmegen breakage syndrome (Borte 2012).
  • United States program. SCID was added to the Recommended Uniform Screening Panel in 2010, and adoption by all 50 states, Washington DC, Guam and Puerto Rico took 8.6 years (Singh 2023).
  • Yield. Across 11 programs and 3,030,083 newborns, screening found typical SCID, leaky SCID and Omenn syndrome in 1 in 58,000 infants (Kwan 2014). In California from 2010 to 2017, clinically significant T-cell lymphopenia was found in 1 in 15,300 births and SCID in 1 in 65,000. Two infants with delayed-onset leaky SCID had normal neonatal TREC results (Amatuni 2019).
  • Positive predictive value. In California, 562 infants (1 in 5800 births) had a nonnormal TREC screen followed by flow cytometry, and 50 had SCID (about 9%). NICU infants were 9% of births but 53% of nonnormal screens (Amatuni 2019). Across 6 US programs, 36% of infants referred for flow cytometry had T-cell lymphopenia <1500/µL (Kwan 2014). Typical and atypical SCID make up about 10% of infants with abnormal TRECs and T lymphopenia, and the other 90% have non-SCID causes (Buchbinder 2021).
  • Non-SCID causes of low TRECs. In decreasing order in California: DiGeorge syndrome, trisomy 21, ataxia-telangiectasia, CHARGE syndrome and diabetic embryopathy (Buchbinder 2021). In utero exposure to purine antagonists caused profound, self-resolving T lymphopenia detected by screening (Kuo 2017). About 5% of patients with 22q11.2 deletion have low TRECs and <1500 CD3 T cells/µL in the neonatal period (Poli 2025).
  • Preterm infants. Preterm newborns have a disproportionate share of false-positive results, and multistate data normalized as multiples of the median support modified screening practices for premature and low-birth-weight infants (Gaviglio 2023). Low TRECs in premature infants often improve with age (Buchbinder 2021).

Follow-up testing after an abnormal TREC screen (PIDTC 2022).

Test Purpose Source
CBC with differential Lymphopenia; eosinophilia as a sign of maternal GVHD or Omenn syndrome Dvorak 2023
T, B and NK cells; naive and memory CD4 T cells SCID phenotype; CD4 naive cells reflect thymic output Dvorak 2023
Repeat TREC with genomic control (actin or RNaseP) Confirmation Dvorak 2023
Quantitative immunoglobulins including IgE IgE as a sign of Omenn syndrome Dvorak 2023
Maternal engraftment testing Typical SCID assignment Dvorak 2023
PHA, anti-CD3 or anti-CD3/CD28 proliferation Supportive; may be omitted when typical SCID criteria are met Dvorak 2023
HIV nucleic acid test or documented negative maternal antibody Exclusion of congenital HIV infection Dvorak 2023

Laboratory findings and confirmatory tests in selected inborn errors of immunity

IEI (gene) Key laboratory findings Confirmatory test Source
X-linked agammaglobulinemia (BTK) All isotypes decreased; profoundly decreased or absent B cells Intracellular BTK protein in monocytes by flow cytometry; BTK sequencing Poli 2025; Igonina 2026
CD40 ligand deficiency (CD40LG), X-linked IgM normal or high, other isotypes low; IgG, IgA and IgE memory B cells absent Flow cytometry; CD40LG sequencing Poli 2025; Kanegane 2018
Wiskott-Aldrich syndrome (WAS), X-linked Thrombocytopenia with small platelets; low IgM; often high IgA and IgE; poor polysaccharide responses WAS protein by flow cytometry; WAS sequencing Poli 2025; Basu 2024
22q11.2 deletion syndrome T cells decreased or normal; hypoparathyroidism; conotruncal cardiac defects Karyotype and comparative genomic hybridization array Poli 2025; Buchbinder 2021
STAT3 hyper-IgE syndrome (autosomal dominant) IgE >1000 IU/mL; reduced Th17 cells; reduced memory B cells Dominant-negative STAT3 variant Woellner 2010; Poli 2025
DOCK8 deficiency (autosomal recessive) T lymphopenia; low IgM; very high IgE; eosinophilia DOCK8 sequencing Poli 2025; Zhang 2009
IPEX (FOXP3), X-linked Absent or dysfunctional CD4+ CD25+ FOXP3+ regulatory T cells; high IgE and IgA Flow cytometry; FOXP3 sequencing Poli 2025; Kanegane 2018
ALPS-FAS Increased TCRαβ+ CD4− CD8− double-negative T cells; elevated FAS ligand, IL-10 and vitamin B12 Germline or somatic FAS sequencing Poli 2025; Rensing-Ehl 2013
  • Agammaglobulinemia (ESID registry definition). Recurrent infections before age 5 years, IgG <500 mg/dL, IgA and IgM below −2 SD and <2% circulating B cells. XLA accounts for about 85% of agammaglobulinemia (Olaya Hernández 2026).
  • BTK flow cytometry. An intracellular BTK assay in monocytes detected abnormal expression in 38 of 40 patients with pathogenic BTK variants (sensitivity 95%, specificity 100%) and supports carrier evaluation in females (Igonina 2026).
  • WASP flow cytometry. Flow cytometry for WAS protein in lymphocytes, monocytes and neutrophils is a rapid, low-cost test for female carriers. Carriers with variants in distal exons can have normal expression, and genetic testing remains the reference standard (Basu 2024).
  • 22q11.2 deletion. The deletion arises in about 1 in 1000 fetuses and is the most common chromosomal microdeletion disorder (McDonald-McGinn 2015).
  • STAT3 hyper-IgE syndrome scoring. The diagnosis is possible with IgE ≥1000 IU/mL and a weighted clinical score >30 based on recurrent pneumonia, newborn rash, pathologic fractures, characteristic face and high palate. It is probable with absent Th17 cells or a family history, and definitive with a dominant-negative heterozygous STAT3 variant (Woellner 2010).
  • DOCK8 deficiency. Patients had recurrent sinopulmonary infections, severe cutaneous herpes simplex, herpes zoster, molluscum contagiosum and papillomavirus infections, severe atopy and squamous cell carcinoma, with low IgM and hypereosinophilia (Zhang 2009).
  • ALPS biomarkers. In 163 patients with lymphoproliferation and autoimmune cytopenia, vitamin B12 >1255 pg/mL combined with soluble FAS ligand >559 pg/mL predicted FAS variants with a positive predictive value of 92% and a negative predictive value of 97%. Double-negative T cells had a positive predictive value of 61%, and 15% of patients had somatic FAS variants (Rensing-Ehl 2013). In a pediatric series, soluble FAS ligand correlated with vitamin B12 and discriminated ALPS with appropriate thresholds (Fernandez 2024).
  • Revised NIH 2009 ALPS criteria. Required: chronic nonmalignant lymphoproliferation (lymphadenopathy and/or splenomegaly) and elevated peripheral blood TCRαβ+ double-negative T cells. Primary accessory: defective in vitro Fas-mediated apoptosis in 2 separate assays, or a somatic or germline variant in FAS, FASLG or CASP10. Secondary accessory: plasma soluble FAS ligand >200 pg/mL, IL-10 >20 pg/mL, vitamin B12 >1500 ng/L or IL-18 >500 pg/mL; typical immunohistochemistry; autoimmune cytopenias with polyclonal hypergammaglobulinemia; or a family history. Definitive ALPS requires both required criteria plus 1 primary accessory criterion, and probable ALPS both required criteria plus 1 secondary accessory criterion (Oliveira 2010, as tabulated by Palmisani 2023). An Italian network used double-negative T cells >1.5% of total lymphocytes in its flow cytometry screening panel (Palmisani 2023).

Genetic testing for inborn errors of immunity

  • Protein expression before sequencing. Genetic analysis establishes the definitive diagnosis but takes time and is costly. Flow cytometry gives a rapid, low-cost assessment of many IEIs (Kanegane 2018).
  • Gene-specific variant rules. The ClinGen SCID expert panel validated its specifications on 90 variants and resolved 17 variants with conflicting ClinVar classifications (Jacovas 2026).

Secondary immunodeficiency and secondary hypogammaglobulinemia

  • Causes. Immunosuppressive medications and protein loss syndromes are the main histories that raise suspicion of secondary hypogammaglobulinemia. Management identifies iatrogenic causes and treats the underlying condition (Otani 2022). Glucocorticoids, antiepileptic drugs, rituximab, chronic lymphocytic leukemia, lymphoma, nephrotic syndrome, protein-losing enteropathy and congenital lymphangiectasia are listed in the differential diagnosis of CVID (Bonilla 2016).
  • Rituximab. Rituximab depletes CD20-expressing B cells and causes hypogammaglobulinemia and late-onset neutropenia. Immunoglobulin levels and peripheral B-cell counts by flow cytometry are measured at baseline and periodically after therapy. Prolonged hypogammaglobulinemia with infections after rituximab prompts evaluation for an IEI (Athni 2023).
  • HIV infection. CD4 T-cell counts in HIV infection are taught in the hematopathology flow cytometry and virology hubs.

Allergy and Hypersensitivity Testing: Total and Specific IgE, Component Diagnostics, Tryptase and Basophil Activation

Definition. Allergy testing confirms IgE sensitization in vivo by skin tests or in vitro by allergen-specific IgE (sIgE) assays (Ansotegui 2020). Sensitization is the presence of sIgE, and allergy is sensitization with clinical symptoms on exposure to the allergen (Ansotegui 2020). Mast cell activation is documented by an event-related rise in serum tryptase over the individual baseline (Valent 2019). Cellular tests include the basophil activation test (BAT) for immediate reactions and the lymphocyte transformation test (LTT) for T-cell-mediated drug reactions (Mayorga 2024; Pichler 2004).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (immunoassay formats, heterophile antibodies and the hook effect) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (immunoglobulin quantitation, hyper-IgE syndromes) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (HLA-B57:01, HLA-B15:02, HLA-A31:01 and HLA-B58:01 in drug hypersensitivity) Related page: Transfusion Reactions (allergic and anaphylactic transfusion reactions, anti-IgA) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (tryptase in hyperbasophilia and eosinophilia)

Classification of hypersensitivity reactions: EAACI 2023 nomenclature and Gell and Coombs

The EAACI 2023 position paper extends the four Gell and Coombs types to nine mechanisms (Jutel 2023).

Type (EAACI 2023) Mechanism Corresponding Gell and Coombs type Source
I–III Antibody-mediated Types I–III Jutel 2023
IVa, IVb, IVc Cell-mediated, by T1, T2 and T3 responses Type IV Jutel 2023
V–VI Tissue-driven mechanisms No equivalent Jutel 2023
VII Direct response to chemicals No equivalent Jutel 2023
  • Drug hypersensitivity. A drug hypersensitivity reaction is a drug reaction that resembles allergy. The term drug allergy is reserved for reactions with evidence of drug-specific antibodies or T cells (Demoly 2014).
  • Laboratory tests by mechanism. IgE-mediated reactions are tested by skin tests, sIgE, tryptase and BAT (Ansotegui 2020; Valent 2020). Drug-specific T cells are tested by the LTT (Pichler 2004). Complement and immune complex tests are taught in Complement Testing, Hereditary Angioedema, Cryoglobulins, Cytokines and Soluble IL-2 Receptor.

Total serum IgE

  • First assay. The first solid-phase sandwich immunoassay for total and specific IgE was described in 1967 (Ansotegui 2020; Wide 1967).
  • Age dependence. Cord serum IgE is <4.8 ng/mL. IgE increases to age 15 years and declines from the second through the eighth decades (Ansotegui 2020).
  • Limited diagnostic value. Total IgE is not a reliable marker of allergic status. High values are associated with atopic disorders, and low or normal values do not exclude IgE-mediated disease (Ansotegui 2020).
  • Very high IgE. Very high IgE occurs with parasitic infestation, rare IgE myeloma and IEIs including IPEX, Omenn syndrome, Wiskott-Aldrich syndrome, Comel-Netherton syndrome, hyper-IgE syndrome and atypical complete DiGeorge syndrome. Allergic bronchopulmonary aspergillosis is the only condition in which the IgE level is strictly related to disease severity. Some smokers have increased IgE (Ansotegui 2020).
  • ABPA criteria (ISHAM-AWG 2024). Diagnosis requires fungal sensitization and total IgE ≥500 IU/mL plus 2 of fungus-specific IgG, peripheral blood eosinophilia or suggestive imaging. Aspergillus fumigatus sIgE ≥0.35 kUA/L defines sensitization. The previous ISHAM-AWG cutoff was total IgE ≥1000 IU/mL, and the lower cutoff is more sensitive (98% versus 91%) (Agarwal 2024).
  • Proficiency testing. In College of American Pathologists proficiency surveys, interlaboratory and intermethod coefficients of variation for 6 total IgE assays were below 15% (Hamilton 2010).

Allergen-specific IgE assays

  • RAST. The radioallergosorbent test used allergen coupled to paper discs and ¹²⁵I-labeled anti-IgE (Ansotegui 2020; Wide 1967). Since 2010, NIAID/NIH has recommended discontinuing RAST in favor of fluorescence enzyme-labeled assays (Ansotegui 2020).
  • Positivity thresholds. Commercial sIgE assays use positivity thresholds from 0.1 to 0.35 kUA/L, and ≥0.35 kU/L is the threshold most widely used across assays (Shifani 2026).
  • Current methods. sIgE assays include ELISA, fluorescence enzyme immunoassay (FEIA), chemiluminescent assays and radioallergosorbent assays. ImmunoCAP is regarded as the reference standard for in vitro IgE testing (Ansotegui 2020). Results are reported in kU/L or kUA/L (Nieminen 2025; Machinena-Spera 2026).
  • Calibration. Quantitative assays interpolate results from a multipoint calibration curve and report units traceable to an international standard (WHO 11/234) (Ansotegui 2020).
  • Method disagreement. Allergen-specific IgE results differ between systems, especially at the low end of the range (Ansotegui 2020). In proficiency surveys, intramethod agreement was good. Between-assay disagreement exceeded 20% in 80% of sIgE measurements, and allergen reagents were the probable cause (Hamilton 2010). Chemiluminescent assays are more often positive at low sIgE levels than ELISA (Ansotegui 2020).
  • Predictive decision points. Food-specific IgE concentrations established in children with atopic dermatitis predicted clinical reactivity to egg, milk, peanut and fish with >95% certainty, and the decision points were evaluated prospectively in 100 children (Sampson 2001).
  • Food-specific IgG4. IgG4 to foods indicates repeated exposure to food components. Testing is not recommended for the diagnosis of food hypersensitivity (Stapel 2008).
  • Drug allergy. sIgE tests are of little or no value for most drug allergies, and few drug reagents exist (Ansotegui 2020).
  • Omalizumab interference. Omalizumab forms IgE:anti-IgE complexes. In proficiency samples sent to 159 laboratories, it reduced total IgE by 2.4%–9.0% in ImmunoCAP assays and by 12.5%–67.2% in 5 other assays, and reduced allergen-specific IgE by 0.8%–27.8% (Hamilton 2006).
  • CAP inhibition. Preincubation of serum with soluble allergen before the solid-phase allergen distinguishes multiple sensitizations from cross-reactivity, particularly in Hymenoptera venom allergy (Ansotegui 2020).
  • Hymenoptera venom. Skin tests and serum IgE are both used, and the positive predictive value depends on the history. Evaluation may include venom component testing. Baseline serum tryptase is routine in venom allergy, and KIT mutation testing in peripheral blood and tryptase genotyping are supplemental tests (Golden 2025).
  • Venom components. A panel of rApi m 1 and rApi m 10 (honeybee) and rVes v 1 and rVes v 5 (yellow jacket) identified the culprit venom in all but 2 of 87 patients, and neither venom sIgE nor rApi m 1 sIgE was associated with reaction severity (Gattinger 2018). Ves v 5 had a sensitivity of 78.5% for isolated wasp allergy (92.3% combined with Ves v 1), and Api m 1 a sensitivity of 25% for isolated honeybee allergy. Hyaluronidases (Api m 2, Ves v 2) and dipeptidyl peptidases IV (Api m 5, Ves v 3) cross-react between species (Turkalj 2025).
  • Diagnostic accuracy across foods. A meta-analysis of 149 studies with 24,489 patients found that skin prick tests and extract sIgE had high sensitivity, and component sIgE and BAT had high specificity (Riggioni 2024).

Skin testing controls and technique

  • Controls. Each skin test includes a positive control (histamine phosphate 2.7 mg/mL, equivalent to 1 mg/mL histamine base) and a negative control (saline or 50% glycerinated human serum albumin-saline). The positive control detects suppression by medication or disease. The negative control detects traumatic reactivity from the device or technique, and some devices produce a negative-control wheal approaching 3 mm (Ansotegui 2020).
  • Intradermal testing. About 0.02 mL of allergen, diluted 10- to 1000-fold from the prick concentration, is injected, and the wheal is read at 20 minutes. Intradermal tests are preceded by a skin prick test (Ansotegui 2020).
  • Clinical relevance. In a GA2LEN survey of 3068 patients, 40% (cockroach) to 87%–89% (grass and house dust mite) of positive prick wheals were associated with reported symptoms (Ansotegui 2020).

Skin prick test compared with serum specific IgE.

Feature Skin prick test Serum sIgE Source
Time to result Tens of minutes A few hours Ansotegui 2020
Allergen range Nearly any allergen, including prick-to-prick with fresh food Commercial extracts and components Ansotegui 2020
Drug effects H1-antihistamines stopped 4–5 days (ideally 7 days) before testing; omalizumab: prick tests possible after 6 weeks, but false negatives can occur up to 1 year Not applicable Ansotegui 2020
Relation to symptoms Larger wheals associated with a higher prevalence of symptoms for most allergens Quantitative level; component results add specificity Ansotegui 2020; Riggioni 2024
Sensitivity for cow's milk and raw egg allergy 90% and 94% Extract sIgE sensitivity is high; component sIgE specificity is high Riggioni 2024

Multiplex allergen arrays

  • Microarrays. The ImmunoCAP ISAC microarray began with 74 allergen proteins, and a version with 112 allergens followed (Ansotegui 2020). Arrays with more than 100 components support component-resolved diagnosis (Altmann 2016).
  • Extract and component discordance. A positive extract with negative components indicates IgE to molecules not available as components, a less sensitive molecular assay, or IgE to cross-reactive minor molecules or carbohydrate determinants (Ansotegui 2020).

Component-resolved diagnosis

  • Guidance. The EAACI Molecular Allergology User's Guide 2.0 (2023) updates the 2016 first edition with allergen molecules, their clinical relevance and diagnostic algorithms (Dramburg 2023). The 2016 edition describes panallergen families from plants (lipid transfer proteins, polcalcins, PR-10 proteins, profilins) and animals (lipocalins, parvalbumins, serum albumins, tropomyosins). IgE to individual components distinguishes cross-reactivity from primary sensitization (Matricardi 2016).
  • Classes of components. Components are classified by cross-reactivity, risk and stability. Ara h 1 is potentially dangerous and Ara h 8 virtually innocuous. Phl p 12 is a pan-allergen. Mal d 1 is sensitive to heat, low pH and gut peptidases, and Pru p 3 is resistant to all three (Ansotegui 2020).
  • Severity markers. Bos d 8 (casein) >1.8 kUA/L raised the risk of anaphylaxis in children with cow's milk allergy up to 6-fold (specificity 77%, sensitivity 65%). Gal d 1 (ovomucoid) is heat-stable, and a cutoff ≥10 kU/L had a specificity of 95% for more severe reactions to raw and cooked egg (Turkalj 2025).
  • Panallergen families. Parvalbumins (Gad c 1 in cod, Cyp c 1 in carp) and tropomyosin (Pen m 1 in shrimp) are animal panallergens, and profilin (Phl p 12) is a plant panallergen. IgE to CCDs or profilin can give a positive test without allergy (Turkalj 2025). The ratio of allergen-specific to total IgE is one of the factors that determine effector cell activation (Turkalj 2025).
  • Food allergy guideline. sIgE to Ara h 2 (peanut), Cor a 14 (hazelnut) and Ana o 3 (cashew) supports the diagnosis, especially in pollen-sensitized individuals. The oral food challenge is the reference standard (Santos 2023).

Allergen components with diagnostic data.

Component (source) Clinical meaning Performance Source
Ara h 2 (peanut) 2S albumin storage protein; supports peanut allergy Specificity 92% Santos 2023; Riggioni 2024; Turkalj 2025
Ara h 6 (peanut) 2S albumin storage protein Not applicable Turkalj 2025
Ara h 8 (peanut) Virtually innocuous component Not applicable Ansotegui 2020
Cor a 14 (hazelnut) Supports hazelnut allergy Specificity 95% Santos 2023; Riggioni 2024
Ana o 3 (cashew) Supports cashew allergy Specificity 94% Santos 2023; Riggioni 2024
Casein, Bos d 8 (cow's milk) Predicts heated milk tolerance Specificity 93% for milk allergy; <0.54 kU/L predicts tolerance with 95% sensitivity and >14.1 kU/L predicts reaction with 95% specificity Riggioni 2024; Nieminen 2025
Ovomucoid, Gal d 1 (egg) Predicts baked egg tolerance Specificity 92% for raw and 91% for cooked egg; cutoff 4.48 kUA/L for baked egg with sensitivity 68.2% and specificity 79.3% Riggioni 2024; Machinena-Spera 2026
Pru p 3 (peach) Component resistant to heat, low pH and gut peptidases Not applicable Ansotegui 2020
Galactose-α-1,3-galactose Delayed reactions to mammalian meat Not applicable Commins 2009; Wilson 2024

Alpha-gal syndrome

  • Clinical pattern. Patients with IgE to galactose-α-1,3-galactose (alpha-gal) reported anaphylaxis or urticaria 3–6 hours after eating beef, pork or lamb. IgE to beef, pork, lamb, cow's milk, cat and dog was explained by alpha-gal IgE, and turkey, chicken and fish were negative (Commins 2009).
  • Ticks. In the United States, alpha-gal syndrome is linked to bites of Amblyomma americanum (lone star tick) (Wilson 2024).
  • Testing. Sensitization is identified by alpha-gal sIgE. Commercial prick tests with meat have limited sensitivity, and intradermal or fresh-meat prick-to-prick tests are often required (Wilson 2024). Commercial meat skin prick tests produced wheals usually <4 mm (Commins 2009).
  • Sensitization without disease. Many people sensitized to alpha-gal tolerate mammalian meat (Wilson 2024).
  • Cetuximab. Investigation of first-infusion anaphylaxis to cetuximab led to recognition of IgE to alpha-gal in the southeastern United States (Wilson 2024).

Cross-reactive carbohydrate determinants

  • Structure. Cross-reactive carbohydrate determinants (CCDs) of plant and insect allergens are α-1,3-fucose residues on N-glycans (Altmann 2016).
  • Clinical relevance. Anti-CCD IgE does not cause noticeable symptoms, and CCD-based results are rated as false positives. Up to 30% of patients can be CCD-reactive (Altmann 2016).
  • Remedies. Nonglycosylated recombinant components and CCD inhibitors remove CCD interference (Altmann 2016).

Tryptase and mast cell activation

  • Kinetics. After experimental bee-sting anaphylaxis, tryptase peaked 1–2 hours after the sting, and histamine peaked at 5–10 minutes. Tryptase may not be elevated during the first 15–30 minutes and then declines with a half-life of about 2 hours (Schwartz 1989).
  • Specimen stability. Tryptase in serum or plasma is not reduced by up to 4 freeze-thaw cycles. More than 50% of endogenous tryptase remained after 4 days at 22 °C or 37 °C (Schwartz 1989).
  • Reference interval. The physiologic serum tryptase in healthy adults ranges from 0 to 11.4 ng/mL. Tryptase genotyping is considered at a level ≥8 ng/mL to evaluate for hereditary α-tryptasemia (Valent 2020).
  • Sampling window. After systemic mast cell activation, tryptase returns to baseline over several hours (up to 24 h), giving a diagnostic window of about 2–4 h after the event (Valent 2019). Baseline tryptase is measured after complete recovery, at least 24–48 h after resolution of symptoms, or in a symptom-free interval (Valent 2020). The 2023 AAAAI/ACAAI practice parameter supports serum tryptase measurement for the diagnosis of anaphylaxis and for identification of underlying mast cell disorders (Golden 2024).
  • Total and mature tryptase. Resting mast cells spontaneously secrete protryptases, and mature tryptase is retained in granules until degranulation (Schwartz 2003). Serum total tryptase in healthy adults is 1–11.4 ng/mL, and mature tryptase is <1 ng/mL (Lyons 2016). Mature tryptase was not detectable in basal serum of people with hereditary α-tryptasemia (Mateja 2022).

The 20% + 2 formula for mast cell activation

  • Origin. The formula was proposed by the consensus group in 2012 (Valent 2019). The 2012 consensus defined mast cell activation by typical symptoms, a substantial transient increase in serum total tryptase or other mast cell mediators, and response to mediator-targeted therapy. It classified MCAS as primary, secondary or idiopathic (Valent 2012).
  • Validation. Independent groups validated the formula in clinical practice, and the 2019 consensus called it the diagnostic gold standard for severe systemic mast cell activation (Valent 2019).
  • Restatement. The 2020 MCAS update restated the formula as acute tryptase ≥ (1.2 × baseline) + 2 ng/mL. MCAS requires typical multiorgan symptoms, the tryptase increase or a clear increase in another mast cell mediator, and response to drugs targeting mast cell mediators. All three criteria must be met (Valent 2020).

Tryptase 20% + 2 threshold.

Input or step Rule Source
Baseline serum tryptase (sBT) Measured when the patient is well Valent 2020
Threshold (1.2 × sBT) + 2 ng/mL Valent 2020
Example sBT 10 ng/mL gives a threshold of 14 ng/mL; an acute value of 20 ng/mL meets the criterion Valent 2020
  • Perioperative reactions. In suspected perioperative hypersensitivity, the consensus formula and an absolute rise of ≥3.2 ng/mL over baseline had the highest accuracy for mast cell activation. Paired acute and baseline samples were required (Ebo 2021).
  • Baseline variability. Because of intraindividual variability in baseline tryptase, 9.7% of a primary cohort without reactions, 18% of people with hereditary α-tryptasemia and 30% of people with indolent systemic mastocytosis met the 20% + 2 rule. An acute-to-baseline ratio >1.685 improved specificity in these groups (Mateja 2022).

Hereditary α-tryptasemia, myeloid neoplasms and baseline tryptase

  • Genetics. Hereditary α-tryptasemia is an autosomal dominant trait caused by increased germline copies of TPSAB1, which encodes α-tryptase. Baseline tryptase rises with each additional replication (Valent 2020).
  • Prevalence. Elevated basal tryptase is found in 4%–6% of the general population, and duplications and triplications of α-tryptase sequences in TPSAB1 segregated with it. Three copies gave higher tryptase and more symptoms than two. The duplications were linked with irritable bowel syndrome, cutaneous complaints, connective tissue abnormalities and dysautonomia (Lyons 2016). An estimated 3%–5% of healthy individuals carry TPSAB1 duplications or multiple copies (Valent 2019).
  • Mechanism. Elevated baseline tryptase arises from overexpression of replicated TPSAB1 loci encoding α-tryptase, owing to a coinherited overactive promoter element (Chovanec 2023).
  • Individualized reference values. Upper limits of normal can be modeled from TPSAB1 replication number. In people without hereditary α-tryptasemia, baseline tryptase >11.4 ng/mL frequently identified indolent clonal mast cell disease. Values >100 ng/mL can result from TPSAB1 replications alone (Chovanec 2023).
  • Myeloid neoplasms and reactive causes. More than 30% of patients with myeloid neoplasms, including mastocytosis, have elevated basal tryptase. Basal tryptase is also raised in chronic renal insufficiency, especially in hemodialysis patients, and in chronic helminth infection. In hereditary α-tryptasemia, each additional gene copy raises tryptase by 7–15 ng/mL (Valent 2019).
  • Systemic mastocytosis criteria. In the WHO 5th edition, basal serum tryptase >20 ng/mL, adjusted for hereditary α-tryptasemia, is a minor criterion for systemic mastocytosis. Bone marrow mastocytosis is a subtype with basal tryptase below 125 ng/mL (Khoury 2022). In the ICC 2022, 1 major criterion is sufficient for the diagnosis, or 3 minor criteria. The WHO 5th edition requires 1 major criterion plus at least 1 minor criterion, or 3 minor criteria. Basal serum tryptase counts as a minor criterion in the absence of an associated myeloid neoplasm (Rets 2026). The full criteria are taught in the hematopathology hub on systemic mastocytosis and myeloid neoplasms.

Interpretation of serum tryptase results.

Finding Interpretation Source
Acute value ≥ (1.2 × baseline) + 2 ng/mL Systemic mast cell activation Valent 2020
Acute value normal at <30 minutes after onset May precede the rise; peak is at 1–2 hours Schwartz 1989
Baseline ≥8 ng/mL Tryptase genotyping for hereditary α-tryptasemia Valent 2020
Baseline >11.4 ng/mL without hereditary α-tryptasemia Frequently indolent clonal mast cell disease Chovanec 2023
Baseline >20 ng/mL, adjusted for hereditary α-tryptasemia Minor criterion for systemic mastocytosis (WHO 5th edition) Khoury 2022
Postmortem femoral blood <23 ng/mL (µg/L) Reference range in nonanaphylactic deaths Garland 2019
  • Postmortem tryptase. In 120 nonanaphylactic deaths sampled from a clamped femoral or external iliac vein, postmortem interval, resuscitation, cause of death, sex and age did not affect tryptase, and the 97.5th percentile was <23 ng/mL (µg/L) (Garland 2019).

Other mast cell mediators

  • Urinary mediators. Serum tryptase, urinary N-methylhistamine, leukotriene E4 and 11β-prostaglandin F2α or 2,3-dinor-11β-prostaglandin F2α are measured routinely. In 108 patients with symptoms of mast cell activation, the prostaglandin metabolite was the most frequent single elevated mediator (Butterfield 2020).
  • Thresholds. Urinary histamine and prostaglandin D2 metabolites are recommended as alternative or confirmatory markers, and no validated diagnostic increase over baseline exists for them (Valent 2020).
  • Method and sex differences. The urinary mediators are quantified by liquid chromatography-tandem mass spectrometry and normalized to creatinine. In 4033 patients, males had higher median leukotriene E4 (102.5 versus 90.0 pg/mg creatinine) and more often had an elevated 2,3-dinor-11β-prostaglandin F2α (8.0% versus 3.7%) (Jaroenpuntaruk 2025).

Basophil activation test

  • Principle. Cross-linking of sIgE on the high-affinity IgE receptor causes basophil degranulation, measured by flow cytometry as upregulation of CD63 or CD203c (Eberlein 2025).
  • Food allergy. BAT to peanut and sesame can be used in addition to skin tests and sIgE (Santos 2023). BAT specificity was 90% for peanut and 93% for sesame allergy (Riggioni 2024).
  • Drug allergy. EAACI 2024 gives technical and drug-specific BAT guidance, including β-lactams, neuromuscular blocking agents, fluoroquinolones and radiocontrast media (Mayorga 2024). BAT sensitivity for immediate drug reactions is generally 50%–60%, and specificity is about 80% (Ansotegui 2020).
  • Nonresponders. Basophils of nonresponders do not upregulate CD63 or CD203c after IgE-dependent stimulation and do respond to the IgE-independent stimulus fMLP. Nonresponders make up 6%–20% of individuals. The definition used in practice is ≤10% CD63-positive basophils after an IgE-dependent positive control (Eberlein 2025). Nonresponder status shows no relation to clinical symptoms (Eberlein 2025).

In vitro tests for drug hypersensitivity

  • Lymphocyte transformation test. The LTT measures in vitro proliferation of T cells to a drug. Its sensitivity for β-lactam allergy is 60%–70%, and the test is technically demanding (Pichler 2004).
  • Immediate reactions. BAT is a complementary test for many drugs (Mayorga 2024).
  • Transfusion reactions. Allergic and anaphylactic transfusion reactions, including anti-IgA in IgA deficiency, are taught in Transfusion Reactions.
  • Pharmacogenomic HLA testing. HLA alleles that predict abacavir, carbamazepine, phenytoin and allopurinol hypersensitivity are taught in HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.

HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing

Definition. Histocompatibility testing types human leukocyte antigen (HLA) genes, detects and characterizes HLA antibodies, and predicts or measures donor-recipient compatibility by virtual or cell-based crossmatch (Tait 2013; ASHI 2025). The HLA genes belong to the major histocompatibility complex on the short arm of chromosome 6 (Karnes 2021). The same laboratories monitor chimerism after hematopoietic cell transplantation and test platelet and neutrophil antigens and antibodies, which share bead and flow cytometry platforms with HLA testing (ASHI 2025; Curtis 2014; Flesch 2018).

Related page: Transfusion Reactions (TRALI with donor HLA and HNA antibodies, post-transfusion purpura, transfusion-associated GVHD) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (platelet refractoriness, corrected count increment, HLA-matched and crossmatched platelets) Related page: Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion (fetal and neonatal alloimmune thrombocytopenia) Related page: Blood Component Modification: Leukoreduction, Irradiation, Washing, Volume Reduction, Pathogen Reduction and CMV-Safe Components (leukoreduction to prevent HLA alloimmunization; irradiation) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (autoimmune neutropenia) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (Banff classification of antibody-mediated rejection) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (antibody removal and HPC products) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (maternal T-cell engraftment in SCID) Related page: Allergy and Hypersensitivity Testing: Total and Specific IgE, Component Diagnostics, Tryptase and Basophil Activation (in vitro tests for drug hypersensitivity)

Major histocompatibility complex: expression and inheritance

  • Expression. Classical class I molecules (HLA-A, -B and -C) are expressed on all nucleated cells. Class II molecules (DR, DQ and DP) are expressed only on professional antigen-presenting cells such as B cells, macrophages and dendritic cells (Feng 2026).
  • Structure and function. The MHC on chromosome 6p21.3 contains the class I, II and III genes, with the classical class I genes HLA-A, -B and -C and the nonclassical genes HLA-E, -F and -G. A class I molecule is a heavy chain with α1 and α2 peptide-binding domains and an immunoglobulin-like α3 domain, bound noncovalently to β2-microglobulin, which is encoded on chromosome 15. The α3 domain binds CD8, and class I–peptide complexes are recognized by CD8 T cells. Class II molecules are α/β heterodimers that present processed exogenous antigen to naive CD4 T cells. HLA genes are inherited as haplotypes and expressed codominantly (Feng 2026).
  • Haplotype inheritance. A pair of siblings inherits identical HLA genes from both parents with a probability of 25% (Feng 2026). HLA loci show linkage disequilibrium (Feng 2026).
  • DPB1 recombination. DPB1 has weak linkage disequilibrium with the other class II loci. About 80% of pairs matched at all other loci are DPB1-mismatched, and DPB1 is typed in genotypically identical sibling pairs to exclude recombination (Crocchiolo 2024).
  • Family studies. HLA-A, -B, -C and -DRB1 are typed at low resolution on the patient and available family members to define haplotype segregation. When parents share a haplotype or one parent is homozygous, an apparently identical donor is defined as phenotypically identical (Crocchiolo 2024).

HLA nomenclature

  • Colon-delimited allele names (since April 2010). Colons separate the fields of an allele name, and a leading zero is added to fields with values 1–9. For example, A01010101 became A01:01:01:01 and Cw0103 became C01:03. The "w" was removed from HLA-C allele names and kept in HLA-C antigen names (Marsh 2010).
  • Fields. The first field is the allele group and often corresponds to the serologic antigen. Alleles that differ in the second field differ in amino acid sequence. The third field distinguishes synonymous substitutions in the coding sequence, and the fourth field distinguishes intron and untranslated-region polymorphisms (WHO Nomenclature Committee 2026).
  • Expression suffixes. Alleles shown not to be expressed (null alleles) carry the suffix N. Alleles with alternative expression may carry L, S, C, A or Q (WHO Nomenclature Committee 2026). The suffix L marks low cell-surface expression, first assigned to A*30:14L (Marsh 2010).
  • P and G groups. A P group contains alleles that encode the same protein sequence of the peptide-binding domains (exons 2 and 3 for class I and exon 2 for class II). A G group contains alleles with identical nucleotide sequences of those exons (Marsh 2010). Alleles identical in the antigen recognition domain are accepted as a match for donor selection (Dehn 2019).
  • Broad and split antigens. Serologic splits are written with the associated broad antigen in brackets, for example A23(9), A24(9), B44(12) and DR11(5) (WHO Nomenclature Committee 2026). HLA-A23 and HLA-A24 were identified as splits of the originally defined HLA-A9 antigen (Feng 2026).
  • Allele numbers. The IPD-IMGT/HLA Database listed 46,146 HLA alleles (31,311 class I and 14,835 class II), including 11,328 HLA-B and 4056 HLA-DRB1 alleles (IPD-IMGT/HLA 2026). The WHO Nomenclature Committee publishes updates of newly named alleles (Marsh 2025).

HLA typing resolution (ASHI 2025 definitions).

Resolution Definition Source
Low resolution Genotype sufficient to assign the level of serologic splits; some alleles need 2-field results ASHI 2025
High resolution Molecular nomenclature to at least the second field, with P or G group designations allowed; one genotype, or alternatives in which only one combination contains common or intermediate alleles; null alleles listed as common, intermediate or well documented must be resolved ASHI 2025
Allele level (2-field) for HCT Discriminates alleles that encode different antigen recognition domains Dehn 2019

HLA typing methods

  • Methods covered by the ASHI standards. Microcytotoxicity, amplification-based nucleic acid testing, sequence-specific oligonucleotide probe (SSOP) and sequence-specific primer (SSP) methods, Sanger sequencing, and next-generation and third-generation sequencing (ASHI 2025).
  • Ambiguity. Sanger sequencing identified more than 8000 alleles, but fewer than 10% were fully sequenced. Analysis of additional exons resolves ambiguity at higher cost (De Santis 2013).
  • Next-generation sequencing. NGS generates many clonal sequences in one run. HLA typing by NGS needs adapted typing strategies and software (Gabriel 2014). Long reads set the phase of linked polymorphisms (De Santis 2013).
  • Deceased donor timing. Kidney, pancreas and islet donor typing must be completed before organ offers. Heart and lung donor typing must be completed before final organ acceptance. Laboratories typing deceased donors for OPTN match runs use a molecular method (ASHI 2025).
  • Loci typed for solid organ transplantation. Donors are typed for HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1, -DPB1 and Bw4/Bw6. Kidney, pancreas and islet recipients are typed for HLA-A, -B, -DRB1 and Bw4/Bw6 (ASHI 2025).
  • Null alleles in deceased donors. Laboratories must distinguish A24:09N, B51:11N, C04:09N, DRB401:03:01:02N and DRB5*01:08:01N/01:08:02N in their stated haplotype contexts (ASHI 2025).

HLA antibody detection

  • Complement-dependent cytotoxicity (CDC). A positive CDC crossmatch was associated with hyperacute or accelerated rejection of kidney transplants (Patel 1969). Solid-phase immunoassays are more sensitive than CDC assays and detect antibodies that CDC does not (Tait 2013).
  • AHG-CDC and DTT. In the antihuman globulin CDC (AHG-CDC), anti-human immunoglobulin is added before complement to crosslink bound antibody, which detects cytotoxicity-negative and class II antibodies. AHG-CDC does not control for non-HLA antibody or autoreactive IgM. Dithiothreitol (DTT) reduces and inactivates IgM, and a CDC crossmatch that stays positive after DTT is not due to IgM autoantibodies (South 2016).
  • Flow PRA. Bead-based fluorescent assays such as FlowPRA use purified HLA antigen on beads, with a sensitive screening test and a specific single-antigen test (South 2016).
  • Sources of sensitization. Pregnancy, transfusion and prior transplantation sensitize. More than 40% of women with previous pregnancies have DSA, often at high titer, and independent risk factors for antibody formation before HSCT are the number of pregnancies and transfusions, female sex and myelodysplastic syndrome (Crocchiolo 2024).
  • Solid-phase assays. HLA molecules bound to ELISA plates or polystyrene beads are tested on a flow cytometer or Luminex fluoroanalyzer. Single-antigen beads detect antibodies to HLA-C, -DQA, -DPA and -DPB, which other methods do not readily detect (Tait 2013). Laboratories must use a solid-phase method that identifies antibody specificities in very highly sensitized patients (ASHI 2025).
  • Mean fluorescence intensity (MFI). In 7 laboratories testing 20 reference sera, MFI variation was 62% with nonstandardized procedures, 25% with a standardized operating procedure and near 20% after global normalization. MFI varied by manufacturer, kit, bead type and lot, and optimal positive cutoffs were 1000–1500 MFI (Reed 2013). Variation in antigen density and denatured antigen on the beads influence results (Tait 2013).
  • Prozone. High-titer sera can give false-negative single-antigen bead results (prozone). The prozone is caused by complement C1 bound to the beads. EDTA plasma, EDTA added to serum, dithiothreitol, C1 inhibitor or heat inactivation abolish it (Schnaidt 2011).
  • IVIG. Immunoglobulin preparations contain anti-HLA class I and II antibodies that can be detected as passive antibodies after administration, with high background and lot-to-lot variability, and dilution of the preparations revealed a prozone (Nakagawa 2025).
  • Other interference. Naturally occurring substances raise background and change specificity. Hypotonic dialysis improved specificity and crossmatch prediction, and dithiothreitol improved crossmatch prediction to a lesser extent (Zachary 2009).
  • Shared epitopes. Antibody to an epitope shared by many beads is distributed across them, so the MFI on each bead can underestimate antibody strength or miss it (Garcia-Sanchez 2020).
  • Complement-binding assays. C1q and C4d assays distinguish complement-fixing from non-complement-fixing antibody. The C1q single-antigen bead assay is sensitive but may overestimate risk, and the C3d assay reflects downstream complement activation but may miss weak or early activity. Neither is routinely applied in current clinical practice (Zajacova 2026). In 1016 kidney recipients, 5-year graft survival was 54% with posttransplant complement-binding DSA, 93% with non-complement-binding DSA and 94% without DSA (Loupy 2013).
  • Posttransplant DSA monitoring. High-risk recipients (desensitized, or DSA-positive with a negative crossmatch) are monitored by DSA and protocol biopsies in the first 3 months. Intermediate-risk recipients (prior DSA, currently negative) are tested for DSA within the first month. Low-risk recipients (nonsensitized first transplant) are screened at least once 3–12 months after transplantation, with a biopsy if DSA appears (Tait 2013).
  • Transplantation without a prospective crossmatch. A kidney can be transplanted without a prospective crossmatch if single-antigen bead screening for all class I and II loci is negative, subject to local programs and regulators (Tait 2013).
  • STAR reports. The STAR 2022 consensus extends posttransplant DSA recommendations to kidney, heart, lung and liver transplantation (Lefaucheur 2023). STAR 2025 addressed donor-derived cell-free DNA, natural killer-cell missing self, molecular mismatch, HLA antibody quantification and non-HLA antibodies (Schinstock 2026).
  • Eplet mismatch. In 926 kidney transplants analyzed with HLAMatchmaker, antibody-verified HLA-DQ eplet mismatch load was associated with de novo DSA and graft failure with no safe threshold. De novo DSA developed in 4.6% of recipients (Senev 2020).

HLA antibody methods compared.

Method Principle Strength Limitation Source
CDC (antibody screen and crossmatch) Complement-mediated lysis of target lymphocytes Detects cytotoxic antibody; associated with hyperacute rejection Less sensitive than solid-phase assays; IgM autoantibodies cause false-positive results Patel 1969; Tait 2013; McCalmon 1997; South 2016
Flow cytometric crossmatch Patient IgG binding to donor T and B cells Sensitive cell-based test Therapeutic antibodies and nonspecific binding cause false-positive results Franz 2021; Krolik 2025
Single-antigen beads Purified HLA alleles on coded beads Specificity and semiquantitative MFI Prozone, denatured antigen, shared epitopes, interlaboratory MFI variation Schnaidt 2011; Tait 2013; Reed 2013; Garcia-Sanchez 2020
C1q and C3d assays C1q binding or C3d deposition on antibody-coated beads Identify complement-binding DSA C1q may overestimate risk; C3d may miss weak activity; not routine Loupy 2013; Zajacova 2026

Crossmatch testing

  • Final crossmatch. Results of final crossmatches must be available before kidney transplantation except in documented emergencies. The serum selection policy for allosensitized patients addresses historic and current sensitizing events (ASHI 2025).
  • Flow crossmatch standards. Each laboratory establishes its positive threshold, whether reported as mean, median or mode channel shift or as quantitative fluorescence, and repeats it after significant changes in protocol, reagents or instruments. T cells, B cells and monocytes are identified with labeled CD antibodies in a fluorochrome distinct from the anti-human immunoglobulin (ASHI 2025).
  • Pronase. Pronase degrades Fc gamma receptors more quickly than CD19, CD20 and MHC class I and II molecules (Kim 2024). Pronase treatment of donor cells increased B-cell crossmatch sensitivity without changing T-cell results (Li 2025). Pronase degrades CD20 and reduces rituximab interference but can also degrade HLA molecules. Concentrations of 2–3 mg/mL removed rituximab interference, and T-cell false positives occurred in 2.9% of pronase-treated tests. Raising pronase from 1 to 2–3 mg/mL turned 8 weak-DSA crossmatches (MFI mostly <3000) negative, so higher concentrations reduce sensitivity (Kim 2024).
  • EDTA treatment of serum. EDTA-treated serum eliminated B-cell false positivity in non-pronase flow crossmatches, with sensitivity 94% and specificity 96%. EDTA performed as well as 2-mercaptoethanol and better than dithiothreitol or heat inactivation (Krolik 2025).
  • Therapeutic antibodies. Anti-idiotype blocking antibodies removed false-positive results from rituximab (B cells, mean −97%) and alemtuzumab (T cells −99%, B cells −95%) (Franz 2021).
  • IgM antibodies. IgM autoantibodies and nonspecific IgM lymphocytotoxic antibodies cause positive CDC crossmatches without hyperacute rejection. Five patients with donor-specific IgM HLA class I antibodies had graft survival equivalent to crossmatch-negative recipients (McCalmon 1997).
  • Interlaboratory agreement. In 6 years of ASHI proficiency surveys with more than 10,000 T-cell and 10,000 B-cell flow crossmatches, 92.5% of T-cell and 91.7% of B-cell results reached consensus and agreed with DSA results (Philogene 2025).

Interpretation of crossmatch results.

T-cell crossmatch B-cell crossmatch Possible causes Source
Positive Positive Donor HLA class I antibody; alemtuzumab Kim 2024; Franz 2021
Negative Positive Donor HLA class II antibody (class II is expressed on B cells and not on resting T cells); rituximab; nonspecific binding from aggregated IgG in stored serum Feng 2026; Kim 2024; Krolik 2025
Positive (CDC) Any IgM autoantibody or nonspecific IgM McCalmon 1997
Negative Negative No detectable donor-specific IgG at the sensitivity of the assay Tait 2013

Calculated PRA and virtual crossmatch

  • Definitions. The calculated PRA (cPRA) estimates the likelihood that a patient will have a positive crossmatch against the donor population, based on donor HLA phenotype frequencies and the unacceptable antigens listed for the patient. A virtual crossmatch compares the patient's alloantibody profile with the donor's HLA antigens (ASHI 2025).
  • Kidney allocation system (KAS) 2014. The policy approved in 2013 gives priority points for cPRA >19% and broader sharing for candidates with cPRA ≥99% (Israni 2014). KAS reduced access disparity due to HLA sensitization (Gragert 2022).
  • ABO-adjusted cPRA. A proposed metric combines HLA cPRA with the fraction of HLA-compatible donors that are ABO-incompatible. In the 99% cPRA point group, 43% of candidates moved to the 100% group (Gragert 2022). The OPTN has proposed a continuous distribution framework with a composite allocation score (Gragert 2022); its current implementation status was not confirmed in an opened OPTN source.
  • Virtual crossmatch without a prospective physical crossmatch. After a program adopted virtual crossmatching in 2017, cold ischemia time decreased from 16.67 to 14.5 hours, and delayed graft function, rejection and 1-year graft loss were unchanged (Rohan 2020).

Example of cPRA and virtual crossmatch for a candidate with anti-A2 and anti-B44.

Step Example Source
Unacceptable antigens entered Antibodies with specificity for donor antigens, for example A2 and B44, listed for the candidate ASHI 2025
cPRA Percentage of deceased donors who would be crossmatch-incompatible, from donor antigen frequencies ASHI 2025; Cecka 2010
Virtual crossmatch A donor typed for A2 is incompatible for this candidate ASHI 2025

Antibody-mediated rejection and posttransplant immune monitoring: laboratory correlates

  • DSA in the rejection classification. Serologic evidence of circulating DSA to HLA or other antigens is a criterion for antibody-mediated rejection, and thorough DSA testing, including non-HLA antibodies when HLA antibodies are negative, is advised when the histologic criteria are met (Loupy 2020). The Banff 2019, 2022 and 2024 categories are taught in Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology.
  • Donor-derived cell-free DNA. At a cutoff of 1.0%, dd-cfDNA had positive and negative predictive values of 61% and 84% for active rejection and 44% and 96% for antibody-mediated rejection. Median dd-cfDNA was 2.9% in antibody-mediated rejection and 0.3% in controls (Bloom 2017).
  • Non-HLA antibodies. Agonistic IgG1 and IgG3 antibodies to the angiotensin II type 1 receptor were found in all 16 kidney recipients with refractory vascular rejection, malignant hypertension and no HLA antibodies (Dragun 2005). MICA antibodies were detected in 11.4% of 1910 deceased-donor kidney recipients by a bead assay and were associated with lower 1-year graft survival (88.3% versus 93.0%) (Zou 2007).
  • T-cell function monitoring. The ImmuKnow assay measures intracellular ATP in CD4 T cells from whole blood (He 2013). In 504 solid organ recipients, a value of 25 ng/mL ATP was associated with a 12-fold higher likelihood of infection than a stronger response, and a value of 700 ng/mL with a 30-fold higher likelihood of cellular rejection than a weaker response (Kowalski 2006). In a meta-analysis of 9 studies, pooled sensitivity and specificity were 0.58 and 0.69 for infection and 0.43 and 0.75 for rejection, and the assay did not identify recipients at risk of either (Ling 2012).

HLA matching and antibodies in hematopoietic cell transplantation

  • 8/8 matching. In 3857 unrelated donor transplants, high-resolution matching at HLA-A, -B, -C and -DRB1 (8/8) was the minimum level associated with the highest survival. A single mismatch (7/8) raised mortality (relative risk 1.25) and lowered 1-year survival from 52% to 43% (Lee 2007).
  • Typing. Patients and adult donors are typed at high resolution for HLA-A, -B, -C, -DRB1 and -DPB1 (Dehn 2019). The patient's typing is verified on a new sample before final donor selection, and the donor's before collection (ASHI 2025).
  • HLA-DPB1. DPB1 mismatches occur in more than 80% of unrelated transplants (Dehn 2019). Mismatches are permissive when the T-cell-epitope groups match and nonpermissive when they differ (Fleischhauer 2012). Nonpermissive DPB1 mismatches adversely affect overall survival (Dehn 2019).
  • Cord blood. Units are typed at high resolution for HLA-A, -B, -C and -DRB1. Matching requires ≥4/6 (HLA-A and -B antigen, HLA-DRB1 high resolution) and ≥4/8 at high resolution. A single unit needs total nucleated cells ≥2.5 × 10⁷/kg and CD34+ cells ≥1.5 × 10⁵/kg (Dehn 2019).
  • Donor-specific antibodies. DSA are an important barrier to engraftment and are associated with primary graft failure in haploidentical transplantation (Ciurea 2018). An MFI >1000 is normally the positive cutoff. Graft failure rates were 9% with MFI <5000 and 54% with MFI >5000, so MFI >5000 is the suggested risk cutoff. Desensitization may not succeed when the CDC crossmatch is positive or the MFI is >20,000 (Crocchiolo 2024). Units targeted by DSA are avoided in nonmalignant diagnoses (Dehn 2019).
  • Haploidentical donor selection. Recipients are screened for DSA. Donors are excluded when high-titer DSA are present, especially in child-to-mother transplantation, or desensitization is used. Without unequivocal haplotype segregation, haploidentity is confirmed by high-resolution typing of the shared haplotype at HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1. KIR gene analysis is an additional selection criterion recommended by EBMT (Crocchiolo 2024).

NMDP/CIBMTR unrelated donor selection order (Dehn 2019).

Rank Criterion Source
1 High-resolution match for antigen recognition domains at HLA-A, -B, -C, -DRB1 (8/8; otherwise 7/8) Dehn 2019
2 Younger donor age Dehn 2019
3 Matched or permissive HLA-DPB1 mismatch Dehn 2019
4 Fewest HLA-DRB3/4/5 and HLA-DQB1 mismatches Dehn 2019
5 For 7/8 donors, a mismatch at the patient's homozygous locus Dehn 2019
6 No allotypes targeted by patient DSA, including DQA1 and DPA1 Dehn 2019

Chimerism testing after hematopoietic cell transplantation

  • Methods. Short tandem repeat PCR is the accepted standard for chimerism. It does not detect mixed chimerism at the level of minimal residual disease, and newer sensitive assays have been adapted for chimerism (Sel 2024).
  • Lineage-specific chimerism. Chimerism in sorted peripheral blood T cells, myeloid cells (CD33+ and CD15+) and CD34+ cells is more sensitive than whole-blood chimerism for predicting relapse. Declining donor myeloid or CD34+ chimerism may precede hematologic relapse, and low circulating CD34+ counts can preclude reliable sorting (Zaucha 2026).
  • Uses. Chimerism monitors engraftment and guides donor lymphocyte infusion and immunosuppressive dosing (Sel 2024).
  • ASHI requirements. Protocols define informative markers, quantification of recipient and donor DNA when results are reported as percentages, the minimum number of informative markers, markers on more than one chromosome for patients at risk of chromosomal deletions, and sensitivity appropriate to the clinical application (ASHI 2025).

HLA disease associations and pharmacogenomic HLA alleles

HLA allele or antigen Association Laboratory point Source
HLA-B27 (HL-A 27) Ankylosing spondylitis Original 1973 association Brewerton 1973
HLA-DRB1 shared epitope Rheumatoid arthritis Common sequence on susceptibility alleles Gregersen 1987
HLA-B51/B5 Behçet disease Pooled odds ratio 5.78 across 78 studies de Menthon 2009
HLA-DQB106:02 with DQA101:02 Narcolepsy with cataplexy Present in almost all patients; homozygotes at highest risk Mignot 2001
HLA-DQ2.5 (DQA105 and DQB102) and DQ8 Celiac disease 90%–95% of patients carry DQ2.5; poor PPV and high NPV Al-Toma 2025
HLA-A29 (A29.2 subtype) Birdshot retinochoroidopathy 93.1% of patients; relative risk 157 LeHoang 1992
HLA-B*57:01 Abacavir hypersensitivity Screening negative predictive value 100% Mallal 2008
HLA-B*15:02 Carbamazepine, oxcarbazepine and phenytoin SJS/TEN Most prevalent in East Asian and Central/South Asian populations (allele frequency 1% to >20%); 0–1% in Europeans Chung 2004; Phillips 2018; Karnes 2021
HLA-A*31:01 Carbamazepine maculopapular exanthema and DRESS Added in the 2017 CPIC update Phillips 2018
HLA-B*58:01 Allopurinol severe cutaneous adverse reactions CPIC 2013 recommendations unchanged in 2015 Hershfield 2013; Saito 2016
  • Abacavir. In 1956 patients, the prevalence of HLA-B*57:01 was 5.6%. Prospective screening eliminated immunologically confirmed hypersensitivity (0% versus 2.7%), with a negative predictive value of 100% and a positive predictive value of 47.9% (Mallal 2008). The 2014 CPIC update kept the 2012 recommendations (Martin 2014).
  • Genotype reporting. HLA-B*15:02 results are reported as positive (heterozygous or homozygous) or negative, with no intermediate phenotype (Karnes 2021).
  • Celiac disease. HLA-DQ2/DQ8 testing is not used routinely for the initial diagnosis of celiac disease because of its poor positive predictive value. Its high negative predictive value supports use when the diagnosis is uncertain (Al-Toma 2025).

Platelet antigens and antibody testing

  • HPA systems. Thirty-three human platelet antigens (HPAs) have been identified on six glycoprotein complexes. Twenty reside on GPIIb/IIIa, including HPA-1a, the HPA most often implicated in FNAIT and post-transfusion purpura in White populations. Twelve HPAs form six biallelic systems in which the -a allele is the more frequent (Curtis 2014).
  • ABO and HLA on platelets. Platelets express ABO and HLA antigens. ABO antibodies are occasionally important in FNAIT, and HLA antibodies in multitransfusion platelet refractoriness (Curtis 2014).
  • MAIPA. The monoclonal antibody-specific immobilization of platelet antigens assay captures specific glycoproteins (GPIIb/IIIa, GPIb and HLA class I) with monoclonal antibodies to identify platelet-reactive autoantibodies and alloantibodies, including anti-PlA1, anti-Bak and anti-Pen (Kiefel 1987).
  • HPA genotyping. Noninvasive fetal HPA genotyping on cell-free fetal DNA uses real-time PCR, allele-specific quantitative PCR, high-resolution melting, droplet digital PCR and NGS. Conventional PCR is reliable for HPA-1, and droplet digital PCR and NGS cover multiple systems at earlier gestational ages (Valentin 2026).
  • Passive alloimmune thrombocytopenia. Donor plasma containing an HPA alloantibody causes thrombocytopenia in the recipient. After a plasma transfusion containing anti-HPA-5b, the platelet count fell to 35 × 10⁹/L. Direct radioimmunoprecipitation showed IgG bound to the recipient's GPIa/IIa, and indirect testing of donor serum identified the specificity. The thrombocytopenia was milder than that caused by passive anti-HPA-1a, which was attributed to the lower copy number of HPA-5 (Warkentin 1992).
  • Clinical syndromes. FNAIT is taught in Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion, post-transfusion purpura in Transfusion Reactions, and platelet refractoriness with HLA-matched and crossmatched platelets in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.

Neutrophil antigens and antibody testing

  • HNA systems. Five human neutrophil antigen (HNA) systems are assigned, and the ISBT nomenclature was updated in 2016. HNA-1 antigens are on the glycoprotein encoded by FCGR3B. A CD177 substitution causes the HNA-2-negative phenotype. HNA-3a and HNA-3b on choline transporter-like protein 2 (CTL2, encoded by SLC44A2) differ at position 152. HNA-4b is on the glycoprotein encoded by ITGAM (Flesch 2018).
  • Clinical relevance. HNA antibodies cause neonatal immune neutropenia, TRALI, refractoriness to granulocyte transfusion, febrile reactions and autoimmune and drug-induced neutropenia (Bux 2008). Autoimmune neutropenia is taught in Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders.
  • Antibody methods. The granulocyte agglutination test (GAT) and the granulocyte immunofluorescence test (GIFT), with a panel of typed cells, are the best means of detection (Bux 2008). GIFT was more sensitive than GAT in titrations, and GAT identified HNA-3a antibodies more readily (Lucas 2002).
  • TRALI investigation. Leucocyte antibody screening includes HLA class I, HLA class II and HNA antibodies. In TRALI with antibody-positive donors, leucocyte incompatibility is shown by crossmatch or by typing the patient for the cognate antigen (Bierling 2009). Antibodies to HLA class II, HNA-3a and HLA-A2 are frequently associated with severe and fatal TRALI (Bux 2011).
  • TRALI risk reduction. At the American Red Cross, plasma-associated TRALI fell from 20.0 to <4 cases per million units after male-predominant plasma (2005–2006), and HLA antibody screening of previously pregnant apheresis platelet donors began in 2016 (Young 2025). TRALI is taught in Transfusion Reactions.

Platelet and neutrophil antigen systems and antibody methods.

System Carrier Main clinical associations Antibody methods Source
HPA-1a GPIIb/IIIa FNAIT, post-transfusion purpura MAIPA; HPA genotyping Curtis 2014; Kiefel 1987
HLA class I on platelets HLA class I Platelet refractoriness Solid-phase HLA antibody assays Curtis 2014; Tait 2013
HNA-1 FCGR3B glycoprotein HNA antibodies as a group: neonatal immune neutropenia, TRALI, autoimmune neutropenia GAT and GIFT with typed panel Flesch 2018; Bux 2008
HNA-2 CD177 glycoprotein; CD177 substitution causes the HNA-2-negative phenotype HNA antibodies as a group GAT and GIFT with typed panel Flesch 2018; Bux 2008
HNA-3a CTL2 (SLC44A2) Severe TRALI GAT Flesch 2018; Lucas 2002; Bux 2011
HNA-4 ITGAM glycoprotein Neonatal alloimmune neutropenia (HNA-4b) GAT and GIFT Flesch 2018

ASHI accreditation and proficiency testing

  • Current standards. The 2025 ASHI Standards for Accredited Laboratories were approved by CMS on January 27, 2026 (ASHI 2025).
  • Proficiency testing. For each accredited analyte, the laboratory participates in a graded external program approved by CMS or by the ASHI Accreditation Review Board, or follows a defined sequence of alternatives ending with semiannual validation procedures. One external provider per analyte is designated in writing each year (ASHI 2025).

References

  1. Abraham RS, Basu A, Heimall JR, et al. Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Clin Immunol. 2024;261:109942. doi:10.1016/j.clim.2024.109942. PMID 38367737 (Abraham 2024)
  2. Agarwal R, Sehgal IS, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061. doi:10.1183/13993003.00061-2024. PMID 38423624 (Agarwal 2024)
  3. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17–23. doi:10.1136/annrheumdis-2013-203863. PMID 24126457
  4. Al-Toma A, Zingone F, Branchi F, et al. European Society for the Study of Coeliac Disease 2025 updated guidelines on the diagnosis and management of coeliac disease in adults. Part 1: diagnostic approach. United European Gastroenterol J. 2025;13(10):1855–1886. doi:10.1002/ueg2.70119. PMID 40999951 (Al-Toma 2025)
  5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584. PMID 20872595
  6. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389. doi:10.1089/thy.2016.0457. PMID 28056690
  7. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701. doi:10.1038/s41584-020-00515-9. PMID 33093664
  8. Altmann F. Coping with cross-reactive carbohydrate determinants in allergy diagnosis. Allergo J Int. 2016;25(4):98–105. doi:10.1007/s40629-016-0115-3. PMID 27656353 (Altmann 2016)
  9. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40(2 Pt 1):167–170. doi:10.1016/s0190-9622(99)70183-0. PMID 10025740
  10. Amatuni GS, Currier RJ, Church JA, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010–2017. Pediatrics. 2019;143(2):e20182300. doi:10.1542/peds.2018-2300. PMID 30683812 (Amatuni 2019)
  11. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. doi:10.2337/dc26-S002. PMID 41358893 (ADA 2026)
  12. American Society for Histocompatibility and Immunogenetics. 2025 ASHI Standards for Accredited Laboratories. Approved by CMS January 27, 2026. https://cdn.ymaws.com/www.ashi-hla.org/resource/resmgr/docs/standards/2025/2025_ashi_standards.pdf. Accessed November 17, 2026 (ASHI 2025)
  13. Ansotegui IJ, Melioli G, Canonica GW, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020;13(2):100080. doi:10.1016/j.waojou.2019.100080. PMID 32128023 (Ansotegui 2020)
  14. Antico A, Platzgummer S, Bassetti D, et al. Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test. Lupus. 2010;19(8):906–912. doi:10.1177/0961203310362995. PMID 20179169
  15. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159. doi:10.1136/annrheumdis-2018-214819. PMID 31383717 (Aringer 2019a)
  16. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412. doi:10.1002/art.40930. PMID 31385462 (Aringer 2019b)
  17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324. doi:10.1002/art.1780310302. PMID 3358796
  18. Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol. 2023;130(6):699–712. doi:10.1016/j.anai.2023.01.018. PMID 36706910 (Athni 2023)
  19. Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73. doi:10.1186/s13023-018-0815-5. PMID 29728119
  20. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268–282. doi:10.1016/S1474-4422(22)00431-8. PMID 36706773
  21. Basu S, Rikhi R, Arora K, et al. Wiskott-Aldrich syndrome protein expression in female WAS carriers: a flow cytometry study from North India. Pediatr Blood Cancer. 2024;71(6):e30972. doi:10.1002/pbc.30972. PMID 38523275 (Basu 2024)
  22. Bayram RO, Özdemir H, Emsen A, et al. Reference ranges for serum immunoglobulin (IgG, IgA, and IgM) and IgG subclass levels in healthy children. Turk J Med Sci. 2019;49(2):497–505. doi:10.3906/sag-1807-282. PMID 30997788 (Bayram 2019)
  23. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi:10.1056/NEJMoa0810457. PMID 19571279
  24. Best M, Molinari N, Chasset F, et al. Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(3):256–262. doi:10.2340/00015555-3091. PMID 30460368
  25. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8–23. doi:10.1111/joim.12451. PMID 26602539
  26. Bielory L, Gascon P, Lawley TJ, Young NS, Frank MM. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore). 1988;67(1):40–57. doi:10.1097/00005792-198801000-00003. PMID 3257288
  27. Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11):5129–5138. doi:10.4049/jimmunol.1402770. PMID 25917093
  28. Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221–2232. doi:10.1681/ASN.2016091034. PMID 28280140 (Bloom 2017)
  29. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(1):38–59. doi:10.1016/j.jaip.2015.07.025. PMID 26563668 (Bonilla 2016)
  30. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–1205. doi:10.1016/j.jaci.2015.04.049. PMID 26371839 (Bonilla 2015)
  31. Bonroy C, Vercammen M, Fierz W, et al. Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP. Clin Chem Lab Med. 2023;61(7):1167–1198. doi:10.1515/cclm-2023-0209. PMID 36989417
  32. Borradori L, Van Beek N, Feliciani C, et al. Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689–1704. doi:10.1111/jdv.18220. PMID 35766904
  33. Borte S, von Döbeln U, Fasth A, et al. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119(11):2552–2555. doi:10.1182/blood-2011-08-371021. PMID 22130802 (Borte 2012)
  34. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683–692. doi:10.1038/nrrheum.2017.140. PMID 28905856
  35. Bossuyt X, De Langhe E, Borghi MO, Meroni PL. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol. 2020;16(12):715–726. doi:10.1038/s41584-020-00522-w. PMID 33154583
  36. Bousfiha AA, Jeddane L, Moundir A, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. 2025;1(1):e20250002. doi:10.70962/jhi.20250002. PMID 41608113 (Bousfiha 2025)
  37. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24. doi:10.1186/1710-1492-6-24. PMID 20667127
  38. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1(7809):904–907. doi:10.1016/s0140-6736(73)91360-3. PMID 4123836 (Brewerton 1973)
  39. Brodszki N, Frazer-Abel A, Grumach AS, et al. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management. J Clin Immunol. 2020;40(4):576–591. doi:10.1007/s10875-020-00754-1. PMID 32064578
  40. Brucato A, Doria A, Frassi M, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus. 2002;11(11):716–721. doi:10.1191/0961203302lu252oa. PMID 12475001
  41. Buchbinder D, Walter JE, Butte MJ, et al. When screening for severe combined immunodeficiency (SCID) with T cell receptor excision circles is not SCID: a case-based review. J Clin Immunol. 2021;41(2):294–302. doi:10.1007/s10875-020-00931-2. PMID 33411155 (Buchbinder 2021)
  42. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150.e3. doi:10.1016/j.jaip.2020.08.046. PMID 32898710
  43. Butterfield JH. Survey of mast cell mediator levels from patients presenting with symptoms of mast cell activation. Int Arch Allergy Immunol. 2020;181(1):43–50. doi:10.1159/000503964. PMID 31722348 (Butterfield 2020)
  44. Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang. 2011;100(1):122–128. doi:10.1111/j.1423-0410.2010.01392.x. PMID 21175662 (Bux 2011)
  45. Bux J. Human neutrophil alloantigens. Vox Sang. 2008;94(4):277–285. doi:10.1111/j.1423-0410.2007.01031.x. PMID 18208407 (Bux 2008)
  46. Cai MT, et al. Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients. BMC Med. 2025;23(1):40. doi:10.1186/s12916-025-03875-9. PMID 39849443
  47. Can B, Aksit Ilki A. Diagnostic performance of ANCA IIF in relation to PR3 and MPO antibodies: impact of formalin reactivity in a large real-world cohort. Diagnostics (Basel). 2026;16(7):996. doi:10.3390/diagnostics16070996. PMID 41975708
  48. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10(1):26–29. doi:10.1111/j.1600-6143.2009.02927.x. PMID 19958328 (Cecka 2010)
  49. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol. 2015;6:412. doi:10.3389/fimmu.2015.00412. PMID 26347739
  50. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005;115(2):391–398. doi:10.1016/j.jaci.2004.10.012. PMID 15696101 (Chan 2005)
  51. Chang YC, Yang L, Budhram A. Positive predictive value of myositis antibody line blot testing in patients with suspected idiopathic inflammatory myopathy. Muscle Nerve. 2024;69(5):626–630. doi:10.1002/mus.28050. PMID 38321821
  52. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31(6):677–679. doi:10.1002/ana.410310619. PMID 1514781
  53. Chinn IK, Chan AY, Chen K, et al. Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: a working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2020;145(1):46–69. doi:10.1016/j.jaci.2019.09.009. PMID 31568798 (Chinn 2020)
  54. Choi MY, FitzPatrick RD, Buhler K, Mahler M, Fritzler MJ. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020;19(3):102463. doi:10.1016/j.autrev.2020.102463. PMID 31927088
  55. Chovanec J, Tunc I, Hughes J, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv. 2023;7(9):1796–1810. doi:10.1182/bloodadvances.2022007936. PMID 36170795 (Chovanec 2023)
  56. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. doi:10.1038/428486a. PMID 15057820 (Chung 2004)
  57. Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(5):521–534. doi:10.1038/s41409-017-0062-8. PMID 29335625 (Ciurea 2018)
  58. Claessens J, Belmondo T, De Langhe E, et al. Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmun Rev. 2018;17(6):533–540. doi:10.1016/j.autrev.2018.03.002. PMID 29526634
  59. Cohen Tervaert JW. Drug- and vaccine induced ANCA-associated vasculitis: an overview. Autoimmun Rev. 2026;25(1):103924. doi:10.1016/j.autrev.2025.103924. PMID 41213309
  60. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–281. doi:10.1002/art.37721. PMID 23044708
  61. Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009;123(2):426–433. doi:10.1016/j.jaci.2008.10.052. PMID 19070355 (Commins 2009)
  62. Corthier A, Jachiet M, Bertin D, et al. Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. BMC Nephrol. 2022;23(1):67. doi:10.1186/s12882-022-02689-8. PMID 35172758
  63. Crocchiolo R, Fusco C, Andreani M, et al. Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Society for Immunogenetics and Transplantation Biology (AIBT). Blood Transfus. 2024;22(4):338–349. doi:10.2450/BloodTransfus.495. PMID 37458719 (Crocchiolo 2024)
  64. Curtis BR, McFarland JG. Human platelet antigens—2013. Vox Sang. 2014;106(2):93–102. doi:10.1111/vox.12085. PMID 24102564 (Curtis 2014)
  65. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med. 2004;199(10):1391–1399. doi:10.1084/jem.20040111. PMID 15148337
  66. Daly TM, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22(2):148–152. doi:10.1128/CVI.00735-14. PMID 25520149 (Daly 2015)
  67. Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–889. doi:10.1136/annrheumdis-2018-214436. PMID 30862649
  68. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647–653. doi:10.1136/annrheumdis-2016-209507. PMID 27481830
  69. De Lorenzo R, Pinal-Fernandez I, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology. 2018;90(23):e2068–e2076. doi:10.1212/WNL.0000000000005638. PMID 29728522
  70. de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–1296. doi:10.1002/art.24642. PMID 19790126 (de Menthon 2009)
  71. De Santis D, Dinauer D, Duke J, et al. 16th IHIW: review of HLA typing by NGS. Int J Immunogenet. 2013;40(1):72–76. doi:10.1111/iji.12024. PMID 23302098 (De Santis 2013)
  72. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70(7):1183–1190. doi:10.1136/ard.2011.150755. PMID 21571735
  73. Debaugnies F, Servais G, Badot V, et al. Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis. Scand J Rheumatol. 2013;42(2):108–114. doi:10.3109/03009742.2012.723746. PMID 23126558
  74. Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924–934. doi:10.1182/blood.2019001212. PMID 31292117 (Dehn 2019)
  75. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437. doi:10.1111/all.12350. PMID 24697291 (Demoly 2014)
  76. Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541. doi:10.3389/fimmu.2018.00541. PMID 29632529
  77. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555–563. doi:10.1681/ASN.2004050380. PMID 15590760
  78. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558–569. doi:10.1056/NEJMoa035717. PMID 15703421 (Dragun 2005)
  79. Dramburg S, Hilger C, Santos AF, et al. EAACI Molecular Allergology User's Guide 2.0. Pediatr Allergy Immunol. 2023;34 Suppl 28:e13854. doi:10.1111/pai.13854. PMID 37186333 (Dramburg 2023)
  80. Dvorak CC, Haddad E, Heimall J, et al. The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. J Allergy Clin Immunol. 2023;151(2):539–546. doi:10.1016/j.jaci.2022.10.022. PMID 36456361 (Dvorak 2023)
  81. Eberlein B, Biedermann T. IgE nonresponders in basophil activation tests: a narrative review from mechanistic insights to clinical implications and future directions. J Immunol Res. 2025;2025:2022127. doi:10.1155/jimr/2022127. PMID 41473389 (Eberlein 2025)
  82. Ebo DG, De Puysseleyr LP, Van Gasse AL, et al. Mast cell activation during suspected perioperative hypersensitivity: a need for paired samples analysis. J Allergy Clin Immunol Pract. 2021;9(8):3051–3059.e1. doi:10.1016/j.jaip.2021.03.050. PMID 33862269 (Ebo 2021)
  83. Egerer K, Roggenbuck D, Hiemann R, et al. Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther. 2010;12(2):R40. doi:10.1186/ar2949. PMID 20214808
  84. Eggleton P, Ukoumunne OC, Cottrell I, et al. Autoantibodies against C1q as a diagnostic measure of lupus nephritis: systematic review and meta-analysis. J Clin Cell Immunol. 2014;5(2):210. doi:10.4172/2155-9899.1000210. PMID 24955287
  85. Epstein A, Barland P. The diagnostic value of antihistone antibodies in drug-induced lupus erythematosus. Arthritis Rheum. 1985;28(2):158–162. doi:10.1002/art.1780280209. PMID 3882094
  86. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025;83(2):453–501. doi:10.1016/j.jhep.2025.03.017. PMID 40348684 (EASL 2025)
  87. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. doi:10.1016/j.jhep.2017.03.022. PMID 28427765 (EASL 2017)
  88. Fabre V, Shoham S, Page KR, et al. High proportion of indeterminate QuantiFERON-TB Gold In-Tube results in an inpatient population is related to host factors and preanalytical steps. Open Forum Infect Dis. 2014;1(2):ofu088. doi:10.1093/ofid/ofu088. PMID 25734154 (Fabre 2014)
  89. Feng K, Chang L, Yan Y, et al. Clinical applications and methodology updates in HLA typing. BMC Immunol. 2026;27(1):62. doi:10.1186/s12865-026-00845-5. PMID 42135629 (Feng 2026)
  90. Fernandez I, Touzot F. Looking for ALPS: the value of a combined assessment of biochemical markers. Pediatr Allergy Immunol. 2024;35(5):e14135. doi:10.1111/pai.14135. PMID 38700373 (Fernandez 2024)
  91. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–987. doi:10.1183/13993003.00150-2015. PMID 26160873
  92. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13(4):366–374. doi:10.1016/S1470-2045(12)70004-9. PMID 22340965 (Fleischhauer 2012)
  93. Flesch BK, Reil A. Molecular genetics of the human neutrophil antigens. Transfus Med Hemother. 2018;45(5):300–309. doi:10.1159/000491031. PMID 30498408 (Flesch 2018)
  94. Franz BJ, Petraroia R, Faust CD, et al. Abrogating biologics interference in flow cytometric crossmatching. Hum Immunol. 2021;82(8):574–580. doi:10.1016/j.humimm.2021.01.016. PMID 33934934 (Franz 2021)
  95. Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding horizons in complement analysis and quality control. Front Immunol. 2021;12:697313. doi:10.3389/fimmu.2021.697313. PMID 34434189
  96. Gabriel C, Fürst D, Faé I, et al. HLA typing by next-generation sequencing—getting closer to reality. Tissue Antigens. 2014;83(2):65–75. doi:10.1111/tan.12298. PMID 24447174 (Gabriel 2014)
  97. Garcia-Sanchez C, Usenko CY, Herrera ND, et al. The shared epitope phenomenon—a potential impediment to virtual crossmatch accuracy. Clin Transplant. 2020;34(8):e13906. doi:10.1111/ctr.13906. PMID 32418254 (Garcia-Sanchez 2020)
  98. Garland J, Philcox W, McCarthy S, et al. Postmortem tryptase level in 120 consecutive nonanaphylactic deaths: establishing a reference range as <23 μg/L. Am J Forensic Med Pathol. 2019;40(4):351–355. doi:10.1097/PAF.0000000000000515. PMID 31687978 (Garland 2019)
  99. Gattinger P, Lupinek C, Kalogiros L, et al. The culprit insect but not severity of allergic reactions to bee and wasp venom can be determined by molecular diagnosis. PLoS One. 2018;13(6):e0199250. doi:10.1371/journal.pone.0199250. PMID 29940036 (Gattinger 2018)
  100. Gaviglio A, Lasarev M, Sheller R, et al. Newborn screening for severe combined immunodeficiency: lessons learned from screening and follow-up of the preterm newborn population. Int J Neonatal Screen. 2023;9(4):68. doi:10.3390/ijns9040068. PMID 38132827 (Gaviglio 2023)
  101. Ghazal K, Brabant S, Prie D, Piketty ML. Hormone immunoassay interference: a 2021 update. Ann Lab Med. 2022;42(1):3–23. doi:10.3343/alm.2022.42.1.3. PMID 34374345
  102. Ghillani P, André C, Toly C, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011;10(9):509–513. doi:10.1016/j.autrev.2011.03.004. PMID 21447407
  103. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. doi:10.1038/s41572-019-0079-y. PMID 31048702
  104. Gligora I, et al. Low prevalence and inconsistency of LRP4-IgG detection in suspected myasthenia gravis: a multicenter CBA comparison. Neurol Neuroimmunol Neuroinflamm. 2026;13(3):e200554. doi:10.1212/NXI.0000000000200554. PMID 41719501
  105. Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124–176. doi:10.1016/j.anai.2023.09.015. PMID 38108678 (Golden 2024)
  106. Golden DBK. Update in stinging insect hypersensitivity. Allergy Asthma Proc. 2025;46(5):382–387. doi:10.2500/aap.2025.46.250060. PMID 40958191 (Golden 2025)
  107. González Rodríguez C, Aparicio Hernández MB, Alarcón Torres I. Update and clinical management of anti-DNA auto-antibodies. Adv Lab Med. 2021;2(3):313–331. doi:10.1515/almed-2021-0008. PMID 37362416
  108. Gragert L, Kadatz M, Alcorn J, et al. ABO-adjusted calculated panel reactive antibody (cPRA): a unified metric for immunologic compatibility in kidney transplantation. Am J Transplant. 2022;22(12):3093–3100. doi:10.1111/ajt.17175. PMID 35975734 (Gragert 2022)
  109. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–1140. doi:10.1136/jnnp.2003.034447. PMID 15258215
  110. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi:10.1016/S1474-4422(15)00401-9. PMID 26906964
  111. Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014. doi:10.1212/NXI.0000000000001014. PMID 34006622
  112. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309–314. doi:10.1136/annrheumdis-2021-221794. PMID 35110334
  113. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–1213. doi:10.1002/art.1780301102. PMID 2446635 (Gregersen 1987)
  114. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167–177. doi:10.1016/S1474-4422(13)70282-5. PMID 24360484
  115. Grochowska-Rak M, et al. Sensitivity and specificity of ELISA tests detecting BP180 and BP230 antibodies in the diagnosis of bullous pemphigoid: a systematic review and meta-analysis. Int J Dermatol. 2026;65(7):1367–1375. doi:10.1111/ijd.70136. PMID 41222109
  116. Grunewald O, Lopez B, Brabant S, et al. Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite reagents. Clin Chem Lab Med. 2018;56(8):1319–1327. doi:10.1515/cclm-2018-0001. PMID 29630506 (Grunewald 2018)
  117. Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol. 2006;117(4):759–766. doi:10.1016/j.jaci.2006.01.012. PMID 16630931 (Hamilton 2006)
  118. Hamilton RG. Proficiency survey-based evaluation of clinical total and allergen-specific IgE assay performance. Arch Pathol Lab Med. 2010;134(7):975–982. doi:10.5858/2009-0518-OA.1. PMID 20586624 (Hamilton 2010)
  119. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295–2306. doi:10.1182/blood-2017-06-793141. PMID 28924019
  120. Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 2017;1(26):2529–2534. doi:10.1182/bloodadvances.2017012310. PMID 29296904
  121. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–176. doi:10.1002/hep.22322. PMID 18537184
  122. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–158. doi:10.1038/clpt.2012.209. PMID 23232549 (Hershfield 2013)
  123. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499. doi:10.1210/jcem.87.2.8182. PMID 11836274
  124. Hu S, Zhao F, Wang Q, Chen W. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014;52(11):1533–1542. doi:10.1515/cclm-2013-0926. PMID 24501161
  125. Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275(2):104–115. doi:10.1111/joim.12162. PMID 24330030
  126. Igonina M, Malakhova E, Fadeeva M, et al. Diagnostic workflow for X-linked agammaglobulinemia integrating BTK expression and B-cell maturation analysis by flow cytometry. Cytometry B Clin Cytom. 2026. doi:10.1002/cyto.b.70038. PMID 42116646 (Igonina 2026)
  127. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727–734. doi:10.1155/2013/726598. PMID 24324289
  128. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974. doi:10.2337/dc15-1419. PMID 26404926
  129. International Consensus on ANA Patterns. AC-0 Negative. https://www.anapatterns.org/view_pattern.php?pattern=0 (last updated August 2025; accessed 2026-11-17) (ICAP AC-0 page)
  130. International Consensus on ANA Patterns. AC-30 Fine speckled with mitotic plate (last updated July 2025). https://www.anapatterns.org/view_pattern.php?pattern=30 (accessed 2026-11-17) (ICAP AC-30 page)
  131. International Consensus on ANA Patterns. AC-31 Myriad discrete (last updated July 2025). https://www.anapatterns.org/view_pattern.php?pattern=31 (accessed 2026-11-17) (ICAP AC-31 page)
  132. IPD-IMGT/HLA Database. Statistics: numbers of HLA alleles. https://www.ebi.ac.uk/ipd/imgt/hla/about/statistics/. Accessed November 17, 2026 (IPD-IMGT/HLA 2026)
  133. ISBT Working Party on Granulocyte Immunobiology; Bierling P, Bux J, et al. Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sang. 2009;96(3):266–269. doi:10.1111/j.1423-0410.2008.01144.x. PMID 19207164 (Bierling 2009)
  134. Israni AK, Salkowski N, Gustafson S, et al. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol. 2014;25(8):1842–1848. doi:10.1681/ASN.2013070784. PMID 24833128 (Israni 2014)
  135. Jacovas VC, Zelnick M, McNulty S, et al. The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2. Genet Med. 2026;28(1):101613. doi:10.1016/j.gim.2025.101613. PMID 41104538 (Jacovas 2026)
  136. Jaroenpuntaruk V, Jenkins SM, Smith CY, et al. Sex differences in urinary mast cell mediators: implications for diagnosing atopic and mast cell disorders. Ann Allergy Asthma Immunol. 2025;135(3):320–327.e2. doi:10.1016/j.anai.2025.05.028. PMID 40480425 (Jaroenpuntaruk 2025)
  137. Jaskowski TD, Martins TB, Litwin CM, Hill HR. Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol. 1999;6(1):137–139. doi:10.1128/CDLI.6.1.137-139.1999. PMID 9874678
  138. Jin Q, Kant S, Alhariri J, Geetha D. Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. J Community Hosp Intern Med Perspect. 2018;8(6):339–344. doi:10.1080/20009666.2018.1536242. PMID 30559941
  139. Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem. 1982;28(1):126–128. PMID 7055895 (Jolliff 1982)
  140. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi:10.1111/jdv.16752. PMID 32830877
  141. Jutel M, Agache I, Zemelka-Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy. 2023;78(11):2851–2874. doi:10.1111/all.15889. PMID 37814905 (Jutel 2023)
  142. Kanegane H, Hoshino A, Okano T, et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol Int. 2018;67(1):43–54. doi:10.1016/j.alit.2017.06.003. PMID 28684198 (Kanegane 2018)
  143. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54(1):312–324. doi:10.1002/art.21539. PMID 16385548
  144. Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109(2):302–309. doi:10.1002/cpt.2008. PMID 32779747 (Karnes 2021)
  145. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010;10(1):46–50. doi:10.1016/j.autrev.2010.07.005. PMID 20656071
  146. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1. PMID 35732831 (Khoury 2022)
  147. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70(6):1722–1726. PMID 2445398 (Kiefel 1987)
  148. Kim TS, Oh I, Choi YJ, et al. Effects of various concentrations of pronase on flow cytometric crossmatching patients treated with rituximab and donor HLA-specific antibodies. Ann Lab Med. 2024;44(6):545–552. doi:10.3343/alm.2024.0132. PMID 38992960 (Kim 2024)
  149. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of autoimmune hepatitis 2022. Clin Mol Hepatol. 2023;29(3):542–592. doi:10.3350/cmh.2023.0087. PMID 37137334 (KASL 2023)
  150. Korevaar TIM, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid. 2026;36(5):481–544. doi:10.1177/10507256261445624. PMID 42219800
  151. Krolik M, Phirke P, Oh ES, et al. EDTA treatment of serum reduces T cell and B cell false positivity in flow cytometry crossmatching: a multicenter study. HLA. 2025;106(3):e70399. doi:10.1111/tan.70399. PMID 40976781 (Krolik 2025)
  152. Kuo CY, Garcia-Lloret MI, Slev P, et al. Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. J Allergy Clin Immunol Pract. 2017;5(1):198–200. doi:10.1016/j.jaip.2016.09.028. PMID 28065337 (Kuo 2017)
  153. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–738. doi:10.1001/jama.2014.9132. PMID 25138334 (Kwan 2014)
  154. Launay D, Schmidt J, Lepers S, et al. Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin Chim Acta. 2010;411(13–14):959–964. doi:10.1016/j.cca.2010.03.016. PMID 20303931
  155. Lawley TJ, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311(22):1407–1413. doi:10.1056/NEJM198411293112204. PMID 6387492
  156. Lazzaroni MG, Marasco E, Campochiaro C, et al. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford). 2021;60(11):5028–5041. doi:10.1093/rheumatology/keab152. PMID 33580257
  157. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33(8):1101–1107. doi:10.1002/art.1780330807. PMID 2202308
  158. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758. PMID 30592986
  159. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576–4583. doi:10.1182/blood-2007-06-097386. PMID 17785583 (Lee 2007)
  160. Lefaucheur C, Louis K, Morris AB, et al. Clinical recommendations for posttransplant assessment of anti-HLA (human leukocyte antigen) donor-specific antibodies: a Sensitization in Transplantation: Assessment of Risk consensus document. Am J Transplant. 2023;23(1):115–132. doi:10.1016/j.ajt.2022.11.013. PMID 36695614 (Lefaucheur 2023)
  161. LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113(1):33–35. doi:10.1016/s0002-9394(14)75749-6. PMID 1728143 (LeHoang 1992)
  162. Li L, Guo Y, Wang J. Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review. Ann Transl Med. 2023;11(7):283. doi:10.21037/atm-21-2434. PMID 37090044
  163. Li Y, Sylvaria D, Billingsley M, et al. Pronase treatment enhances the sensitivity of B cell flow cytometry crossmatch: a single-center data analysis. Transpl Immunol. 2025;93:102325. doi:10.1016/j.trim.2025.102325. PMID 41176035 (Li 2025)
  164. Lin M, Park S, Hayden A, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Ann Hematol. 2017;96(8):1241–1251. doi:10.1007/s00277-017-2993-y. PMID 28497365
  165. Liu T, Ji X, Wei Y, et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis. Rheumatology (Oxford). 2026;65(7):keag311. doi:10.1093/rheumatology/keag311. PMID 42334960
  166. Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60(10):3091–3097. doi:10.1002/art.24768. PMID 19790064
  167. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–2331. doi:10.1111/ajt.15898. PMID 32463180 (Loupy 2020)
  168. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215–1226. doi:10.1056/NEJMoa1302506. PMID 24066742 (Loupy 2013)
  169. Lucas G, Rogers S, de Haas M, et al. Report on the Fourth International Granulocyte Immunology Workshop: progress toward quality assessment. Transfusion. 2002;42(4):462–468. doi:10.1046/j.1525-1438.2002.00053.x. PMID 12076294 (Lucas 2002)
  170. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964. doi:10.1136/annrheumdis-2017-211468. PMID 29079590
  171. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564–1569. doi:10.1038/ng.3696. PMID 27749843 (Lyons 2016)
  172. Machinena-Spera A, Lozano-Blasco J, Jiménez-Feijoo R, et al. Clinical and immunological predictors of baked egg tolerance in children with IgE-mediated hen's egg allergy: a cross-sectional diagnostic accuracy study. Eur J Pediatr. 2026;185(10):742. doi:10.1007/s00431-026-07398-0. PMID 42726140 (Machinena-Spera 2026)
  173. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. doi:10.1002/hep.31065. PMID 31863477
  174. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–579. doi:10.1056/NEJMoa0706135. PMID 18256392 (Mallal 2008)
  175. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–721. doi:10.1002/art.30156. PMID 21360500
  176. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012;64(2):269–272. doi:10.1002/acr.20662. PMID 21972203
  177. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291–455. doi:10.1111/j.1399-0039.2010.01466.x. PMID 20356336 (Marsh 2010)
  178. Marsh SGE; WHO Nomenclature Committee for Factors of the HLA System. Nomenclature for factors of the HLA system, update April, May and June 2025. Int J Immunogenet. 2025;52(5):278–310. doi:10.1111/iji.70005. PMID 40702666 (Marsh 2025)
  179. Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499–500. doi:10.1038/clpt.2014.38. PMID 24561393 (Martin 2014)
  180. Mateja A, Wang Q, Chovanec J, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol. 2022;149(3):1010–1017.e10. doi:10.1016/j.jaci.2021.08.007. PMID 34425177 (Mateja 2022)
  181. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, et al. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016;27 Suppl 23:1–250. doi:10.1111/pai.12563. PMID 27288833 (Matricardi 2016)
  182. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575–1596. doi:10.1111/all.13384. PMID 29318628
  183. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi:10.1111/all.15214. PMID 35006617 (Maurer 2022a)
  184. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. World Allergy Organ J. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627. PMID 35497649 (Maurer 2022b; open text of the same guideline)
  185. Mayorga C, Çelik GE, Pascal M, et al. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper. Allergy. 2024;79(3):580–600. doi:10.1111/all.15957. PMID 38084472 (Mayorga 2024)
  186. McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease—treatment standard. Nephrol Dial Transplant. 2025;41(1):42–54. doi:10.1093/ndt/gfaf190. PMID 40973182 (McAdoo 2025)
  187. McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693–702. doi:10.1016/j.kint.2017.03.014. PMID 28506760 (McAdoo 2017)
  188. McCalmon RT, Tardif GN, Sheehan MA, et al. IgM antibodies in renal transplantation. Clin Transplant. 1997;11(6):558–564. PMID 9408684 (McCalmon 1997)
  189. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. doi:10.1038/nrdp.2015.71. PMID 27189754 (McDonald-McGinn 2015)
  190. McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737. doi:10.15585/mmwr.mm6627e1. PMID 28704351
  191. Melegari A, Bonaguri C, Russo A, et al. A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev. 2012;11(10):713–716. doi:10.1016/j.autrev.2011.12.010. PMID 22269861
  192. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68(3):686–699. doi:10.1086/318799. PMID 11179016 (Mignot 2001)
  193. Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16(1):R53. doi:10.1186/ar4486. PMID 24524733
  194. Müller SM, Ege M, Pottharst A, et al. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood. 2001;98(6):1847–1851. doi:10.1182/blood.v98.6.1847. PMID 11535520 (Müller 2001)
  195. Nakagawa R, Matsuura H, Kojima H, et al. Impact of immunoglobulin preparations on anti-HLA antibody specificity analysis. Lab Med. 2025;56(2):171–177. doi:10.1093/labmed/lmae078. PMID 39306804 (Nakagawa 2025)
  196. Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897–908. doi:10.1016/j.kint.2016.02.001. PMID 26994577
  197. Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582–2591. doi:10.1002/art.27580. PMID 20872596
  198. Nieminen O, Palosuo K, Mäkelä MJ. Casein sIgE as the most accurate predictor for heated milk tolerance in Finnish children. Pediatr Allergy Immunol. 2025;36(7):e70152. doi:10.1111/pai.70152. PMID 40679134 (Nieminen 2025)
  199. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808. doi:10.7326/0003-4819-146-11-200706050-00008. PMID 17548411
  200. Okazaki T, Shinagawa S, Mikage H. Vasculitis syndrome—diagnosis and therapy. J Gen Fam Med. 2017;18(2):72–78. doi:10.1002/jgf2.4. PMID 29263994
  201. Olaya Hernández M, Triviño Arias J, Arias Valderrama O, et al. Clinical and genetic characterization of X-linked agammaglobulinemia in a Colombian cohort. World Allergy Organ J. 2026;19(9):101441. doi:10.1016/j.waojou.2026.101441. PMID 42733469 (Olaya Hernández 2026)
  202. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–e40. doi:10.1182/blood-2010-04-280347. PMID 20538792 (Oliveira 2010)
  203. Op De Beeck K, Vermeersch P, Verschueren P, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev. 2011;10(12):801–808. doi:10.1016/j.autrev.2011.06.005. PMID 21741497
  204. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1–S24. doi:10.1016/j.jaci.2012.07.002. PMID 22935624 (Orange 2012)
  205. Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149(5):1525–1560. doi:10.1016/j.jaci.2022.01.025. PMID 35176351 (Otani 2022)
  206. Palmisani E, Miano M, Grossi A, et al. Autoimmune lymphoproliferative syndrome (ALPS) disease and ALPS phenotype: are they two distinct entities? Hemasphere. 2023;7(3):e845. doi:10.1097/HS9.0000000000000845. PMID 36844186 (Palmisani 2023)
  207. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735–739. doi:10.1056/NEJM196904032801401. PMID 4886455 (Patel 1969)
  208. Perales MA, et al. ASTCT consensus grading for toxicities after immune effector cell therapy. Transplant Cell Ther. 2026;32(10):1189–1211. doi:10.1016/j.jtct.2026.05.020. PMID 42711241
  209. Petri M, Goldman DW, Alarcón GS, et al. Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology systemic lupus erythematosus classification criteria with two sets of earlier systemic lupus erythematosus classification criteria. Arthritis Care Res (Hoboken). 2021;73(9):1231–1235. doi:10.1002/acr.24263. PMID 32433832
  210. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi:10.1002/art.34473. PMID 22553077
  211. Petrovic I, et al. Influence of thyroglobulin autoantibodies on thyroglobulin levels measured by different methodologies: IMA, LC-MS/MS, and RIA. J Clin Endocrinol Metab. 2024;109(12):3254–3263. doi:10.1210/clinem/dgae286. PMID 38686504
  212. Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574–581. doi:10.1002/cpt.1004. PMID 29392710 (Phillips 2018)
  213. Philogene MC, Timofeeva OA, Gimferrer I, et al. Assessment of inter-laboratory variability for flow cytometric crossmatch testing: lessons learned from proficiency surveys. Hum Immunol. 2025;86(1):111176. doi:10.1016/j.humimm.2024.111176. PMID 39626409 (Philogene 2025)
  214. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–820. doi:10.1111/j.1398-9995.2004.00547.x. PMID 15230812 (Pichler 2004)
  215. Poli MC, Aksentijevich I, Bousfiha AA, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immun. 2025;1(1):e20250003. doi:10.70962/jhi.20250003. PMID 41608114
  216. Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update: mutation spectrum and C1 inhibitor phenotypes. Hum Mutat. 2020;41(1):38–57. doi:10.1002/humu.23917. PMID 31517426
  217. Prain K, Woodhall M, Vincent A, et al. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol. 2019;10:1028. doi:10.3389/fneur.2019.01028. PMID 31636597
  218. Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016;221(11):1247–1258. doi:10.1016/j.imbio.2016.06.008. PMID 27475991
  219. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–360. doi:10.1016/S0140-6736(11)60242-0. PMID 21868085
  220. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 glomerulopathy: ten years' experience at Mayo Clinic. Mayo Clin Proc. 2018;93(8):991–1008. doi:10.1016/j.mayocp.2018.05.019. PMID 30077216
  221. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant. 2013;13(7):1859–1870. doi:10.1111/ajt.12287. PMID 23763485 (Reed 2013)
  222. Rensing-Ehl A, Janda A, Lorenz MR, et al. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. Haematologica. 2013;98(12):1948–1955. doi:10.3324/haematol.2012.081901. PMID 23850805 (Rensing-Ehl 2013)
  223. Rets A, George TI. Diagnosing systemic mastocytosis: state of the art. Int J Lab Hematol. 2026;48(3):551–560. doi:10.1111/ijlh.70011. PMID 41058066 (Rets 2026)
  224. Riggioni C, Ricci C, Moya B, et al. Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy. Allergy. 2024;79(2):324–352. doi:10.1111/all.15939. PMID 38009299 (Riggioni 2024)
  225. Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315–320. doi:10.1136/annrheumdis-2021-221795. PMID 35110333
  226. Rohan VS, Pilch N, Moussa O, et al. Virtual crossmatching in kidney transplantation: the wait is over. J Am Coll Surg. 2020;230(4):373–379. doi:10.1016/j.jamcollsurg.2019.12.031. PMID 32035182 (Rohan 2020)
  227. Ross C, Makhzoum JP, Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2022;9(3):153–166. doi:10.5152/eujrheum.2022.20248. PMID 35156630
  228. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi:10.1089/thy.2016.0229. PMID 27521067
  229. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore). 1984;63(5):243–273. PMID 6433145
  230. Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36–37. doi:10.1002/cpt.161. PMID 26094938 (Saito 2016)
  231. Saleh L, et al. Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease. J Clin Endocrinol Metab. 2026;111(9):e2161–e2170. doi:10.1210/clinem/dgag118. PMID 41846542
  232. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol. 2001;107(5):891–896. doi:10.1067/mai.2001.114708. PMID 11344358 (Sampson 2001)
  233. Sanchez-Hernandez ES, Ortiz-Hernandez GL, Ochoa PT, et al. The nuclear dense fine speckled (DFS) immunofluorescence pattern: not all roads lead to DFS70/LEDGFp75. Diagnostics (Basel). 2023;13(2):222. doi:10.3390/diagnostics13020222. PMID 36673033
  234. Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy. 2023;78(12):3057–3076. doi:10.1111/all.15902. PMID 37815205 (Santos 2023)
  235. Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319–2327. doi:10.1002/art.34380. PMID 22237992
  236. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111(4):507–513. doi:10.1093/ajcp/111.4.507. PMID 10191771
  237. Schinstock CA, Gebel H, Gimferrer I, et al. Sensitization in organ transplantation: Assessment of Risk (STAR) 2025 meeting group report. Am J Transplant. 2026;26(5):1048–1069. doi:10.1016/j.ajt.2025.12.286. PMID 41519473 (Schinstock 2026)
  238. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads—a technical solution for the prozone effect. Transplantation. 2011;92(5):510–515. doi:10.1097/TP.0b013e31822872dd. PMID 21869744 (Schnaidt 2011)
  239. Schwartz LB, Min HK, Ren S, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol. 2003;170(11):5667–5673. doi:10.4049/jimmunol.170.11.5667. PMID 12759448 (Schwartz 2003)
  240. Schwartz LB, Yunginger JW, Miller J, et al. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551–1555. doi:10.1172/JCI114051. PMID 2468689 (Schwartz 1989)
  241. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763–1770. doi:10.1016/j.jaip.2019.02.004. PMID 30776527 (Seidel 2019)
  242. Sel FA, Oğuz FS. Can novel methods replace the gold standard chimerism method after allogeneic hematopoietic stem cell transplantation? Ann Hematol. 2024;103(4):1035–1047. doi:10.1007/s00277-023-05448-3. PMID 37801085 (Sel 2024)
  243. Senev A, Coemans M, Lerut E, et al. Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study. J Am Soc Nephrol. 2020;31(9):2193–2204. doi:10.1681/ASN.2020010019. PMID 32764139 (Senev 2020)
  244. Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–464. doi:10.1038/ki.2012.63. PMID 22456601
  245. Shao P, et al. Frequency of anti-GQ1b IgG antibody in Miller Fisher syndrome: a Chinese single center study. Neurol Sci. 2025;46(9):4593–4599. doi:10.1007/s10072-025-08290-9. PMID 40484917
  246. Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092–1098. doi:10.1016/j.jaci.2013.09.044. PMID 24290292 (Shearer 2014)
  247. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973–980. doi:10.1016/j.jaci.2003.07.003. PMID 14610491 (Shearer 2003)
  248. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Arthritis Rheumatol. 2017;69(1):35–45. doi:10.1002/art.39859. PMID 27785888
  249. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475–487. doi:10.1002/acr.21591. PMID 22563590
  250. Shifani N, Denning DW. Concordance between different methods of detecting fungal-specific IgE antibody in asthma. Front Allergy. 2026;7:1788615. doi:10.3389/falgy.2026.1788615. PMID 41993995 (Shifani 2026)
  251. Silva de Souza AW. Autoantibodies in systemic vasculitis. Front Immunol. 2015;6:184. doi:10.3389/fimmu.2015.00184. PMID 25954277
  252. Singh S, Ojodu J, Kemper AR, et al. Implementation of newborn screening for conditions in the United States first recommended during 2010–2018. Int J Neonatal Screen. 2023;9(2):20. doi:10.3390/ijns9020020. PMID 37092514 (Singh 2023)
  253. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–2935. doi:10.1002/art.21250. PMID 16142760
  254. South AM, Grimm PC. Transplant immuno-diagnostics: crossmatch and antigen detection. Pediatr Nephrol. 2016;31(6):897–905. doi:10.1007/s00467-015-3145-z. PMID 26139577 (South 2016)
  255. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83(4):1121–1127. doi:10.1210/jcem.83.4.4683. PMID 9543128
  256. Stapel SO, Asero R, Ballmer-Weber BK, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy. 2008;63(7):793–796. doi:10.1111/j.1398-9995.2008.01705.x. PMID 18489614 (Stapel 2008)
  257. Steiner G, Verschueren P, Van Hoovels L, Studenic P, et al. Classification of rheumatoid arthritis: is it time to revise the criteria? RMD Open. 2024;10(2). doi:10.1136/rmdopen-2023-003851. PMID 38642926
  258. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581–590. doi:10.1002/art.1780230510. PMID 7378088 (Masi 1980)
  259. Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321–326. doi:10.1136/annrheumdis-2021-221796. PMID 35110332
  260. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19–47. doi:10.1097/TP.0b013e31827a19cc. PMID 23238534 (Tait 2013)
  261. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277. doi:10.1002/art.1780251101. PMID 7138600
  262. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40(9):1601–1611. doi:10.1002/art.1780400909. PMID 9324014
  263. Tan Y, Pang W, Jia X, Zhao MH. Comparison of the performance of a chemiluminescence assay and an ELISA for detection of anti-GBM antibodies. Ren Fail. 2020;42(1):48–53. doi:10.1080/0886022X.2019.1702056. PMID 31885301
  264. Tanaka A. Autoimmune hepatitis: 2019 update. Gut Liver. 2020;14(4):430–438. doi:10.5009/gnl19261. PMID 32301319
  265. Tanaka Y. Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis? Semin Arthritis Rheum. 2025;72S:152678. doi:10.1016/j.semarthrit.2025.152678. PMID 40024856
  266. Tanboon J, Inoue M, Saito Y, et al. Dermatomyositis: muscle pathology according to antibody subtypes. Neurology. 2022;98(7):e739–e749. doi:10.1212/WNL.0000000000013176. PMID 34873015
  267. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–1507. doi:10.1007/s10875-022-01289-3. PMID 35748970 (Tangye 2022)
  268. Tarzi MD, Hickey A, Förster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol. 2007;149(3):513–516. doi:10.1111/j.1365-2249.2007.03438.x. PMID 17614974
  269. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–679. doi:10.1158/2159-8290.CD-16-0040. PMID 27076371
  270. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119(2):310–322. doi:10.1053/gast.2000.9366. PMID 10930366
  271. Thomma RCM, et al. Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome. Brain. 2025;148(11):4000–4015. doi:10.1093/brain/awaf102. PMID 40096525
  272. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–1107. doi:10.1016/S1474-4422(11)70245-9. PMID 22094130
  273. Tomasson G, Grayson PC, Mahr AD, LaValley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology (Oxford). 2012;51(1):100–109. doi:10.1093/rheumatology/ker280. PMID 22039267
  274. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi:10.1016/j.autrev.2012.07.003. PMID 22776786
  275. Turkalj M, Banić I, Fressl Juroš G. Component-resolved and multiplex-specific IgE diagnostics: utility in anaphylaxis and beyond. Children (Basel). 2025;12(7):933. doi:10.3390/children12070933. PMID 40723126 (Turkalj 2025)
  276. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–225. doi:10.1159/000328760. PMID 22041891 (Valent 2012)
  277. Valent P, Akin C, Nedoszytko B, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020;21(23):9030. doi:10.3390/ijms21239030. PMID 33261124 (Valent 2020)
  278. Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180(1):44–51. doi:10.1159/000501079. PMID 31256161 (Valent 2019)
  279. Valentin A, Windhorst AC, Sachs UJ, et al. Noninvasive fetal HPA genotyping for FNAIT: diagnostic accuracy and technical performance of molecular methods. Transfus Med Rev. 2026;40(3):151017. doi:10.1016/j.tmrv.2026.151017. PMID 42435657 (Valentin 2026)
  280. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747. doi:10.1002/art.38098. PMID 24122180
  281. Van Hoovels L, Chatzichristos C, Irure-Ventura J, et al. Refining serological scores in rheumatoid arthritis classification: an international study. RMD Open. 2026;12(3). doi:10.1136/rmdopen-2026-007007. PMID 42476632
  282. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–558. doi:10.1136/ard.61.6.554. PMID 12006334
  283. von Mühlen CA, Garcia-De La Torre I, Infantino M, et al. How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. Immunol Res. 2021;69(6):594–608. doi:10.1007/s12026-021-09233-0. PMID 34625914
  284. Wagenaar-Bos IG, Drouet C, Aygören-Pursun E, et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods. 2008;338(1–2):14–20. doi:10.1016/j.jim.2008.06.004. PMID 18655790
  285. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4(Suppl 3):S279–S293. doi:10.1186/ar586. PMID 12110148
  286. Wang G, Tanaka A, Zhao H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–257. doi:10.1007/s12072-021-10170-1. PMID 33942203
  287. Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250–e1255. doi:10.1212/WNL.0000000000007096. PMID 30728305
  288. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85. doi:10.1182/blood-2007-06-091744. PMID 17898316 (Wehr 2008)
  289. WHO Nomenclature Committee for Factors of the HLA System. Naming alleles. HLA Nomenclature. https://hla.alleles.org/pages/nomenclature/naming_alleles/. Accessed November 17, 2026 (WHO Nomenclature Committee 2026)
  290. Wide L, Bennich H, Johansson SG. Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet. 1967;2(7526):1105–1107. doi:10.1016/s0140-6736(67)90615-0. PMID 4168552 (Wide 1967)
  291. Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021;58(7):447–478. doi:10.1080/10408363.2021.1907297. PMID 33962553
  292. Wilson JM, Erickson L, Levin M, et al. Tick bites, IgE to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: the alpha-gal syndrome. Allergy. 2024;79(6):1440–1454. doi:10.1111/all.16003. PMID 38193233 (Wilson 2024)
  293. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi:10.1212/WNL.0000000000001729. PMID 26092914
  294. Woellner C, Gertz EM, Schäffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(2):424–432.e8. doi:10.1016/j.jaci.2009.10.059. PMID 20159255 (Woellner 2010)
  295. Yamamoto S, Kubotsu K, Kida M, et al. Automated homogeneous liposome-based assay system for total complement activity. Clin Chem. 1995;41(4):586–590. doi:10.1093/clinchem/41.4.586. PMID 7720251
  296. Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10–16. doi:10.1007/s10875-009-9357-x. PMID 20101521 (Yel 2010)
  297. Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21(10):1088–1097. doi:10.1177/0961203312451202. PMID 22777943
  298. Young PP, Singh U, Webb J, et al. Evolving TRALI risk across apheresis and whole blood platelet products in the United States: an 18-year American Red Cross hemovigilance analysis. Transfusion. 2025;65(12):2317–2323. doi:10.1111/trf.18457. PMID 41122822 (Young 2025)
  299. Zachary AA, Lucas DP, Detrick B, et al. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol. 2009;70(7):496–501. doi:10.1016/j.humimm.2009.04.001. PMID 19364516 (Zachary 2009)
  300. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004;1(1):2. doi:10.1186/1740-2557-1-2. PMID 15679907
  301. Zajacova A, Revilla-Lopez E, Guney M, et al. Anti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions. Eur Respir Rev. 2026;35(179):250298. doi:10.1183/16000617.0298-2025. PMID 41813012 (Zajacova 2026)
  302. Zanichelli A, Azin GM, Wu MA, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2017;5(5):1307–1313. doi:10.1016/j.jaip.2016.12.032. PMID 28284781
  303. Zaucha JM, Zaucha JM, Piekarska A. Lineage-specific chimerism analysis after allogeneic hematopoietic cell transplantation in patients with myeloid neoplasms: current evidence and considerations in the post-transplant cyclophosphamide setting. Biomedicines. 2026;14(5):952. doi:10.3390/biomedicines14050952. PMID 42193279 (Zaucha 2026)
  304. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046–2055. doi:10.1056/NEJMoa0905506. PMID 19776401 (Zhang 2009)
  305. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145. doi:10.1016/j.jaut.2013.12.004. PMID 24373505
  306. Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007;357(13):1293–1300. doi:10.1056/NEJMoa067160. PMID 17898098 (Zou 2007)
  307. Zuzolo J, Zulfiqar MF, Spoelhof B, et al. Functional testing of humoral immunity in the Prevnar 20 era. Ann Allergy Asthma Immunol. 2025;134(3):279–283. doi:10.1016/j.anai.2024.12.011. PMID 39681261 (Zuzolo 2025)